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I have not failed. 
I’ve just found 10,000 ways that won’t work.
Just because something doesn’t do what you planned it to do 
doesn’t mean it’s useless.
~Thomas Edison~
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Introduction
Currently, the second leading cause of death in the world is cancer. Both biomedical 
researchers as well as health care institutions and pharmaceutical companies are 
focusing on the development of more effective therapeutic options and improvement 
of the quality of life and disease outcome for cancer patients [95]. Many different 
types of cancer exist and each requires tailored treatment options and comes with its 
own specific prognostics. Central nervous system (CNS) tumors, including gliomas 
are amongst the cancers with the highest number of lost life years per patient [13]. 
Gliomas represent a group of primary brain tumors that originate from (precursors 
of) glial cells. It is the most frequent primary tumor in the brain, with an incidence of 
3.55 per 100,000 people each year [80].
Classification and histopathology of glioma.
According to the classification used by the World Health Organization (WHO), glio-
mas can be subdivided into four grades (I-IV). The most frequent WHO Grade I glio-
mas are named pilocytic astrocytomas, that are characterized by activating BRAF fu-
sions or BRAF mutations, mostly affect children, generally show slow and relatively 
circumscribed growth and only very infrequently progress to a higher malignancy 
grade. Grade II-IV gliomas are so-called diffuse gliomas, reflecting their diffuse infil-
trative migratory behavior in the brain parenchyma [63]. Diffuse gliomas are further 
classified by their histological resemblance to non-neoplastic glial cells (astrocytes 
and oligodendrocytes). Within the different diffuse glioma categories, the  presence 
of necrosis and microvascular proliferations and mitotic activity are determinants 
for the grade assignment. Both grade II and grade III gliomas can present as oli-
godendrogliomas as well as astrocytomas. The vast majority of gliomas are more 
widely known as glioblastomas and display the most aggressive behavior. Primary 
glioblastomas originate de novo whereas secondary glioblastomas progress from 
lower-grade diffuse gliomas. 
Nowadays the classification of gliomas involves more than just malignancy grade 
and is in fact based on a combination of histopathological and molecular diagnostic 
features of the tumors [63] (Fig. 1). Not only does this provide more information to 
build the proper diagnosis, it may also yield molecular entry points that aid in the de-
sign of treatment plans. Correct classification of diffuse gliomas is important because 
treatment efficacy differs greatly between grades, subtypes and molecular aberra-
tions, and the outcome of clinical trials would benefit from more homogeneously 
defined groups (e.g [109] for glioblastomas, [49, 92] for lower-grade gliomas and [28, 
87] for O6-methylguanin-DNA-methyltransferase (MGMT) status).
Some of the most important diagnostic and prognostic biomarkers are mutations 
in the isocitrate dehydrogenase 1 (IDH1) and IDH2 genes [63]. Mutations in these 
genes are associated with a unique DNA methylation status and are found in the 
vast majority of lower-grade diffuse gliomas and high-grade secondary glioblasto-
mas, the most common being R132H in IDH1 [5, 99, 111] (for details see below). 
Presence of IDH mutations is a predictor of prolonged survival [8, 9]. Primary glio-
blastomas, which originate de novo, are wild type (WT) for IDH1 and IDH2 [81]. 
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IDH  WT glioblastomas have several known histological variants, including giant cell 
glioblastoma and gliosarcoma.  
Another diagnostic classifier is the co-deletion of chromosome arms 1p and 19q pre-
sent in oligodendrogliomas [63]. Patients with tumors carrying the co-deletion have 
a better prognosis compared to individuals with tumors of a similar grade without the 
co-deletion [43, 71]. 1p/19 co-deleted tumors are almost exclusively IDH mutated 
[49, 104]. Tumors without the co-deletion but with an oligodendroglioma component 
are similar to astrocytomas in both clinical outcome and genetic profile (reviewed in 
[92]). 
Expression signatures:
Nowadays, glioblastomas, are being subdivided based on extensive genetic and 
transcriptional profiling, resulting in three distinct groups instead of only primary and 
secondary. Tumors in each of these subgroups have  a particular transcriptional sig-
nature, distinct genetic aberrations and diverse clinical outcome and are now often 
referred to as being of the pro-neural, mesenchymal or classical type [11, 109]. The 
frequency of occurrence of these different subtypes is similar [109].
Diuse Glioma
High-grade (IV)
IDH mut
Lower-grade (II-III)
1p/19q 
co-deletion
often carry 
mutations 
in ATRX 
and/or TP53
(Anaplastic)
Oligodendroglioma
 
Diuse (Anaplastic)
astrocytoma
Primary glioblastoma 
(including giant cell
 glioblastoma and 
gliosarcoma)
Secondary glioblastoma
Histology AstrocyteHistology Astrocyte
Histology 
Oligodendrocyte
IDH mut IDH WT
Diuse (Anaplastic)
 astrocytoma
No genetic testing available or inconclusive:  oligodendroglioma NOS; diuse astrocytoma NOS; glioblastoma NOS
Figure 1: Schematic overview of classification of diffuse glioma. According to the WHO 2016 classifica-
tion of tumors of the CNS a more precise diagnosis of diffuse gliomas can be made based on presence/
absence of particular molecular aberrations [63] . Abbreviations, 1p/19q, chromosomal arms 1p and 19q; 
ATRX, ATP-dependent helicase; TP53, Tumor protein 53; IDH, Isocitrate dehydrogenase; mut, mutant; 
WT, wild type; NOS, Not otherwise specified.
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Classical glioblastomas show an amplification of chromosome 7 containing the Epi-
dermal growth factor receptor (EGFR) gene in almost all cases. Deletion of chromo-
seme 10 harboring the tumor suppressor gene phosphatase and tensin homolog 
(PTEN) is very common. Unexpectedly, inactivating mutations in tumor protein p53 
(TP53) are hardly present even though it is the most common mutation found in 
glioblastomas overall. Classical glioblastomas show high expression of several stem 
cell markers and when looking at expression of mRNA, resemble primary astrocytes 
the most.
Mesenchymal glioblastomas often have a neurofibromin gene (NF1) deletion and 
high levels of the tyrosine-protein kinase c-MET. Also dysfunctional TP53 and/or 
PTEN are often encountered in these tumors, both separate as well as in combina-
tion. Mesenchymal tumors show EMT (epithelial to mesenchymal transition) and 
appear dedifferentiated or transdifferentiated. Also they show more necrosis and 
inflammatory responses than found in the other glioblastoma tumor types. The ex-
pression profiles of normal cultured astroglia cells are most similar to the profiles of 
this group of glioblastomas.
Proneural tumors frequently show a high amount of platelet-derived growth factor 
receptor alpha (PDGFRα) alterations and IDH1 or, less frequently, IDH2 mutations. 
Although PDGFRα mutations are mutually exclusive with IDH mutations they both 
only occur within this glioblastoma subtype. Furthermore proneural tumors are of-
ten TP53 mutated. They show a more oligodendrocyte–like expression profile and 
resemble the lower-grade gliomas in that respect. The mean age of diagnosis in the 
proneural group is also significantly lower than for the other three subtypes. 
Treatment of diffuse glioma
The standard treatment for glioblastoma patients follows the so-called Stupp proto-
col which combines surgery with radiotherapy and temozolomide (TMZ) treatment 
[97, 98]. Application of this protocol helps to extend the median survival period to 
up to 15 months although response between subgroups of patients with primary 
glioblastoma (as mentioned above) varies greatly. Glioblastomas ideally are first 
excised to the maximum feasible extent. Next, radiotherapy is applied, with con-
comitant TMZ administration and irradiation to increase the DNA damage resulting 
from the radiotherapy. Subsequently six more rounds of TMZ treatment are given. 
Standard care for lower-grade gliomas is often more diverse. Some centers prefer a 
‘wait and see’ policy whereas other centers perform a resection of the tumor followed 
by radiotherapy. Caution is advised as lower-grade gliomas can acquire additional 
mutations from radio- or chemotherapy and thus may progress to a high-grade glio-
mas faster [44]. However, all lower-grade diffuse gliomas will eventually progress to 
a higher grade, so intervention will ultimately be needed.  
The migratory behavior of diffuse gliomas is a major reason why treatment is so dif-
ficult. Cells disseminate from the main mass of the tumor and extensively infiltrate 
into the neuropil creating complex networks deep in the brain [82]. Due to this diffuse 
nature, a complete resection of the tumor by surgery is impossible. Furthermore, 
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the cellular composition of glioblastomas around the time of diagnosis can already 
be very diverse, with great intra- and inter-heterogeneity of tumors [94], associated 
with large variability in response to treatment and incidence of recurrence. Together 
this results in glioma being one of the most incurable malignancies (reviewed in 
[19]). Some cells have a high proliferative capacity and contribute significantly to 
the growth of the tumor. These are the cells that are most likely hit by the current 
treatment. There are also stem cell-like cells within the tumor which are relatively 
dormant. These cells are mostly unaffected by treatment and can increase their 
proliferative capacity after treatment has been terminated (reviewed in [96]). To be 
able to effectively treat glioblastoma, all these cells with different properties and dif-
ferent survival programs must be targeted simultaneously. For future improvement 
of glioblastoma therapy and the development of personalized therapy, strategies 
for comprehensive characterization of tumor composition for each individual patient 
and more extensive a priori knowledge about drug effects on the growth and survival 
capacity of different tumor cell types is therefore urgently needed.  
Already now, many new treatment strategies involve therapy with combinations of 
drugs that are tailored to the individual patient, aimed to target specific genetic aber-
rations. For instance, tyrosine kinases inhibitors (TKIs) are used, that block the activ-
ity of hyperactive receptor tyrosine kinases (RTKs), like the EGFR that is frequently 
mutated in these tumors (specifics discussed below). Cancer cells displaying stem 
cell-like properties inside the tumor are often slow-cycling cells which are not sus-
ceptible to EGFR inhibitors due to increased genetic stability, decreased oxidative 
stress, or the expression of efflux pumps that cause drug resistance. A frequently ob-
served problem with treatment with such drugs is that it can cause secondary point 
mutations in EGFR, upregulation of other receptor tyrosine kinases and upregulation 
of drug efflux pumps. For instance, when EGFR is inhibited, another RTK, c-MET 
can become upregulated. Additional inhibition of c-MET thus may help to increase 
treatment efficacy [46], and by targeting multiple RTKs at the same time resistance-
generating compensation mechanisms may be prevented (reviewed in [102]). 
Another example of where combination treatment may be beneficial, or maybe even 
necessary, is in combating angiogenesis. In tumorigenesis, neovascularization is 
important to supply the growing tumor with nutrients and to eliminate waste. Tumors 
secrete Vascular Endothelial Growth Factor (VEGF) which binds to the Vascular 
Endothelial Growth Factor Receptor 2 (VEGFR2) on the surrounding endothelium of 
blood vessels. Activation of this transmembrane receptor tyrosine kinase facilitates 
neovascularization as endothelial cells will start to proliferate and migrate to create 
new blood vessels. Attempts have been made to improve survival of glioma pa-
tients suffering from VEGFR2-associated angiogenesis using bevacizumab, an anti 
VEGF-A blocking antibody, which reduces angiogenesis and leakiness of vessels in 
perinecrotic areas of the brain tumor. Although the quality of life was improved, no 
increase in survival was measured when patients were treated with bevacizumab 
[18, 37, 110]. To suppress associated problems caused by vessel normalization, 
drug insensitivity and increased invasiveness [24, 84] due to upregulation of c-MET 
[69], trials with combined inhibition of VEGFR2 and c-MET are now being initiated. 
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The above examples illustrate that reliable and detailed diagnosis is necessary in 
combatting gliomas. Genetic characterization can be informative and and provide 
clues about the nature of deranged signalling pathways and help in the design of 
targeted drug therapies.
Molecular pathways affected in diffuse gliomas
In the last few years large large-scale DNA and RNA databases resulting from con-
sortia, such as the The Cancer Genome Atlas (TCGA), have provided insight into the 
core pathways affected in glioblastoma. Below – not necessarily in order of impor-
tance or the incidence of mutation - we will discuss the significance of these differ-
ent pathways for fundamental understanding of glioma biology and for translational 
medicine. 
P53 pathway
TP53 is one of the most commonly mutated/deleted genes in human cancers. TP53 
encodes for the protein p53 which is a transcription factor that can inhibit cell cycle 
progression, promote senescence and induce cell death. Upon oncogenic stress 
such as DNA damage, ARF, an alternate reading frame tumor suppressor, is tran-
scribed from the cyclin-dependent kinase inhibitor 2A gene (CDKN2A) and inhibits 
the E3 ubiquitin-ligase protein mouse double minute 2 homolog (MDM2). Under nor-
mal physiological conditions MDM2 targets p53 for degradation. Inhibition of MDM2 
results in stabilization of p53, which in turn can initiate transcription programs to 
either induce cell cycle arrest or force cells into apoptosis, depending on the cell 
type and magnitude of stress (for review and overview of the pathways in cancer see 
[12]). Because of the high abundance of mutant p53 protein in cancer cells it was 
first thought that p53 functioned as an oncogene. It is now well-established that such 
mutant versions of p53 contain substitutions, mostly in the DNA binding domain, that 
stabilize and inactivate the protein. Mutations in one allele of p53 are often accompa-
nied by loss of the other allele. Studies on TP53 null mice as well as humans having 
a germ-line mutations in TP53 (Li-Fraumeni Syndrome) have revealed a dramatic 
increase in the formation of neoplasms. Collectively, these findings unveil the p53 
protein as a hallmark tumor suppressor. Also proteins that regulate p53, such as 
MDM1, 2 and 4 and E3 ubiquitin ligase (reviewed in [32]), are often found mutated 
and (in)activated in cancers. In glioblastoma approximately 85% of tumors contain a 
mutation or deletion in the p53 pathway; 28% in TP53 itself, 15% in MDM1, 2, or 4, 
and 58% in CDKN2A [11].
RB pathway
Loss of the retinoblastoma protein (RB) by mutation in the RB gene was first dis-
covered as being causative for retinoblastoma, a rare and highly malignant pediatric 
cancer that develops from immature retinal cells. As such it represents the first tumor 
suppressor gene found [50]. Since this discovery RB loss has also been implicated 
in many other cancers, including glioblastoma [63]. The RB protein and its partners 
control cell cycle progression by binding to members of the E2F family of transcrip-
tion factor proteins. E2F proteins and their partner proteins form dimeric complexes 
that upon nuclear entry mediate the progression into S-phase of the cell cycle. RB 
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can disrupt the dimeric complex and bind E2F to arrest it in the cytosol, consequently 
preventing the cell from entering S-phase and thus stalling the cell in the G1 phase. 
Upon phosphorylation of RB by cyclin-dependent kinases (CDKs) in late G1 the as-
sociation with E2F is lost, allowing nuclear entry and expression of products required 
for the cell’s progression into S-phase (reviewed in [56]). In glioblastoma mutations 
and deletions in RB and especially activating mutations in CDKs are common; 79% 
of glioblastomas contain a mutation or deletion in the RB pathway. The RB protein 
itself is affected in almost 8% of the cases whereas CDK4 and CDKN2A are affected 
in 15.5% and 57.8% of glioblastoma samples, respectively [11]. CDKN2A-derived 
alternative transcripts in fact encode different proteins. When translated into ARF it 
will influence the p53 pathway, when translated into p16 (INK4A) it will inhibit CDKs 
and in turn affect the RB pathway (for an overview of the interactions between p53 
and RB pathways see [14]).
Mutations in IDH1/2
Specific mutations in types of genes that do not encode cell signaling proteins but 
for example have a metabolic role, are also a known hallmark of glioma. Prominent 
examples are mutations in IDH1 and IDH2, abnormalities which are rare in other 
pathologies, except in chondrosarcoma and acute myeloid leukemia. Nowadays, 
mutations in IDH1/2 are used as a biomolecular marker to differentiate between dif-
ferent glioma subtypes and patient outcomes. Mutations in IDH1 are most common; 
in particular the R132H missense mutation, although other amino acid changes (to 
C or G, for instance) can be found as well at that position. Occasionally mutations 
at other sites in IDH1 are reported, including the R314H inactivating mutation [60]. 
In IDH2, R172 and R140 are the hotspots [5, 118]. Normal IDH proteins form dimers 
that convert isocitrate to alpha-ketoglutarate (α-KG) while reducing NADP+ to NA-
DPH. The mutant IDH1 R132H/C/G variants have lost this function but gained the 
ability to reduce α-KG to D-2-hydroxyglutarate (D-2-HG) while oxidizing NADPH to 
NADP+ [21]. D-2-HG then inhibits α-KG dependent enzymes via competitive inhibi-
tion [117]. This results not only in altered metabolism but importantly, also in changes 
in epigenetic regulation [10]. For instance TET2 and KDM4C, two demethylating 
enzymes, are both regulated in part by α-KG. In IDH mutated tumors these two en-
zymes are inhibited resulting in DNA hypermethylation profiles and histone demeth-
ylation, which in turn inhibits cell differentiation [64]. Because mutated IDH proteins 
consume α-KG as a substrate to create D-2-HG the tumor cell becomes dependent 
on α-KG provision. Tumors almost exclusively contain heterozygous, and rarely con-
tain homozygous IDH mutations [5], Three types of dimers may then form; homo-
dimers consisting of two wildtype proteins or two mutant proteins, or a heterodimer 
consisting of a wildtype protein and a mutant protein. The wildtype protein converts 
isocitrate to α-KG and the mutant subunit converts it subsequently to D-2-HG. Next 
to converting α-KG, IDH mutant cells also have low levels of NADPH because the 
mutant proteins oxidizes NAPDH back to NADP+, significantly altering the redox 
status of the cell [60]. Furthermore, D-2-HG inhibits succinate dehydrogenase which 
alters the succinylation levels of proteins [59]. Additionally, IDH mutants lack the abil-
ity to reduce α-KG back to isocitrate, which can function as a carbon source for fatty 
acid and lipid synthesis [74, 113]. 
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In addition to these pathways in cell survival, growth and metabolism, pathways 
governed by kinases are often affected in glioma’s. More details of these pathways 
and mutations found in these proteins are discussed below.
Pathways regulating proper phosphorylation balance in the cell
RTKs and downstream pathways are affected in over 90% of glioblastomas [11]. 
RTKs are transmembrane receptors which upon binding of their cognate ligand will 
dimerize and phosphorylate one another. This phosphorylation leads to hyperacti-
vation of their kinase activity. The consequentz phosphorylation burst will affect the 
localization or activity of other proteins in the cell, ultimately leading to changes in 
the cell’s behavior. In cancer, amplification and auto-activation by mutations of these 
RTKs leads to increased downstream signaling. These signaling pathways may in-
volve multiple downstream effectors and bifurcate signals via the RAS/RAF-initiated 
mitogen-activated protein kinase (MAPK) cascade or the Phosphatidylinositol-4,5-
bisphosphate 3-kinase pathway (PI3K) that are involved in cell cycle progression 
and cell survival, respectively. 
EGFR – C-MET and PDGFR α
EGFR amplification and mutations are highly frequent in glioblastomas with aber-
rations found in 57% of the cases. Next to EGFR, mutations and amplifications can 
also be found in other RTKs such as c-MET and PDGFRα. EGFR aberrations are 
almost exclusively found in IDH WT glioblastomas, indicating that EGFR mutations 
contribute to the formation of the de novo tumor. EGFR is part of a larger family of 
RTKs consisting of EGFR, ERBB2, ERBB3, and ERBB4. All members contain an 
extracellular ligand-binding domain with two cysteine-rich regions; a transmembrane 
domain and an intracellular cytoplasmic tyrosine kinase domain. Normally upon 
binding of EGF or TGFα to EGFR, the receptor homo-dimerizes or hetero-dimerizes 
(notably with ERBB2) and phosphorylates tyrosine residues which signal towards 
other pathways such as MAPK, RAS/RAF, proto-oncogene tyrosine-protein kinase 
Src, PI3K and JAK/STAT, regulating cell survival, growth and migration (Fig. 2). Het-
erogeneity of the tumor plays a major role where not all cells within the tumor suffer 
from EGFR amplifications or mutations leading to oncogene addiction [94]. 
The c-MET tyrosine kinase can also be mutated/amplified or overexpressed in glio-
blastoma [11, 54]. The c-MET protein consists of an alpha and a beta subunit. These 
two subunits originate from a precursor protein which is post-translationally cleaved. 
The two subunits are connected via a disulfide bond to form the mature receptor 
[103]. c-MET has only two known ligands, HGF and its splicing isoforms NK1/NK2. 
Upon ligand binding, c-MET dimerizes and is transphosphorylated on tyrosine resi-
dues Y1234/Y1235 in its kinase domain and additionally on tyrosine residues Y1349 
and Y1356 [30, 61]. The latter function as docking sites for substrates such as Gab1, 
Grb2 and PI3K [90, 112]. Phosphorylation of c-MET can activate MAPK cascades as 
well as PI3K downstream signaling, leading to cell survival and invasion [39]. 
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Figure 2: Overlap in function between RTKs. Activation of RTKs by homo-dimerization and subsequent 
phosphorylation of tyrosine residues leads to downstream signaling via several key pathways that regulate 
oncogenic transformation and maintenance such as angiogenesis, proliferation, survival and migration. 
RTKs show a large overlap in the pathways they can activate, and inhibition of one could lead to activation 
of the other, complicating treatment. EGF-BS, Epidermal growth factor-binding site; IG, Immunoglobulin-
like domain. IPT, Ig-like, plexin and transcription factor domain; KD, kinase domain; PSI, domain found in 
plexins, semaphorins and integrins; TM, transmembrane domain; Tyr, tyrosine residues (can consist of 
multiple tyrosine residues scattered over the C-terminal tail, number varies per RTK); VEGF-BS, vascular 
endothelial growth factor-binding site.
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Next to the amplifications of RTK genes, resulting in highly activated RTK down-
stream effectors, most of the RTK genes mentioned above also have constitutively 
active variants as drivers of these tumors. The best-known one is EGFR variant III 
(EGFRvIII) where exons 2-7 are deleted in the gene, resulting in aberrant transcripts 
encoding a protein with a shorter extracellular domain that mediates ligand-inde-
pendent auto-activation. Also mutant PDGFRα, with deletions in the PDGFRA gene 
in exons 8-9, and the newly discovered mutant c-MET with deletions of exons 7-8 (c-
MET Δ7-8), are present in a subset of glioblastomas [11, 79]. PDGFRα Δ8-9 results 
in a deletion of an extracellular fragment responsible for receptor-receptor interac-
tions, leaving the PDGFRα Δ8-9 constitutively active [83]. The deletion of exon 7 and 
8 from the c-MET transcript results in a truncated protein that remains intracellular 
and is auto-active, leading to increased ligand-independent c-MET signaling [79]. 
PI3K/AKT pathway
Mutations in PI3Ks and inhibitory enzymes in the PI3K pathway are found with high 
frequency in glioblastoma. The PI3K enzyme family is an important relay and bal-
ance system that transduces signaling from various growth factors such as the above 
mentioned RTKs. PI3Ks can phosphorylate the hydroxyl group at the 3’ position in 
the inositol ring of phosphatidylinositol. For instance, protein kinase B, also known as 
AKT, can bind to PtdIns(3,4,5)P3 and PtdIns(3,4)P2 that results from activated PI3K. 
AKT can then be effectively translocated to the membrane. In a similar manner phos-
phoinositide-dependent kinase-1 (PDK1) is translocated to the membrane where it 
then phosphorylates AKT. When finally also the mTORC2 complex phosphorylates 
AKT, AKT is fully activated and in the position to influence its downstream processes 
such as cell growth, proliferation, survival, metabolism and autophagy [108]. An in-
tensely studied mutational event in the P13K-pathways is the inactivating deletion of 
the tumor suppressor protein PTEN found in 41% of the glioma cases. PTEN acts 
as an inhibitor on the AKT and PI3K pathway by dephosphorylating PtdIns(3,4,5)P3, 
hence counteracting PI3Ks specific activity (see further detailed explanation below). 
Furthermore, in 25% of glioblastomas mutations are found in genes encoding subu-
nits and family members of PI3K3 (e.g. PIK3CA, PIK3R1, PIK3C2G). 
The high incidence of RTK mutations in cancers, including gliomas, highlights the 
importance of the balance of phosphorylation of proteins in the cell. Deregulated 
phosphorylation may lead to increased signaling in survival and growth pathways 
(Fig. 2). Maintaining precise balance of phosphorylation and dephosphorylation of 
target tyrosine, serine and threonine residues in its proteins is thus of central impor-
tance for any cell.
Protein tyrosine phosphatases
Tight regulation of the specific phosphorylation status of proteins within the cell is 
in fact controlled by opposing kinase and phosphatase activities. Tyrosine kinases 
add a phosphate group to certain tyrosine residues on a protein and on the other 
hand the highly conserved protein tyrosine phosphatases (PTPs) dephosphorylate 
these tyrosine residues. Most phosphorylation events don’t target a single signal-
ing pathway but have effects that span across a multitude of interacting networks. 
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Kinases are thought to control the amplitude of a response whereas phosphatases 
are more involved in controlling the rate and duration of a response in a signaling 
cascade [40, 42].
PTPs are evolutionary well preserved proteins, which have a conserved region in 
their catalytic site (HCX5R) with the essential cysteine residue that is responsible for 
removing the phosphate group from phosphorylated residues. PTPs can be classi-
fied into five classes (I-V). Class I PTPs represent the largest group in which a dis-
tinction can be made between cytosolic non-receptor PTPs, transmembrane recep-
tor PTPs (RPTPs) and dual-specificity PTPs (DUSPs). The dual-specificity subgroup 
can be further divided into MAPK phosphatases (MKPs), PTEN-related (PTENs), 
phosphatase of regenerating liver (PRLs), myotubularin-related phosphatase (MT-
MRs) and atypical PTPs. The remaining four classes are much smaller and consist 
of low-molecular weight PTP (Lmw) (class II), cell division cycle (cdc25) (class III), 
eyes absent (EYA) (class IV) and the newly discovered T-cell ubiquitin ligand (TULA) 
(class V) enzymes, totaling 109 PTP genes found in the human genome [4, 105, 
106]. There is molecular evolutionary evidence to also include the arsenate reduc-
tase, rhodanese, haloacid dehalogenase (HAD) and His phosphatase (HP) families 
that also dephosphorylate tyrosine residues. However instead of the critical cysteine 
they use aspartate or histidine, respectively [3], in their active site resulting in a PTP 
superfamily of 125 protein-encoding genes (Fig. 3)
PTEN
PTEN is one of the best studied tumor suppressor genes and, as mentioned above, 
found to be often mutated in glioblastoma. PTEN was originally also named MMAC 
(mutated in multiple advanced cancers) showing that early on PTEN was recog-
nized as a tumor suppressor gene. PTEN is a dual-specificity phosphatase which 
can dephosphorylate serine/threonine and tyrosine residues. More important was 
the finding that PTEN can dephosphorylate phosphatidylinositol-3,4,5-trisphosphate 
(PIP3). Downregulation or deletion of PTEN results in increased phosphorylation of 
AKT, hence leading to increased survival signaling and stimulation of cell growth. 
Studies with mutant PTEN proteins deficient in key functions have shown that loss 
of phospholipid phosphatase activity results in the prevention of recruitment of AKT 
to the cell membrane (reviewed in [27]). Therefore AKT cannot be phosphorylated 
by its target kinases and downstream targets that are involved in cellular growth, 
proliferation and survival (for illustrations and review see [48]). PTEN, unlike many 
other phosphatases, has no closely related members which can compensate for loss 
of expression of PTEN even though there are several PTPs that show similarities 
to PTEN (legend to Fig. 3). Somatically, even a slight reduction in the expression of 
PTEN may have transforming effects [16]. Mutations and alterations in PTEN often 
suffice to induce somatic tumors in many different tissues. In PTEN knockout mice 
and patients with germline PTEN mutations who develop PTEN hamartoma tumor 
syndrome (PHTS) a wide variety of tumors is observed, but brain tumors do not 
develop. Nevertheless, Cowden Lhermitte-Duclos syndrome, caused by mutations 
in PTEN, does lead to formation of dysplastic cerebellar gangliocytoma, a WHO 
grade I CNS tumor [22]. Another important observation is that PTEN deletions have 
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been shown to occur later in tumor progression [94]. Therefore, although PTEN dele-
tion may contribute to vulnerability in gliomagenesis, it is not enough to be the sole 
cause of glioma. PTEN mutations and deletions are rarely found in IDH mut glioblas-
toma or lower-grade gliomas (reviewed in [27]). 
Next to its activity of dephosphorylating PIP3, recently other functions have been 
attributed to PTEN. One of those is PTEN’s involvement in regulating chromosomal 
integrity by increasing transcription of RAD51 and facilitating homologous recombi-
nation to repair double-stranded DNA breaks [93]. Mutations or deletions in PTEN 
therefore result in hampered double stranded break repair, leaving cancer cells more 
vulnerable to DNA damaging agents such as chemotherapy and radiotherapy [70]. 
TMZ treatment of glioblastomas results in mostly single-stranded DNA breaks [101]. 
One of the proteins that regulates single-stranded DNA break repair is PARP [72]. If 
not repaired, the single-stranded DNA breaks will develop into double-stranded ones 
in proliferating cells. Thus, by effectively hindering single-stranded DNA break repair 
in PTEN-deficient glioblastomas through PARP inhibition, a more effective irradiation 
and chemotherapy regime may be obtained. Strategies based on this principle have 
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Figure 3: Classification of protein tyrosine phosohatases. Schematic domain structure of PTPs relevant 
for this thesis are shown and their respective (sub)classes are indicated. Abbreviations; C2, protein kinase 
C conserved region 2; CA, carbonic anhydrase-like domain; Cl, class; CS, chondroitin sulfate attachment 
region; D1, catalytic active PTP domain 1; D2, catalytic inactive PTP domain 2; FERM, 4.1 protein-ezrin-
radixin-moesin domain; FNIII, fibronectin type three domain; FYVE, fab1/Yotb/Vac1p/early endosomal 
antigen-1 homology; IG, Immunoglobulin-like domain; JMD, juxta-membrane domain; KIND, kinase non-
catalytic C-lobe domain; MAM, meprin-A5-receptor protein tyrosine phosphatase mu homology domain; 
PDZ, postsynaptic density-95/discs large/ZO1 homology domain; PH-G, pleckstrin homology-“GRAM” 
domain; PTP*, protein tyrosine phosphatase catalytic inactive domain; PTP, catalytic active protein ty-
rosine phosphatase domain; RGDS, RGDS-adhesion recognition motif; SLV/TKV, terminal amino acid 
residues of PDZ binding domains.; TM, transmembrane domain. Adapted from [41].
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already been successfully exploited in the treatment of breast cancer [20]. 
Protein tyrosine phosphatase receptor z (PTPRZ) in cancer and 
glioma
Besides PTEN, other PTPs have been implicated in glioma [78] and in other cancers 
[45] and diseases [105]. One typical member of the family of PTPs with a prominent 
role in glioma pathobiology is PTPRZ. PTPRZ belongs to the class I transmem-
brane receptor PTPs (RPTPs), often resembling cell-adhesion molecules in their 
extracellular domains. In the intracellular section RPTPs usually have two phos-
phatase domains: D1 and D2, where D2 usually lacks the crucial cysteine and can-
not dephosphorylate tyrosine residues (Fig. 3). However D2 is thought to be impor-
tant in regulating enzyme activity, stability and specificity [105] (see below). PTPRZ’s 
activity can be ligand controlled, for instance by pleiotrophin. Ligand binding leads to 
dimerization and this leads to blocking of an active site from one PTPRZ molecule 
by the other PTPRZ molecule [36, 67]. This is in contrast to RTKs, where ligand–in-
duced dimerization leads to activation of the kinase molecules [57]. 
PTPRZ structure
The gene PTPRZ1 encodes three PTPRZ protein isoforms; PTPRZ-A, PTPRZ-B and 
phosphacan [52, 66, 68]. All isoforms share an N-terminal carbonic anhydrase-like 
domain (CA) and a fibronectin type III domain (FNIII). A spacer with sites for chon-
droitin sulfate proteoglycan attachment is only present in PTPRZ-A and phosphacan. 
Isoform PTPRZ-B contains a small extracellular domain that lacks this spacer and 
consequently only limited chondroitin sulfate chains can be added to this isoform. 
Phosphacan is secreted into the extracellular space because it contains neither the 
transmembrane nor the intracellular part present in the two other isoforms. [7, 52, 
58]. The C-terminus of the intracellular part in PTPRZ-A and PTPRZ-B contains a 
PDZ binding motif ending in the amino acid sequence SLV.
PTPRZ function in normal brain
PTPRZ has known functions in development of the brain and in oligodendrocyte 
maturation. PTPRZ is expressed abundantly in both glial cells and in neurons in 
the central nervous system, especially in oligodendrocyte precursor cells, which re-
side in the subventricular zone during early development. The extracellular form 
of PTPRZ, phosphacan, is the most abundant proteoglycan in the brain [15, 29, 
53, 55, 75]. PTPRZ can influence oligodendrocyte maturation and differentiation in 
several ways and plays a part in memory formation. Intracellularly the dephospho-
rylation of the p190RhoGAP protein by PTPRZ results in inhibition of differentiation 
of oligodendrocytes [53]. Furthermore, p190RhpGAP and its interaction with PT-
PRZ are involved in memory formation in the hippocampus in a Rho dependent 
manner [100]. PTPRZ can also modulate oligodendrocyte maturation extracellularly 
through binding to contactin-1. A complex between the two can inhibit proliferation 
of oligodendrocyte precursor cells and stimulate the differentiation into mature oligo-
dendrocytes. This interaction is mostly facilitated by phosphacan, lacking the trans-
membrane and intracellular domain [55]. Thus, these two studies [53, 55] apparently 
contradict each other; in one PTPRZ is shown to inhibit differentiation and in the 
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other it rather promotes differentiation of oligodendrocytes. This work demonstrates 
that the configuration and balance of PTPRZ isoforms is important and that different 
parts of PTPRZ have different roles. To promote maturation in early development 
the extracellular domain is important in forming the complex with contactin-1 and to 
mature oligodendrocyte from oligodendrocyte precursor cells. In later development 
the full-length, intracellular domain-containing PTPRZ isoforms can dephosphoryl-
ate p190RhoGAP and inhibit differentiation of oligodendrocytes.
Another example of how delicate the balance of proteins can be is seen in neu-
ronal outgrowth. PTPRZ on glial cells interacts with contactin-1 on neuronal cells. 
The short isoform (PTPRZ-B) promotes neuronal outgrowth while the proteoglycan 
versions (PTPRZ-A and Phosphacan) have inhibitory and repulsive effects. Con-
tactin-1 can interact with cell adhesion molecules (CAMs), which bind to the spacer 
region that is lacking in the short form. Furthermore, phosphacan can function as a 
dominant-negative version against PTPRZ-B to sequester CAMs and ECM binding 
components necessary for neuronal outgrowth [66, 75, 91]. Most of the extracellular 
interaction partners of PTPRZ can also interact with other cell recognition molecules. 
For instance, tenascin can also bind to contactin-1 and Nr-CAM can bind both pro-
teins as well (reviewed in [88]). 
PTPRZ different modes of action
The extracellular domain of PTPRZ is large and can connect different ligands to dif-
ferent parts. An important ligand of PTPRZ is pleiotrophin (PTN) [66]. Furthermore, 
the heparin-binding growth factor midkine, which has a 45% sequence identity to 
PTN, binds to PTPRZ. Both ligands bind to the chondroitin sulfate region of PTPRZ 
[65]. Binding of PTN to PTPRZ leads to interaction with integrin receptor αvβ3 and 
subsequent activation of c-Src mediated signaling. Similar effects have been found 
when VEGFR2 receptor associates with integrin receptor αvβ3 upon binding of 
VEGF-A isoform VEGF165. VEGF165 is also known to bind PTPRZ and this in-
teraction can be inhibited when PTN is overexpressed. Thus, PTN and VEGF165 
compete for binding with PTPRZ to associate with αvβ3 and its subsequent signaling 
through c-Src [51]. Furthermore PTPRZ can associate with interleukin-34 at similar 
sites as PTN/midkine and VEGF165 [77]. PTPRZ and, more specifically, phospha-
can are also known to bind FGF-2, another growth factor. However, chondroitinase 
treatment did not abolish the interaction between FGF-2 and PTPRZ, suggesting 
that not the chondroitin sulfate region but the CA and/or FNIII domain is involved 
[88]. This is in contrast to PTN and midkine, which bind to the CS region. Other 
binding partners of the CA and FNIII domain are N-CAM, Ng-CAM, contactin-1 and 
tenascin C and R [2, 55, 75, 88] (Fig. 4). 
Intracellularly, PTPRZ has both a phosphatase and a scaffolding function. The former 
role involves direct interaction, whereby binding of its ligand PTN results in dimeri-
zation of the receptor and subsequent inactivation of its phosphatase domain. This 
leads to an increase of phosphorylated β-catenin [73], β-adducin [86], the Src-family 
member Fyn [85] and increased auto-activation of ALK [89]. Other direct substrates 
of PTPRZ are MAGI1 and ErbB4. ErbB4 phosphorylation is modulated by binding of 
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Figure 4: PTPRZ interacts with multiple partners, both intracellularly as well as extracellularly. Schematic 
representation of some of the known interactions of PTPRZ. Extracellularly, binding of domains of PTPRZ 
to growth factors and neuronal adhesion molecules is shown. Intracellularly, both PTPRZ’s dephospho-
rylating function as well as its scaffolding role are shown. Direct substrates of PTPRZ include fyn, paxilin, 
β-catenin, ALK and c-Src. PTPRZ’s scaffolding function is depicted in the interaction with MAGI1, where 
MAGI1 binds to the PTPRZ C-terminus and can subsequently be dephosphorylated. Furthermore, PT-
PRZ’s interaction with PSD95 and Erbb4 is shown, where PSD95 functions as a scaffolding protein to 
bring PTPRZ and Erbb4 in close enough proximity for Erbb4 dephosphorylation. Acronyms for PTPRZ 
domains are explained in the legends to Figure 3.  
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both PTPRZ and ErbB4 to protein PSD95. PSD95 functions as a scaffold, forming 
a bridge between PTPRZ and Erbb4, so PTPRZ can dephosphorylate Erbb4 [33]. 
PTPRZ binds to PDZ domain 2 in the scaffolding protein MAGI1 and subsequently 
dephosphorylates MAGI1 at tyrosine residues Y373 and Y858 [34]. Furthermore, 
PTPRZ can dephosphorylate the GTPase activating protein GIT1 [47] and  the adap-
tor protein paxillin, which localized to focal adhesions. Both proteins contain a similar 
substrate consensus sequence as found in MAGI1 [34]. 
The scaffolding function of PTPRZ partly serves in support of the enzymes’ dephos-
phorylation activity, for example as in the interaction with Erbb4 and PSD95 that was 
discussed above. But PTPRZ can also be part of scaffolding complexes that do not 
serve to dephosphorylate targets. For example, it is thought that Nr-CAM’s interac-
tion with PTPRZ, contactin-1 and the contactin-interacting protein Caspr recruits pro-
teins to the cell membrane [88]. PTPRZ contains a PDZ binding sequence ending in 
SLV whereas the Nr-CAM C-terminal sequence ends in SFV. Binding through these 
two PDZ binding motifs facilitates the formation of such a membrane-associated 
heteromeric complexes. Another example is the interaction of PTPRZ with MAGI3. 
Unlike MAGI1, MAGI3 is not dephosphorylated by PTPRZ but it can bind to its C-
terminal PDZ binding sequence with one of its five PDZ domains [1], leaving plenty 
of anchoring possibilities for other proteins having PDZ binding tails.
PTPRZ in glioma
In diffuse gliomas (both with oligodendrocytic and astrocytic phenotype) PTPRZ is 
highly overexpressed [62, 76, 107]. The same holds true for many of its binding 
partners: pleiotrophin, contactin-1 and tenascin C [25, 26, 76]. PTPRZ is involved in 
glioma cell migration as knockdown of PTPRZ resulted in a reduction of the migra-
tory potential of glioma cells [76, 107]. Overexpression of PTPRZ in glioblastoma 
cells increased migration of these cells further [62]. Knockdown of PTPRZ resulted 
in reduced tumor growth in vivo [76, 107]. PTPRZ related migration can be inhibited 
by expression of LRRC4, a leucine-rich repeat-containing synaptic adhesion protein, 
which in turn down-regulates PTPRZ expression [114]. In gliomas LRRC4 is known 
to be downregulated, further contributing to the oncogenic overexpression of PTPRZ 
[115, 119]. When LRRC4 is overexpressed in glioma it inhibits migration of glioma 
cells and normalizes RTK signaling [116]. Taken together, these findings put forward 
PTPRZ as an oncogenic contributor in glioma. Peptides against PTPRZ are now in-
cluded in a clinical trial to immunize patients against glioblastoma [23]. Blocking an-
tibodies against PTPRZ’s extracellular region have also been generated. The block-
ing antibody alone inhibited anchorage independent growth. When the antibody was 
paired with saporin, a ribosome-inactivating protein which inhibits protein synthesis, 
it reduced cell growth in vitro and in vivo. The antibody thus served in targeted deliv-
ery of the toxin [31]. Recently an inhibitor of the catalytic activity of PTPRZ has been 
constructed and it was found to reduce tumor growth, both in vitro and in vivo [35].
Many of PTPRZ’s binding partners are also involved in migration or adhesion. Tenas-
cin C can, upon binding to the FNIII domain of PTPRZ, facilitate adhesion of glioma 
cells [2]. Blocking tenascin C binding using an antibody inhibited the migratory effect 
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of tenascin C through PTPRZ [26]. Furthermore, blocking binding of tenascin C to 
the transmembrane version of PTPRZ by adding Phosphacan showed a decrease 
in adhesion [38]. The overexpression of contactin-1 in glioma cells has a repellant 
effect on cells [25]. Both contacin-1 and tenascin C expression are elevated with 
increasing malignancy in diffuse gliomas [25, 26].
Finally, even fusion transcripts of PTPRZ have been found in glioma samples (2.5%) 
[6]. Fusion transcripts occur due to translocation events in the genome; the novel 
combination of components of existing genes results in hybrid transcripts and pro-
teins that are aberrantly expressed. Translocations involving the genes PTPRZ1 and 
MET resulted in fusion transcripts that encode proteins which contain the entire c-
MET sequence N-terminally preceded by pieces of varying length of PTPRZ’s extra-
cellular domain [6, 17]. The fusion event correlated with a faster tumor progression 
and a shorter survival of patients compared to patients not carrying the translocation. 
Expression of the fusion transcript enhances cell migration and invasion in vitro [6]. 
Furthermore, expression of the transcripts upregulates expression of both PTPRZ 
and c-MET [17] and increases phosphorylation of c-MET. The fusion protein has 
similar processing and dimerization properties as c-MET and can enhance phos-
phorylation in both a HGF dependent and independent manner. It is noteworthy that, 
the larger the piece of PTPRZ in the fusion protein is, the less effect it has on phos-
phorylation of c-MET. The fusion protein only containing the tip of the N-terminus of 
PTPRZ shows the largest increase in phosphorylation of the wildtype c-MET [17]. 
 
Outline of this thesis.
It is clear that a correct balance of protein phosphorylation in the cell is important for 
maintaining normalcy in its growth and behavior. In this thesis, we present work in 
which we investigate the regulating role of PTPs and their counterparts, the RTKs, 
in diffuse glioma. Better understanding of the role that PTPs play in these tumors is 
important because they may function dually as oncogenic drivers and/or as tumor 
suppressors, thus forming an interesting class of targets for the design of novel 
therapeutic approaches. Improvement of  treatment regimes is urgently needed be-
cause patients with glioblastoma have currently a median survival of only 15 months. 
Obtaining insight in the PTP- and RTK-associated pathways can thereby provide 
help. In chapter 2 we investigate new ways to reduce the excessive phosphoryla-
tion by tyrosine kinases VEGFR and c-MET. Next to chemical inhibitors of excess 
phosphorylation we examine the potential role of PTPs in regulating tumorigenic 
pathways by assessing their expression in glioma samples. In chapter 3 we also test 
the effect of potential candidates on tumorigenicity and explore the overall relation 
between PTP expression and the malignancy grade of glioma tumors. We next fo-
cus on PTPRZ as a possible oncogene in glioma and study its mechanism of action 
using a clinically relevant glioma cell model that recapitulates the diffuse infiltrative 
character of gliomas. In chapter 4 we investigate the functions of different domains 
of PTPRZ on glioma diffuse migration and proliferation and signaling using truncated 
proteins. In chapter 5 we continue this line of research and search for interactors of 
the intracellular domains of PTPRZ that regulates glioma proliferation. In chapter 6 
we discuss the implications of the results presented in this thesis. We also provide 
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an outlook on future research strategies that will help in the further elucidation of the 
role of PTPs in glioma etiology and in the translation of new insight into novel treat-
ment opportunities. 
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Chapter 2
Effects of dual targeting of tumor cells and stroma in human glio-
blastoma xenografts with a tyrosine kinase inhibitor against c-
MET and VEGFR2.
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Abstract
Anti-angiogenic treatment of glioblastoma with Vascular Endothelial Growth Factor 
(VEGF)- or VEGF Receptor 2 (VEGFR2) inhibitors normalizes tumor vessels, result-
ing in a profound radiologic response and improved quality of life. This approach 
however does not halt tumor progression by diffuse infiltration, as this phenotype 
is less angiogenesis dependent. Combined inhibition of angiogenesis and diffuse 
infiltrative growth would therefore be a more effective treatment approach in these 
tumors. 
The HGF/c-MET axis is important in both angiogenesis and cell migration in several 
tumor types including glioma. We therefore analyzed the effects of the c-MET- and 
VEGFR2 tyrosine kinase inhibitor cabozantinib (XL184, Exelixis) on c-MET positive 
orthotopic E98 glioblastoma xenografts, which routinely present with angiogenesis-
dependent areas of tumor growth, as well as diffuse infiltrative growth. In in vitro 
cultures of E98 cells, cabozantinib effectively inhibited c-MET phosphorylation, con-
comitant with inhibitory effects on AKT and ERK1/2 phosphorylation, and cell pro-
liferation and migration. VEGFR2 activation in endothelial cells was also effectively 
inhibited in vitro. Treatment of BALB/c nu/nu mice carrying orthotopic E98 xenografts 
resulted in a significant increase in overall survival. Cabozantinib effectively inhib-
ited angiogenesis, resulting in increased hypoxia in angiogenesis-dependent tumor 
areas, and induced vessel normalization. Yet, tumors ultimately escaped cabozan-
tinib therapy by diffuse infiltrative outgrowth via vessel co-option. Of importance, in 
contrast to the results from in vitro experiments, in vivo blockade of c-MET activation 
was incomplete, possibly due to multiple factors including restoration of the blood-
brain barrier resulting from cabozantinib-induced VEGFR2 inhibition. In conclusion, 
cabozantinib is a promising therapy for c-MET positive glioma, but improving delivery 
of the drug to the tumor and/or the surrounding tissue may be needed for full activity.
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Introduction
Glioblastoma is a highly aggressive primary brain tumor that is characterized by 
extensive areas in which tumor cells diffusely infiltrate the brain parenchyma. A well-
known hallmark of this cancer type is the presence of a necrotic core, surrounded by 
a rim in which hypoxia-induced neovascularization occurs [1]. Angiogenesis in these 
areas is associated with vessel leakiness, which contributes to edema and high in-
tracranial pressure, aggravating symptoms that by themselves can be lethal. Local 
vessel leakage is exploited to diagnose glioblastoma, as it results in extravasation of 
intravenously administered contrast agents like Gd-DTPA which can be readily visu-
alized by MRI. Glioblastomas are generally operated upon to the maximum feasible 
extent, followed by radiotherapy and chemotherapy with temozolomide. Remnants 
of diffusely growing tumor cells will however inevitably result in tumor recurrence and 
median survival is currently still only 14.6 months [2]. 
It is well recognized now that inhibition of VEGF-A signaling pathways in neovas-
cular endothelial cells, either by the neutralizing antibody bevacizumab or selective 
VEGFR2 tyrosine kinase inhibitors, induces a radiological response, significantly 
reduces edema and may substantially improve quality of life [3-6]. Bevacizumab is 
now approved by the FDA for treatment of recurrent glioma. However, it has also 
become clear from a number of preclinical but also clinical studies that the diffuse 
infiltrative phenotype of glioblastomas is not sensitive to angiogenesis inhibition [5,7-
9]. We previously showed that different anti-angiogenic treatments of orthotopic E98 
xenografts (displaying both angiogenesis and diffuse infiltration [10]) affect only the 
angiogenic tumor component [8,9,11]. Apparently, anti-angiogenic therapies drive 
tumor cells to adapt a resistant, angiogenesis-independent phenotype in which tu-
mor cells obtain their blood supply entirely from pre-existent vasculature [12-16]. 
These therapies have even been suggested to increase tumor cell invasion in glioma 
and other tumor types [17,18] and this appears to be associated with induction of 
hypoxia [19]. It is therefore of major importance for effective glioma treatment that 
approaches become available that tackle diffuse infiltrative tumor growth. 
The c-MET tyrosine kinase receptor has been linked to both tumor angiogenesis and 
the invasive phenotype of glial and other tumors [19,20]. Upon binding of its ligand 
hepatocyte growth factor (HGF, scatter factor), c-MET is phosphorylated on tyrosine 
residues Y1234/1235 (kinase domain) and Y1349 and Y1356, the latter two residues 
with their surrounding amino acids functioning as docking sites for substrates such 
as Gab1, Grb2 and phosphatidylinositol 3 kinase (PI3K) [21,22]. Downstream sig-
nalling of c-MET involves important pathways including RAS/PI3K and ERK/MAPK, 
which are associated with tumorigenesis and cancer progression [23]. 
Amplification of the c-MET gene (located on chromosome 7) is seen in glioblastomas 
[24] and both c-MET and HGF are frequently overexpressed in glioma specimens 
and cell lines. HGF is a strong stimulator of in vitro glioma cell migration [25-27] and 
c-MET expression has also been demonstrated in invasive glioma cells [25]. Simul-
taneous targeting of the VEGF and c-MET pathways may therefore be an interesting 
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therapeutic approach for c-MET-positive glioblastoma because it will reduce vessel 
leakage (resulting in edema reduction) and simultaneously may reduce tumor cell 
migration and thus tumor progression. Cabozantinib (XL-184, Exelixis, South San 
Francisco, CA) is a small compound tyrosine kinase inhibitor of VEGFR2, c-MET 
and RET and has been shown to block tumor development in the RipTAG2 mouse 
model of pancreatic carcinogenesis more effectively than blockade of c-MET or 
VEGFR2 alone [19,28,29]. Cabozantinib was recently FDA-approved for treatment 
of medullary thyroid cancer.
The aim of the current work was therefore to test the effects of cabozantinib in mice 
carrying highly aggressive orthotopic E98 glioma xenografts [10]. We show that 
cabozantinib blocks vascular leakage in this c-MET positive tumor model and gives 
a significant survival benefit which was not observed in previous experiments from 
our lab with bevacizumab or other VEGFR2 inhibitors [8,9]. Interestingly, whereas 
cabozantinib completely blocked c-MET tyrosine phosphorylation in vitro in E98 cell 
cultures, phosphorylated c-MET was still present in remaining diffuse infiltrative tu-
mor areas in treated mice. We propose that the anti-VEGFR2 activity of cabozantinib 
results in a restoration of the blood-brain barrier, thereby precluding an efficient dis-
tribution of the compound to the tumor cells and reducing c-MET inhibitory activity. 
Materials and methods
Cell culture 
E98NT cells (cell line derived from E98 xenografts, described in [30]) were cultured 
in DMEM supplemented with 10% FCS and pen/strep in the presence of 5% CO2 at 
37°C. HUVECs were cultured in EBM medium, supplemented with FCS, bFGF and 
VEGF (Lonza) according to the manufacturer’s instructions.
Protein expression analysis
E98NT cells or HUVECs were plated in 6 well dishes in appropriate media at a den-
sity of 5x105  cells per well. The following day cabozantinib (0, 0.01, 0.1, 0.5, 1 and 
10 μM in DMSO) was added. After a 30 min incubation, cells were washed with ice-
cold PBS and protein extracts were generated using RIPA buffer supplemented with 
protease and phosphatase inhibitors (Roche Applied Science). Similarly, extracts 
were generated from E98NT cells treated for 24 h with 1 and 10 μM cabozantinib (for 
assaying apoptosis) and sections of snap frozen xenograft brains (approximately 
20 mg of tissue). Protein lysates were cleared by centrifugation and protein con-
centrations were measured using the BCA Protein Assay Kit (Thermo Scientific) ac-
cording to manufacturer’s instructions. Proteins (20-40 µg/lane) were subjected to 
SDS-PAGE and Western Blotting using antibodies directed against c-MET (clone 
EP1454Y, Epitomics and clone D1C2, Cell Signaling Technology (CST)), phospho-
c-MET (Y1234/1235, clone D26, CST), phospho-AKT (S473, clone D9E, CST) phos-
pho-ERK1/2 (Thr202/Tyr204, clone 20G11, CST), anti-U1-70 (to detect apoptosis, 
[31]) and α-tubulin (clone 236-10501, Molecular Probes) or γ-tubulin (clone C20, 
goat, Santa Cruz Biotechnology) as internal control. Antibodies were detected us-
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ing appropriate secondary antibodies, labeled with IRDye700 or IRDye800 infrared 
dyes. Signals were visualized and quantified when appropriate, using the Odyssey 
Infrared Imaging System (LI-COR Biosciences Odyssey Application Software ver-
sion 3.0.30). 
Dose response analysis
IC50 of cabozantinib was determined as follows: cells were plated at a concentration 
of 2x104 cells per well in 96-wells plates. The next day increasing concentrations of 
cabozantinib (in DMSO) were added to the medium. Each condition was tested in 
quadruplicate in at least three independent experiments. Metabolic activity of the 
cells was determined 4 days following start of TKI treatment by incubation with 0.5 
mg/ml MTT in PBS (Sigma-Aldrich, St. Louis, MO). After a 3.5 hr incubation at 37˚C 
formazan crystals were dissolved in MTT solvent (0.1% NP40 and 3.4 mM HCl in 
isopropanol) and optical densities were measured at 560 nm.  IC50 concentrations 
were determined using sigmoidal dose-response (variable slope) statistics and nor-
malized in GraphPad Prism. 
Cell migration assays
E98 spheroids were generated by the hanging drop method. In brief, 0.7 ml methyl-
cellulose (Sigma M6385, final concentration 1.68 mg/ml) was added to 4.3 ml E98 
cell suspension in normal culture medium (500,000 cells total) and drops of 25 µl 
containing approximately 2,500 E98 cells were seeded in a dry culture dish. The 
dish was then inverted and incubated overnight at 37°C in the presence of 5% CO2. 
The next day, individual spheroids were seeded in a matrigel-coated 96-well imaging 
culture dish (Matrigel: BD cat 356237, 96-well plates: BD falcon imaging plates cat 
353219) and grown further at 37°C and 5% CO2. Individual spheroids were photo-
graphed at t=0 h in a culture system which allows for live cell imaging, after which 
they were incubated with 0, 1 or 10 µM cabozantinib. After 24 h, wells were washed 
with PBS and cells were fixed with 4% PFA in 0.1M phosphate buffer, followed by 
DAPI staining. Fluorescent and phase-contrast images were then taken and Image 
J software was used to quantify spheroid outgrowth. Briefly, cells which had mi-
grated from the spheroids were selected automatically using a cell mask. Numbers 
of cells that had migrated out of the spheroids (n=at least 32 for each condition) 
were measured. Statistical analyses involved ANOVA and post-hoc Tukey’s Multiple 
Comparison Test.
Animals 
Athymic female BALB/c nu/nu mice (18-25 gram, age 6-8 weeks) were kept under 
specified pathogen free conditions and received food and water ad libitum. The lo-
cal Animal Experimental Committee of the Radboud University Nijmegen Medical 
Center approved all experiments. E98 glioblastoma cells derived from subcutane-
ous xenograft tumors were injected intracranially under isoflurane anesthesia  as 
described previously [10]. All efforts were made to minimize suffering. Animals were 
closely monitored by visual inspection and weighed daily from start of treatment 
(see below) and sacrificed when evident signs of tumor burden (especially weight 
loss >20%, severe neurological dysfunction) were observed. Brain, liver and kidneys 
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were harvested, and parts were formalin fixed and paraffin embedded or snap-fro-
zen in liquid nitrogen for further analysis.
Therapy 
Animals carrying E98 tumors were randomly divided into placebo and cabozantinib 
treatment groups. Treatment was started at day 12, when signs of tumor growth 
became apparent, as evidenced by the presence of edema in T2 weighted MR im-
aging. Water-suspended cabozantinib (XL184, Exelixis, South San Francisco) was 
given daily by oral gavage in doses of either 60 mg/kg (n=3) or 100 mg/kg (n=10) in 
a volume of 100 μl. A control group (n=10) received water daily by oral gavage. 
Immunohistochemistry  (IHC)
Immunohistochemical stainings were performed as described before [9]. In short, af-
ter epitope retrieval by boiling in citrate buffer (pH 6.0), 4 µm tissue sections were incu-
bated with primary antibodies against GLUT1 (Neomarkers), CD34 (clone MEC14.7, 
Hycult biotech), c-MET (clone EP1454Y, Epitomics), phospho-c-MET (Y1234/1235, 
clone D26, CST), MCT4 (clone H90, Santa Cruz), cleaved caspase 3A (clone C92-
605, BD Pharmingen) and Ki-67 (clone Sp6, Thermo Fisher Scientific). Appropriate 
biotinylated secondary antibodies were used for detection using the Avidine Biotine 
Complex (ABC) method (Vector Laboratories). Specific signals were visualized by 
staining with 3-amino-9-ethyl-carbazole (AEC, Scytek Laboratories) or 3,3’-diamin-
obenzidine (Power-DAB, ImmunoLogic) solution. All sections were counterstained 
with haematoxylin and mounted in Imsol Mounting medium (Klinipath B.V.). 
Image analysis
Cell proliferation, hypoxia and vessel densities were quantified using KS400 soft-
ware (Carl Zeiss AG, Germany) with a custom-written macro on images acquired on 
a Zeiss Axioskop II microscope coupled to a CCD-RGB camera. For proliferation, 
five random non-overlapping diffuse infiltrative or compact tumor containing micro-
scopic fields (magnification x200) were analyzed per section. Compact and diffuse 
areas were recognized by gross histology, with compact areas being present in the 
ventricles or leptomeninges, and diffuse areas defined by the intermittent presence 
of white matter tracts in H&E staining.  The proliferative fraction was defined as the 
number of proliferative cells (based on Ki-67 positivity) divided by the total number 
of nuclei in a tumor region. Ratios were determined and the average value for the 
different fields per slide was used in further calculations. 
For hypoxia quantification, compact tumor areas, defined as sharply bordered re-
gions lacking normal brain parenchyma in between the tumor cells, and hypoxic 
regions (based on MCT4 positivity) were selected interactively. The hypoxic fraction 
was defined as the total hypoxic area divided by the total tumor area. 
Vessel densities were measured in GLUT-1 immunostainings and counted in 5 high 
power fields per section in both compact and diffuse areas. Since neovasculature 
in compact areas often lack blood-brain barrier characteristics (e.g. GLUT-1 expres-
sion), also CD34 stainings were performed.
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Statistical comparisons were done by normality analysis, followed by a Student’s 
t-test (two-sided) using GraphPad Prism v4. For both control and 100 mg/kg cabo-
zantinib treated brains, n=10. A p value of ≤0.05 was considered as statistically sig-
nificant.
Contrast-enhanced Magnetic Resonance Imaging 
CE-MRI was performed in a 7T MR system (ClinScan, Bruker BioSpin, Ettlingen, 
Germany) equipped with a clinical user interface (syngo MR, Siemens, Erlangen, 
Germany). When tumor-related symptoms became apparent, animals were anes-
thetized using 1-2% isoflurane in a 70% N2O and 30% O2 mixture and placed in 
a prone position in an MR cradle. Breathing was monitored throughout the MR ex-
periment and the animals’ core temperature was maintained at 37.5°C using a con-
tinuous flow of warm air (SA Instruments, Inc., Sunny Brook, NY, USA). Anatomical 
references were acquired using a multi-slice localizer with slices in the three main 
orthogonal directions. A turbo spin echo sequence with following settings were used: 
repetition time (TR) 3880 ms, echo time (TE) 43 ms and a turbo factor of 7. The 
scans had a resolution of 98 μm in-plane and a thickness of 0.7 mm per slice. A 
bolus of 0.2 ml of Gd-DTPA (20 mM, Magnevist®, Schering, Germany) was injected 
intravenously via a pre-inserted tail vein catheter and additional sets of T1-weighted 
images were acquired 2-3 minutes after injection.
Results
Elevated expression of c-MET in glioma specimens has been documented by sev-
eral groups. Whereas up to 35% of primary gliomas overexpress this RTK, this per-
centage increases to up to 75% in recurrent glioblastomas [32]. Often, heterogene-
ity in c-MET expression is found between tumor cells [33] and some papers have 
reported on the expression of c-MET on endothelial cells too [34]. This is especially 
interesting since multi-targeted tyrosine kinase inhibitors such as cabozantinib have 
been developed that have specificity against both VEGFR2 and c-MET. 
In the past we have established a number of glioblastoma xenograft lines by either 
subcutaneous or direct intracerebral implantation of surgically derived tumor cell 
suspensions in immunodeficient mice, which are subsequently maintained by se-
rial transplantation [10]. One xenograft line that has been extensively analyzed for 
its response to anti-angiogenic treatment is E98. This line routinely presents with 
diffuse tumor growth in the brain parenchyma, using co-opted blood vessels and 
white matter tracts as scaffold. The presence of additional areas of angiogenesis-
dependent growth makes this model of high translational relevance for testing of 
targeted therapies. Western blot analysis using c-MET and phospho-c-MET specific 
antibodies (recognizing the phospho-tyrosines Y1234 and Y1235) revealed that only 
E98 xenografts express significant amounts of the activated receptor, consistent 
with our observation that chromosome 7 is amplified in this xenograft line  (Figure 
1A and [10]). IHC analysis confirmed c-MET expression in E98, showing expression 
in all tumor cells (note that the non-stained structures in Figure 1D correspond to 
white matter tracts, as is clear from H&E staining of the serial section in Figure 1B). 
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IHC using the phospho-specific anti-c-MET antibody also confirmed the presence of 
activated c-MET, although in a heterogeneous fashion, being present predominantly 
in diffuse infiltrating tumor cells in the corpus callosum and adjacent white matter 
(Figure 1E, arrow and 1F). Furthermore, activated c-MET was detected in a rim of 
non-infiltrative tumor cells (routinely present in this model in the leptominges and 
Figure 1 – c-MET is activated in E98 xenografts. Panel A shows a Western blot containing protein extracts 
of different xenografts as indicated (40 µg/lane) and stained with a pan and an Y1234/1235 phosphoryl-
ated (P-) c-MET specific antibody. As a loading control, γ-tubulin was included. Immunohistochemical 
analysis reveals prominent c-MET expression and activation in orthotopic E98 xenografts (C-F). Gross 
appearances of an E98 tumor are shown in C and E, while D and F show magnifications of the boxed 
areas in C and E. The H&E section in B illustrates the diffuse nature of these tumors, arrows pointing at 
white matter tracts and comparison with D shows homogeneous expression of c-MET by tumor cells. Ar-
row in E points at diffuse infiltrative tumor cells in white matter with activated c-MET, while the arrowhead 
points at a more compact paraventricular tumor area. The inset in E represents an area with compact 
leptomeningeal growth partly positive for activated c-MET. The pictures shown are representative for this 
xenograft model. Size bars: B, D, F 200 µm; C 1 mm and E 500 µm. 
Dual Targeting of Tumor Cells and Stroma in Glioma
53
2
ventricles) at the interface with normal brain parenchyma (inset in Figure 1E and not 
shown). In central regions of compact growing tumor areas c-MET was not activated 
(arrowhead in Figure 1E). 
We reasoned that the partially angiogenic character of the E98 xenograft model, in 
combination with high c-MET expression and activation in diffuse infiltrative areas 
makes this model highly relevant to study simultaneous inhibition of VEGFR2 and c-
MET signaling. First, we investigated whether cabozantinib therapy blocked c-MET 
activation in vitro. Treatment of the E98NT cell line, derived from the E98 xenograft 
model [30] resulted in an efficient and dose-dependent inhibition of c-MET phos-
phorylation after 30 minutes (Figure 2A). Downstream signaling via AKT was also 
significantly inhibited by cabozantinib (note the ~82% reduction of phosphorylated 
AKT and the accompanying decrease in phosphorylated ERK1/2 at concentrations 
higher than 0.5 µM). Consistently, cabozantinib caused a dose-dependent inhibi-
tion of proliferation in E98NT cells (Figure 2B, IC50 ~ 89 nM). Cabozantinib did not 
induce apoptosis in vitro as demonstrated by Western blot staining with anti-U1-70 
antibody (Figure 2F). In an in vitro spheroid-based cell migration assay, we observed 
that cabozantinib significantly reduced the number of E98 cells that are able to mi-
grate away from the spheroids (Figure 2C-D, p<0.001, Post-hoc Tukey’s Multiple 
Comparison Test). Thus, c-MET signals have bearing for E98 tumor cell migratory 
potential as well. These inhibitory effects can be attributed to c-MET inhibition since 
E98 cells do not express VEGFR2 (Figure 2E). The inhibitory activity of cabozantinib 
on VEGFR2 [28] was confirmed on cultures of HUVECs and was complete at con-
centrations of 10 µM (Figure 2E). 
We next subjected mice carrying established orthotopic E98 xenografts, as de-
termined by visibility of edema on T2-weighted MR imaging (see Figure 3A for an 
example) to treatment with cabozantinib. An initial pilot experiment with 60 mg/kg 
cabozantinib (n=3) resulted in a full radiologic response using Gd-DTPA enhanced 
MRI, similar to our previous observations with bevacizumab, vandetanib and suni-
tinib [7-9]. However, large invasive tumors with hypoxic compact regions (identified 
by MCT4 expression) remained present after treatment while no signs of hypoxia 
were seen in the diffuse tumor areas (not shown). There was a non-significant trend 
towards increased survival (mean survival of 19 days in control vs. 23 days in 60 
mg/kg cabozantinib treated animals). A larger group of animals (n=10) was there-
fore treated with 100 mg/kg cabozantinib, which did result in significantly prolonged 
survival compared to control-treated mice (median survival of tumor-bearing control 
mice was 20 days vs. 32 days for the 100 mg/kg cabozantinib group, log rank test 
p<0.0001, Figure 3B). All further experiments refer to this group. Prior to sacrifice, 
mice were subjected to Gd-DTPA-enhanced MRI. Treatment with 100 mg/kg cabo-
zantinib resulted, as expected, again in a complete absence of contrast enhance-
ment (Figure 3C, lower panels) despite clear presence of extensive tumor (H&E 
staining in figure 3D, note that these sections correspond to the MR scans). Upon 
100 mg/kg cabozantinib treatment, tumors generally had converted to a mainly dif-
fuse infiltrative phenotype (see figure 3D, lower panels) similar to our previous find-
ings with vandetanib and sunitinib [8,9]. In all animals limited areas of compact tumor 
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were present to varying extent and these areas were significantly more hypoxic than 
in control animals (p=0.003, see IHC for hypoxia induced monocarboxylate trans-
porter-4 (MCT4, Figure 4A-C) confirming previous observations with other angio-
genesis inhibitors [9]. Staining for GLUT-1, another marker for hypoxia, gave similar 
results (not shown). 
Figure 2 – In vitro effects of Cabozantinib on c-MET and VEGFR2 signaling. Panel A shows a Western 
blot of E98NT cell extracts (20 μg per lane) treated for 30 minutes with different concentrations of cabo-
zantinib as indicated. Protein extracts were analyzed for c-MET, phospho-c-MET, AKT, and ERK1/2, using 
α-tubulin as a loading control. B) MTT assays were done to determine the IC50 concentration of cabo-
zantinib on E98NT cells. Experiments were performed at least in triplicate. C) Effects of cabozantinib on 
cell migration. Shown are representative examples of DAPI-stained spheroids after 24 hr incubation with 
indicated concentrations. Number of outgrowing and migrating cells per spheroid are shown in panel D 
(***: p<0.001). Number of migrating cells were significantly different between groups (one-way ANOVA, 
p<0.0001). Post-hoc Tukey’s Multiple Comparison Test revealed significant differences groups as indi-
cated (***: p<0.001). E) Western blot of cell lysates of E98NT and HUVEC extracts, treated with 10 ng/ml 
VEGF with or without cabozantinib, and stained for VEGFR2, phospho-VEGFR2 and α-tubulin as an inter-
nal control. Note the absence of VEGFR2 in E98NT cells. F) Western blot of treated E98NT cell extracts 
with the anti-apoptotic antibody U1-70. Control sample consists of Jurkat cells treated with anisomycin. 
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Diffuse infiltrative tumor regions did not show signs of hypoxia in control and treated 
tumors and based on caspase stainings apoptotic cells were very infrequent, also 
in treated tumors (not shown). Both compact and more invasive tumor areas were 
analyzed for proliferation differences, based on Ki-67 positivity in IHC. The prolifera-
Figure 3 – Cabozantinib prolongs survival of mice bearing orthotopic E98- xenografts. Mice were treated 
with 100 mg/kg cabozantinib from day 12 post tumor inoculation, when tumor was detected via abnormali-
ties in T2 images (see panel A for a representative example). B) Survival curves for placebo (n=10) and 
cabozantinib (n=10) treated animals. Note that, for ethical reasons, mice were sacrificed when excessive 
weight loss and signs of neurological dysfunction occurred. Median survival was significantly different be-
tween the groups (20 and 32 days respectively, log rank test, p < 0.0001). C) Representative examples of 
T1-weighted MRI of control (upper row) and treated (lower row) E98 bearing animals before (pre) and 2-3 
minutes after (post) Gd-DTPA injection. [Post-pre]/pre represents subtracted images. Note the complete 
loss of contrast enhancement in treated animals. Panel D shows H&E staining of sections, corresponding 
to the slices shown in the MR images.  Bars: overviews 2 mm, zoom 200 μm.
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tive fraction did not differ between controls and treated tumors in diffuse infiltrative 
regions, but proliferation was significantly less in compact tumor regions after treat-
ment (p=0.04, Figure 4D-F).  
GLUT-1 is, except for hypoxic cells, also expressed on brain capillaries and can be 
utilized as a blood vessel marker in the CNS. Tumor vessel densities were quanti-
fied and did not differ in diffuse areas between treatment and placebo groups (Figure 
4G-I). Vessel densities in compact areas were difficult to quantify based on GLUT-1 
Figure 4 – In vivo effects of cabozantinib treatment in E98 xenografts.  Panels A and B show representa-
tive examples of IHC for the hypoxia marker MCT4 in control and cabozantinib-treated tumor bearing 
animals. Hypoxia in compact tumor regions is significantly increased after treatment (Students t-test, 
p=0.003, panel C). D and E show examples of Ki67 stainings in compact tumor areas. Proliferation indices 
were significantly different in these regions (Students t-test p=0.04), but no difference was detected in 
diffuse tumor areas (panel F).  Panels G and H show representative examples of GLUT-1 vessel staining. 
Automated quantification revealed no differences between vessel densities of diffuse tumor areas in con-
trol vs treated mice (I). Numbers of CD34-positive vessels were lower in cabozantinib treated mice (see 
panels J and K, arrows point at blood vessels), but these data were not quantified because vessels with-
out CD34 expression were also observed in these mice. L: Western blot analysis of protein extracts (50 
μg protein/lane), derived from cabozantinib-treated xenografts reveals a substantial, though not complete, 
reduction of c-MET phosphorylation. As a loading control, γ-tubulin was included. Immunohistochemistry 
for phospho-c-MET (Y1234/1235) also shows the presence of phosphorylated c-MET in treated animals, 
as visualized in panel K. Size bars: A-B 2 mm, D-E 100 μm,  G, H, J, K 200 μm, 
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staining because neovasculature often does not express this differentiation marker. 
Based on CD34 stainings (a marker of activated (neo)vasculature), vessel densities 
appeared lower in cabozantinib treated animals (compare Figure 4J and K), but as 
this treatment may also result in a downregulation of CD34 expression on vessels, 
these data are difficult to interpret in terms of vascular densities. It is important to re-
alize that our studies were not time-matched, making it impossible to compare tumor 
volumes in treated and control animals.
To investigate whether the remaining diffuse infiltrative tumor might be the result of 
incomplete c-MET inhibition, we prepared tumor extracts from treated and control 
animal brains and prepared Western blots. As opposed to our in vitro data, even 
dosing as high as 100 mg/kg cabozantinib (resulting in plasma levels of 30 µM [29]) 
was not able to fully prevent c-MET phosphorylation (Figure 4L) and this finding was 
confirmed with IHC for phospho-c-MET (Y1234/1235, Figure 4M). 
Discussion:
The proposed functional role of c-MET in tumor cell migration makes this receptor 
an attractive therapeutic target in c-MET positive glioblastoma. The high expression 
and activation levels of c-MET in diffuse E98 tumor areas supports the notion that 
c-MET is actively involved in tumor cell migration [20]. Targeting of c-MET may fur-
ther be beneficial as signaling from this receptor may induce and maintain the glio-
blastoma stem cell-like phenotype and therefore resistance to chemotherapy and 
radiotherapy [35]. 
 
Cabozantinib treatment of in vitro cultures of E98 cells greatly reduced phosphoryla-
tion of AKT and ERK. This was accompanied by a 50% inhibition of cell growth at 
concentrations as low as 89 nM, which is consistent with the involvement of these 
signal transducers in PI3K and MAPK signaling. In vitro migration assays showed 
potent effects of cabozantinib on single cell migration, further strengthening a role of 
c-MET in cell migration as well.
E98 tumors became largely invisible in CE-MRI under cabozantinib therapy, and 
similar phenomena have been observed in clinical studies, with a radiological re-
sponse as early as one day after start of therapy [36]. This effect of vascular nor-
malization, rendering capillaries in brain tumors impermeable to MR contrast agents 
by restoring the blood-brain barrier, is a well known phenomenon which is the result 
of VEGFR2 inhibition [7,15,37]. A reduced vessel density in compact tumor areas in 
Automated quantification revealed no differences between vessel densities of diffuse tumor areas in con-
trol vs treated mice (I). Numbers of CD34-positive vessels were lower in cabozantinib treated mice (see 
panels J and K, arrows point at blood vessels), but these data were not quantified because vessels with-
out CD34 expression were also observed in these mice. L: Western blot analysis of protein extracts (50 
μg protein/lane), derived from cabozantinib-treated xenografts reveals a substantial, though not complete, 
reduction of c-MET phosphorylation. As a loading control, γ-tubulin was included. Immunohistochemistry 
for phospho-c-MET (Y1234/1235) also shows the presence of phosphorylated c-MET in treated animals, 
as visualized in panel K. Size bars: A-B 2 mm, D-E 100 μm,  G, H, J, K 200 μm, 
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cabozantinib treated mice may also have contributed to some extent to the reduced 
visibility in CE-MRI. The persistent presence of MRI-invisible tumor confirms our 
earlier finding that the high blood vessel density in brain can accommodate tumor 
growth via vessel cooption [14], i.e. without the necessity for neovascularization.
High dose cabozantinib treatment in our study resulted in a significant improvement 
of survival. Kamoun et al. have shown that anti-angiogenic treatment of mice carry-
ing orthotopic glioma may result in improved survival by a sole reduction of edema 
[38]. In previous experiments, we examined the effects of VEGFR2 inhibition by 
bevacizumab, vandetanib and sunitinib, alone or in combination. Even combinations 
of these compounds did not result in improved survival of E98-carrying mice, al-
though there seemed to be a complete blood-brain barrier restoration [9]. Therefore, 
it is likely that improved survival is the result of additional c-MET targeting.  Of note, a 
phase II trial of cabozantinib for recurrent glioblastoma also revealed clinical activity 
of this compound [36]. 
The high efficacy of cabozantinib to E98 cells in vitro contrasts with our in vivo re-
sults. Although the increased survival was unprecedented compared to previously 
used angiogenesis inhibitors, tumors could still escape therapy via diffuse growth. 
The exact contribution of c-MET during tumor progression in E98 xenografts is some-
what difficult to assess. In a recent paper an interesting explanation for increased in-
vasiveness of glioblastoma in response to VEGF inhibition has been proposed [20]. 
These authors demonstrated that c-MET activation is inhibited in glioblastoma cells 
that also express VEGFR2 in the presence of VEGF. This was suggested to be the 
result of activation of the VEGFR2-associated protein tyrosine phosphatase PTP1B, 
resulting in dephosphorylation of its target c-MET. According to this hypothesis, in-
hibition of VEGF-A releases PTP1B from the multi-receptor complex, unleashing 
c-MET and resulting in increased diffuse infiltrative tumor growth. This might compli-
cate the use of compounds like cabozantinib, as it may bear antagonistic activities in 
itself. However, it must be realized that this is only relevant for glioblastomas that are 
positive for both c-MET and VEGFR2. As E98 tumor cells do not express VEGFR2 
this hypothesis is not applicable to this model and other explanations must be found 
for the escape from therapy. 
One such alternative explanation comes from our finding that cabozantinib plasma 
concentrations of approximately 30 µM [29] did not entirely annihilate c-MET activa-
tion whereas in vitro, concentrations as low as 0.5 µM sufficed to achieve complete 
inhibition. Reduced penetration of the drug into the tumor and surrounding tissue, 
as well as reduced free concentrations of drug due to protein-binding in blood and 
tissue, may account for the apparent reduction in potency. Pharmacokinetic studies 
and measurement of steady-state levels in brain would be appropriate.
The difference between the apparent in vitro and in vivo potency of cabozantinib with 
respect to c-MET inhibition poses us with an interesting dilemma. We demonstrated 
in a previous study that the combination of vandetanib and the DNA-alkylating agent 
temozolomide was less effective than temozolomide alone [8]. This was attributed to 
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vessel normalization and concomitant ‘restoration’ of the blood-brain barrier, result-
ing in a hampered distribution of the chemotherapeutic agent to the tumor cells. To 
what extent cabozantinib can pass the blood-brain barrier is not exactly known. If 
passage would be inefficient, it may be envisioned that a short period of cabozan-
tinib treatment, enough to restore the blood-brain barrier, will result in inhibition of 
distribution of the compound to tumor cells in later stages of treatment. According to 
this hypothesis, only during the initial cabozantinib administrations, the compound 
will reach tumor cells and have anti-migratory and anti-proliferative effects. In later 
stages of tumor growth, tumor access may be limited by the restored blood-brain 
barrier, although it is likely that this block is not 100%, given that phospho-c-MET is 
still significantly reduced in treated tumors. This may indeed explain the significant 
delay in tumor growth that we observed. In this respect it would be very worthwhile to 
investigate whether sequential targeting of c-MET and VEGFR2 with monotargeted 
compounds would be more effective. Such schemes may involve giving intermittent 
cycles of c-MET inhibitor, followed by VEGFR2 inhibitors, which would effectively 
result in locking up the c-MET inhibitors in the tumor cell compartment. Such studies 
are underway in our lab.
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Comprehensive protein tyrosine phosphatase mRNA profiling 
identifies new regulators in the progression of glioma.
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Abstract
The infiltrative behavior of diffuse gliomas severely reduces therapeutic potential 
of surgical resection and radiotherapy, and urges for the identification of new drug-
targets affecting glioma growth and migration. To address the potential role of protein 
tyrosine phosphatases (PTPs), we performed mRNA expression profiling for 91 of 
the 109 known human PTP genes on a series of clinical diffuse glioma samples of 
different grades and compared our findings with in silico knowledge from 
REMBRANDT and TCGA databases. Overall PTP family expression levels appeared 
independent of characteristic genetic aberrations associated with lower grade or 
high grade gliomas. Notably, seven PTP genes (DUSP26, MTMR4, PTEN, PTPRM, 
PTPRN2, PTPRT and PTPRZ1) were differentially expressed between grade II-III gli-
omas and (grade IV) glioblastomas. For DUSP26, PTEN, PTPRM and PTPRT, lower 
expression levels correlated with poor prognosis, and overexpression of DUSP26 or 
PTPRT in E98 glioblastoma cells reduced tumorigenicity. Our study represents the 
first in-depth analysis of PTP family expression in diffuse glioma subtypes and war-
rants further investigations into PTP-dependent signaling events as new entry points 
for improved therapy.
Comprehensive PTP mRNA profiling indentifies new regulators in the progression of glioma. 
67
3
Introduction
Gliomas arise from glial (precursor) cells and represent the most frequent type of 
primary brain tumor. The vast majority is classified as diffuse gliomas, reflecting their 
infiltrative growth into the brain parenchyma along myelinated axon bundles and 
blood vessels [1, 2]. Diffuse gliomas are histopathologically graded into WHO grades 
II-IV, with grade IV astrocytoma (glioblastoma) being most malignant [3]. Their dif-
fuse infiltrative character severely complicates glioma treatment. Whereas surgery 
and radiotherapy mostly address the central part of the tumor, cells that have mi-
grated into the surrounding brain tissue remain relatively unaffected and give rise to 
recurrences. Although glioblastoma patient survival time has slightly improved over 
the past decades, the prospect with current treatment is only a median 15 months 
following diagnosis [4], urging for the development of novel drug modalities to com-
bat these tumors.
Diffuse gliomas can also be subdivided into several classes based on molecular cri-
teria. Lower grade (grade II-III) gliomas and secondary grade IV glioblastomas (aris-
ing from lower grade gliomas) display mutations in isocitrate dehydrogenase genes 
(IDH1/2) in 80% of the cases [5]. Primary glioblastomas (originating de novo) are 
wild type for IDH1 and IDH2 [6]. Presence of these mutations is now often used as 
an independent predictor of prolonged survival [7, 8]. Glioblastomas have been fur-
ther subdivided on the basis of transcriptional profiles as cancers of the pro-neural, 
neural, mesenchymal and classical subtype [9, 10]. Pro-neural glioblastomas display 
IDH1/2 mutations, whereas classical and mesenchymal gliomas often show loss of 
chromosome 10 (containing the tumor suppressor gene PTEN at 10q23), and/or 
amplification of chromosome 7 (containing the proto-oncogene EGFR at 7p12) [3]. 
Constitutively active mutant versions of receptor tyrosine kinases (RTKs), e.g. EGFR 
(EGFRvIII), PDGFRA or MET (METΔ7-8 [11]), are commonly encountered in primary 
glioblastomas [12]. As a result, in about 90% of primary glioblastomas the RTK/
RAS/PI3K signaling pathway is affected by mutations [10], underscoring deregulated 
phosphotyrosine-based signaling as a major driver in glioma etiology. 
Protein tyrosine phosphorylation is controlled via balanced actions of protein tyros-
ine kinases and protein tyrosine phosphatases (PTPs) [13]. Tumor cell biological 
research has mostly focused on the druggable kinases, and many tyrosine kinase 
genes are listed as proto-oncogenes (e.g. EGFR, MET, ERBB2, and PDGFRA) [10]. 
Consequently, investigations on the counteracting, hence potentially tumor suppres-
sive, PTPs [13, 14] lag behind. A well-known exception is PTEN [15, 16], the PTP 
family member that is mutated or deleted in 41% of primary glioblastomas [10] and 
whose tumor suppressive action is linked to its phospholipid phosphatase activity 
[17]. Although seemingly counter-intuitive, it has become clear that some PTPs (e.g. 
SHP2, DUSP6 and PTPRZ1) behave as oncogenes [18, 19]. Thus, the relevance 
of specific PTPs in certain cancer types is emerging [19, 20] but PTPome studies in 
diffuse glioma specimens are lacking so far.
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We performed expression profiling of the PTP gene family in diffuse glioma samples 
of different grades and genetic backgrounds, and found that overall PTP expression 
levels decrease with increasing glioma grade and appear independent of character-
istic genetic aberrations. Furthermore, for two of the PTPs whose expression levels 
differed consistently and significantly between lower grade (II-III) and high grade (IV, 
glioblastoma) gliomas and correlated with patient survival, we could demonstrate 
tumor suppressive activity. These findings highlight PTP impact on glioma tumori-
genicity.
Materials and methods
Tumor samples and cell lines
Analyses of patient material were performed in accordance with the guidelines of 
the local medical ethical committee of the Radboud University Medical Center, Ni-
jmegen, The Netherlands. Patient glioma samples (n=83), comprising 19 grade II, 15 
grade III and 49 grade IV tumors, were obtained from the archives of the Radboud 
University Medical Center [see Additional file 1]. Histologically normal brain control 
tissue (temporal neocortex and white matter) was obtained from surgery on epilepsy 
patients at the VU University Medical Center, Amsterdam, The Netherlands. 
HEK293FT cells were purchased from Invitrogen, LN-229 glioblastoma cells were 
from the American Type Culture Collection, and U-251 MG cells were kindly provided 
by Joost Schalkwijk (Radboudumc). Derivation and use of the xenograft-derived glio-
blastoma cell model E98 has been described elsewhere [21]. U-251 MG, LN-229, 
HEK293FT and E98 cells were cultured in high glucose Dulbecco’s Modified Eagle 
Medium (Life Technologies; cat.no.11960-044) supplemented with 10% Fetal Bovine 
Serum (PAA laboratories; Cat.no. A15-101), 4 mM glutamine and 1 mM pyruvate 
(Life Technologies), at 37 °C in a humidified incubator under 7.5% CO2.  For some 
experiments 1 μM Gefitinib (Selleck Chemicals), 4 mM 2-hydroxyglutarate (Sigma 
H8378), or DMSO (solvent control) was added 48 hrs prior to isolation.
RNA isolation
Total RNA was isolated from frozen tumor material or from cell lines. Ten 4 μm cry-
osections were homogenized in 1.3 ml RNA-Bee (Tel-Test Inc., cs104B) through 
mechanical dissociation. Next, 260 μl chloroform was added and samples were vor-
texed and incubated on ice for 15 min before being centrifuged at maximum speed 
for 15 min at 4 °C. The top clear supernatant was transferred into a new tube and 
RNA was precipitated with 1 volume of isopropanol. The RNA pellet was dissolved 
in 400 μl NSE (50 mM NaAc, pH 5.2; 0.2 % SDS; 2 mM EDTA in RNase-free water) 
and re-precipitated with 1 ml ethanol and collected by centrifugation (30 min at 4 °C, 
14,000 g). The RNA pellet was briefly air-dried and dissolved in 30 μl of RNase-free 
water. Concentrations were determined on a NanoVue plus spectrophotometer (GE 
Healthcare).
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RT-reaction
Reverse transcriptase reactions were performed using the iScripttm cDNA synthesis 
kit (Bio-Rad). RNA concentrations that were used ranged from 20 ng/μl to 2 μg/μl, 
and applied RNA and RT-mix volumes were according to the manufacturers’ specifi-
cations. Synthesis of cDNA was performed by incubating for 5 min at 25 °C, followed 
by 30 min at 42 °C and 5 min at 85 °C. Resulting cDNA samples were diluted in 
distilled water (1:3 – 1:5) and stored at -80°C until further use.
qRT-PCR
Validated qPCR primer sets for mRNA transcripts from 91 PTPs and housekeeping 
genes ACTB, CANX and PSMB (described in [22]) were purchased from Qiagen and 
SABiosciences. Transcript abundance was determined real-time in 10 μl reactions 
using SYBR GREEN (Bio-Rad) and 3 μl of the diluted cDNA samples on a CFX96TM 
system using the C1000TM Thermal Cycler (Bio-Rad). PCR reactions were initial-
ized at 95 °C for 15 minutes and followed by 40 cycles of 15 sec at 95 °C and 40 sec 
at 60 °C. To monitor primer specificity, at the end of the last cycle a melting curve 
with increments of 0.5 °C was recorded between 60 °C and 95 °C. PTP transcript 
amounts were normalized to housekeeping gene expression levels (ΔC¬t). Normali-
zation to any of three housekeeping genes gave comparable results, and values 
normalized towards ACTB are used here. The ΔCt values are presented relative to 
the transcript levels in control brain tissue, according to the ΔΔCt method of Livak 
and Schmittgen [23]. The average expression level for a given PTP was considered 
to be meaningfully different between tumor grades when p<0.05 and │ΔΔCt│>1.5.
Tissue Micro-array staining
Immunohistochemical stainings were performed on 4-μm sections of tissue micro-
arrays (TMAs) containing formalin-fixed paraffin-embedded (FFPE) glioma (lower 
grade, n=16; high grade, n=47). Slides were deparaffinised and rehydrated accord-
ing to standard methods. Heat-induced epitope retrieval (HIER) was performed in 
TRIS/EDTA buffer, pH 9 (Klinipath), for 10 minutes in a microwave oven at 180 W. 
After cooling down, endogenous peroxidase activity was blocked using 3% H2O2 
in PBS for 10 minutes at room temperature. After washing with PBS, primary anti-
bodies against PTPRZ (BD Transduction Laboratories; #610179), DUSP26 (Atlas 
antibodies; HPA018221), MTMR4 (Pierce; #Pa5-13711), or PTPRT (Ab frontier; 
#LFMA0345 clone T20-3C7) were diluted in Normal Antibody Diluent (ImmunoLogic) 
and incubated for 1 hour at room temperature. Slides were then washed with PBS 
and incubated with Poly-HRP-GAM/R/R IgG (ImmunoLogic) as secondary antibody 
for 30 minutes at room temperature prior to detection with 3,3-diaminobenzidine 
staining (Power-DAB, ImmunoLogic). All sections were counter-stained with haema-
toxylin and mounted in QuickD Mounting Medium (Klinipath). Sections were scored 
by two observers (AB and KV), after instructions and partly supervised by a neuro-
pathologist (PW), for intensity and percentage of cells stained. Samples were binned 
into three classes: high staining (high intensity staining, in the majority of tumor 
cells), medium staining (lower intensity staining, in a considerable amount of tumor 
cells) and low or no staining (low intensity or no staining, in a minor part of the tumor 
cells). For DUSP26 we defined a sample as low staining if there were positive cells 
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in the sample and as no staining if not a single stained tumor cells was present. 
Generation of cells with aberrant EGFR expression
Third generation lentiviral constructs that drive expression of wildtype (EGFR WT) 
or variant III (EGFRvIII) epidermal growth factor receptor were generated as fol-
lows. A NotI linker (self-annealed 5’- CTA GTC CGG GCG GCC GCC CGG A -3’) 
was ligated into the cleaved XbaI site in PRK5-EGFR-WT (a mammalian expression 
vector harboring wild-type human EGFR cDNA, kindly provided by Reiner Lammers, 
Tübingen, Germany). The resulting plasmid was digested using NotI and HindIII 
and the EGFR WT-encoding fragment was ligated into NotI/HindIII-digested pENTR/
NotI-XhoI [21]. EGFRvIII cDNA was obtained using primers fw: 5’- GAT ATC ACC 
ATG CGA CCC TCC GGG -3’ and rev: 5’- CAG CGG CCG CTC ATG CTC CAA TAA 
ATT CAC TG -3’ in a PCR reaction with an EGFRvIII-positive glioblastoma cDNA 
pool as template. The amplicon was digested with NotI and resulting NotI/blunt-end 
EGFRvIII cDNA was ligated into HincII/NotI-digested vector pENTR-1A (Invitrogen). 
Resulting pENTR plasmids were subjected to an LR reaction (Gateway® LR clona-
setm II Enzyme mix; Invitrogen # 11791-020) with pLenti6.2/V5-DEST as destination 
vector, and pENTR/NotI-XhoI served to generate the empty vector control. 
Lentiviruses were generated in HEK293FT cells as described earlier [21]. Small sam-
ples of virus-containing medium were diluted 1:2 with methanol to monitor viral titers 
by dot blot on nitrocellulose membranes (0.45 μM Schleicher&Schuell #401196). 
After blocking for 30 min with 3% non-fat dry milk in TBST (10 mM Tris-HCl, pH 8.0; 
150 mM NaCl; 0.1% Tween-20 (Sigma-Aldrich)) membranes were incubated with 
anti-VSV monoclonal antibody P5D4 [24] in blocking buffer for 1 hr. Membranes 
were then washed three times for 10 min in TBST and subsequently incubated 
with IRDye® 800CW-conjugated goat-anti-mouse IgG (Li-COR Biosciences, #926-
32350) for 1 hr at room temperature in the dark. Blots were analyzed using the Odys-
sey imaging system (LI-COR Biosciences). 
U-251 MG glioblastoma cells were transduced with lentiviral expression constructs 
for EGFR WT, EGFRvIII or empty vector control, and cultured in blasticidin-contain-
ing medium for 2 weeks. Resulting cell pools were cultured for 48 hrs in presence or 
absence of Gefitinib before being harvested for RNA and protein isolation. RNA was 
used for qRT-PCR as described above, to quantify transcript levels of three genes; 
PTPRT, DUSP16 and PTPRG. Proteins from cell lysates were size-separated on 
8% SDS-PAGE gels and immunoblotted as described previously [21] except that 
for detection of phosphorylation-dependent epitopes 5% Bovine Serum Albumin in 
TBST was used as blocking and incubation buffer. Primary antibodies were directed 
against EGFR (rabbit 1:2000 SC03; #1005), pTyr (mouse 1:1000 pY20; sc508), and 
GAPDH (rabbit 1:5000; Cell Signaling Technology #2118). Secondary antibodies 
were IRDye-680- or -800-conjugated goat-anti-mouse and goat-anti-rabbit antibod-
ies. Detection was performed on the Odyssey imaging system.
Generation of glioblastoma cells with PTEN deletion
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PTEN-deficient LN-229 cells were created using CRISPR/Cas9 technology and a 
previously described PTEN targeting sequence [25] aimed at the start of the coding 
sequence in exon 1 of PTEN. Oligonucleotides that contained the target sequence 
and overlapped with sequences in the receiving guide RNA expression plasmid 
(PTEN-CRISPR-1-Fw: 5’- TTT CTT GGC TTT ATA TAT CTT GTG GAA AGG ACG 
AAA CAC CGG ATC GTT AGC AGA AAC AAA -3’; PTEN-CRISPR-1-Rev: 5’- GAC 
TAG CCT TAT TTT AAC TTG CTA TTT CTA GCT CTA AAA CTT TGT TTC TGC TAA 
CGA TCC -3’) were annealed and extended using Klenow DNA Polymerase frag-
ment. The PTEN CRISPR-1 heteroduplex was introduced into the AflII-linearized 
gRNA cloning vector (a gift from George Church; Addgene plasmid # 41824 [26]) 
using Gibson assembly (New England Biolabs) according to manufacturer’s instruc-
tions. PTEN wildtype LN-229 glioma cells were transfected with a 1:1:0.1 mixture 
of the PTEN-targeting gRNA plasmid, plasmid hCas (a gift from George Church; 
Addgene plasmid # 41815 [26]), and a GFP expression plasmid (pLenti6/shSCR-
GFP [21]), respectively, using jetPRIME (Polyplus; Cat.no 114-07). Individual clones 
were derived via limiting dilution and tested for successful CRISPR/Cas9-mediated 
PTEN gene editing using a T7 endonuclease I assay. Briefly, cells were lysed (100 
mM Tris-HCl, pH 7.5; 5 mM EDTA; 0.2 % SDS; 200 mM NaCl; 100 μg/mL Proteinase 
K) overnight at 50 °C. Subsequently, samples were cleared by centrifugation (5 min, 
8,000 rpm) and DNA in the supernatant was precipitated using an equal volume 
of isopropanol, washed once with 70% ethanol, air-dried and finally dissolved in 
T10E0.1 (10 mM Tris-HCl, pH 8.0; 0.1 mM EDTA). Genomic DNA was then used 
in a PCR reaction with Q5 polymerase (NEB) containing Q5 GC enhancer accord-
ing to manufacturer’s instructions. Primers used were: PTEN-T7-fw: 5’-GGC TGG 
GAA CGC CGG AGA GT-3’ and PTEN-T7-rev: 5’-CTA TCC TAC ATC ACC CCA 
TAG GG-3’. Amplicons were purified using the NucleoSpin® Gel and PCR Clean-up 
kit (Macherey-Nagel) and subjected to a T7 endonuclease I digestion assay (NEB, 
M0302S) for 15 min according to manufacturer’s instructions. Clones displaying edit-
ed PTEN alleles were further tested for PTEN status through qRT-PCR and immuno-
blot analyses as described above. Primary antibodies used were: rabbit anti-PTEN 
(1:2,000, CST#9559), mouse anti-tubulin monoclonal E7 (1:5,000; DSHB, University 
of Iowa), and rabbit anti-pAKT-Ser473 (1:2,000; CST #4058).
PTPRT and DUSP26 expression constructs
PTPRT cDNA encompassing the full-length coding sequence was isolated from 
plasmid pGW-PTPRT (a kind gift from Jae-Ran Lee, Daejeon, Korea) using Bam-
HI and NotI, and ligated into the corresponding sites in vector pENTR/NotI-XhoI 
[21]. Similarly, plasmid pEF-HA-DUSP26 (a kind gift from Rafael Pulido, Barakaldo, 
Spain) was digested using EcoRI and XbaI and the DUSP26 open reading frame 
was ligated into pENTR/NotI-XhoI. An empty vector control (EV) was constructed 
as described above. An EGFP vector control was generated by PCR (Fw: 5’- TAT 
AGG ATC CAT GGT GAG CAA GGG CGA GG -3’; Rev: 5’- TAT ACT CGA GTT 
ACT TGT ACA GCT CGT CC -3’) using pEGFP as template, and the obtained am-
plicon was digested with BamHI and XhoI and ligated into pENTR/NotI-XhoI. All 
resulting plasmids were used in LR Gateway® reactions (Invitrogen) using pLenti6/
PGK-DEST-TagRFP [21] as destination vector. Obtained expression plasmids were 
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used in HEK293FT cells to produce lentiviruses, as described above. E98 human 
glioblastoma cells [27] were lentivirally transduced twice, and three days later further 
processed for glioma cell behavior assays.
Proliferation and migration assays
E98 cells were grown on collagen I-coated (10 µg/cm2; Invitrogen) coverslips to 
60-80% confluency over 48 hours, and incubated for 1 hr with culture medium con-
taining 10 μM EdU (5-ethynyl-2’-deoxyuridine). EdU incorporation was visualized 
using the click-iT® EdU Imaging kit (Thermo Fisher Scientific, #C10086) via the 
manufacturers’ instruction. Coverslips were mounted on microscope slides in DAPI-
containing Mowiol (Sigma-Aldrich) and images were collected on a Leica DMRA 
Fluorescence microscope, equipped with a DFC340 FX CCD camera, using 40x and 
63x objectives. DAPI- and EdU-positive nuclei were counted automatically using FIJI 
software [28].
Migration of E98 cells was assessed in spheroid outgrowth assays as follows. E98 
spheroids were generated in hanging drops using methylcellulose (12 mg/mL; Sig-
ma, M6385) in DMEM supplemented with 10% FCS (2500 cells per spheroid). The 
next day, individual spheroids were seeded in a 96-well imaging culture dish (BD 
Falcon, #353219) on top of a confluent mouse astrocyte layer in Matrigel-coated (30 
μg/mL PBS; BD Biosciences, #356237) culture wells. 24 hrs later, cells were fixed 
and fluorescent (tagRFP) images were collected. Average migration distance of cells 
from spheroids (n>37), calculated as change in radius of the spheroid over 24 hours, 
were analyzed semi-automatically using FIJI software.
In silico analyses
REpository for Molecular BRAin Neoplasia DaTa (REMBRANDT) was used to de-
termine Kaplan-Meier curves based on PTP transcript levels (as determined via 
micro-array analyses) using the online Project Betastasis representation tool (http://
betastasis.com/glioma/rembrandt/). Threshold was set at median expression for the 
respective PTP transcript. RNA-seq data from two different TCGA datasets (Brain 
Lower Grade Glioma [29] and Glioblastoma Multiforme; Provisional) were download-
ed using cBioPortal (http://www.cbioportal.org/index.do) [30, 31]. These represented 
RNA-seq data of 166 IDH1 WT glioblastoma samples, 9 IDH1 mutant glioblastoma 
samples, 221 IDH1 mutant lower grade glioma samples and 309 IDH1 WT lower 
grade glioma samples.
Statistics 
Statistical significance was tested using non-paired two-tailed Student’s t-test or 
non-parametric Kruskal-Wallis one-way analysis of variance with post-hoc Dunn’s 
Multiple Comparison Test. Patient survival data was automatically calculated by Pro-
ject Betastasis using a log-rank test. Heat map was generated in R (version 3.0.1).
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Results
Differential expression of PTP transcripts between lower grade and high grade glio-
ma samples
To investigate which members of the family of PTPs play roles in the biology of 
gliomas of different grades, we exploited a previously established and validated set 
of qPCR primers for 91 human PTP transcripts [22] to screen glioma specimens. 
Following cDNA synthesis and qPCR, PTP transcript levels were determined rela-
tive to those in control brain tissue. Strikingly, a pattern emerged showing signifi-
cantly lower overall PTP transcript levels in the glioblastoma samples as compared 
to lower grade gliomas (Figure 1a-b). In the first cohort of samples, expression lev-
els of 36 PTPs differed significantly between lower grade (WHO grade II-III; n>11) 
and glioblastoma (WHO grade IV; n>15) samples [see Additional file 2]. To validate 
these findings, a second, independent cohort was tested with these 36 primer sets 
[see Additional file 3], resulting in the identification of seven PTP genes (DUSP26, 
MTMR4, PTEN, PTPRM, PTPRN2, PTPRT and PTPRZ1) that consistently and sig-
nificantly differed in expression between lower and high grade gliomas (Figure 1c). 
To investigate whether differences in transcript levels are reflected at the protein 
level, we performed immunohistochemical (IHC) staining on tissue micro-arrays con-
taining 47 glioblastoma, 16 lower grade glioma samples and normal brain tissue. 
IHC could not be performed for PTPRN2-encoded IA-2β protein due to lack of appro-
priate antibodies. PTPRT protein levels were below detection limits in both normal 
brain tissue and in glioma tumor samples [see Additional file 4], in line with the high 
qPCR Ct values obtained for this PTP. Reduced PTEN and PTPRM protein levels 
in glioma specimens have been well documented (e.g. [19, 32]). The other PTPs 
were amenable for analysis by IHC. PTPRZ1 immunostainings revealed a clear 
membrane staining that was higher in lower grade specimens than in high grade 
counterparts (Figure 2a), substantiating our RNA data and earlier reports [19]. Im-
munodetection of MTMR4 resulted in high signals in normal brain tissue in structures 
resembling astrocytes (Figure 2b). In all samples (tumor and normal) also strong 
staining of the neuropil could be observed, with some samples additionally showing 
strong cytoplasmic staining in tumor cells (Figure 2biii). DUSP26 was detected in 
neurons and neuropil of normal brain tissue but staining was usually low or absent 
in tumor areas (Figure 2c). Low-level DUSP26 stainings were observed in 21% and 
12% of lower grade and glioblastoma samples, respectively (Figure 2d), in concord-
ance with our qPCR findings (Figure 1c). Also MTMR4 expression levels were higher 
in grade II-III gliomas than in glioblastoma samples (Figure 2d), in line with our RNA 
expression data (Figure 1c).
PTP expression patterns correlate with disease outcome
To corroborate our data, we performed in silico analysis of RNA-seq data from two 
TCGA glioma datasets and of micro-array data and survival probabilities as docu-
mented in the REMBRANDT brain tumor database. Out of the seven PTPs, all but 
PTPRZ1 had significantly lower expression levels in glioblastoma tumors as com-
pared to lower grade glioma samples (Figure 3), in agreement with our qPCR find-
ings. Especially DUSP26 and PTPRT show a very strong difference between grades. 
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Figure 1, Bourgonje et al.
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Figure 1: Seven PTP genes display significantly different expression levels in lower grade and high grade 
gliomas. a) Graph showing differential expression between lower grade (II-III) and high grade (IV) glioma 
samples for seven PTPs. PTP mRNA expression levels were determined by qRT-PCR and were normal-
ized to β-actin transcript levels and depicted relative to expression levels in histologically normal brain 
tissue. Data depicted correspond to data obtained in the first cohort of tumor samples (i.e. supplementary 
Table S1). Error bars indicate standard error of the mean (SEM). Asterisks indicate significance levels (** 
p<0.001 ***p<0.001) as determined by two-tailed Student’s t-test. b-d) Representative images of formalin-
fixed paraffin embedded specimens stained with antisera against PTPRZ1 (b), MTMR4 (c) or DUSP26 
(d). For each protein an example is given of staining of (i)  from normal brain tissue, (ii) negative or low 
intensity staining tumor area and (ii) high intensity staining. For DUPS26 a medium staining is shown in 
(iii).  e) Trichotome analysis of PTP immunopositivity in lower grade and high grade specimens.
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PTPRZ1 is in fact overexpressed in both glioma subgroups as evident by the high 
RSEM RNA expression values. 
Using the Project Betastasis online representation tool, we subdivided all available 
tumors represented in the REMBRANDT dataset into low- and high-expressing types 
on the basis of available RNA micro-array data for our set of PTPs. Kaplan-Meier 
curves revealed a strong and significant correlation between low DUSP26, PTPRT, 
PTEN and PTPRM expression and disease progression (p<0.001; Figure 4a,f,c,d). 
MTMR4, PTPRN2 and PTPRZ1 did not correlate with survival (Figure 4b,e,g). Also 
within the individual histological types (oligodendroglioma (grade II-III), astrocytoma 
(grade II-III) and glioblastoma (grade IV)) we observed expression-dependent sur-
vival probabilities for DUSP26 and PTPRT (data not shown). PTEN expression cor-
related with survival probability in glioblastoma and astrocytoma samples, while for 
PTPRM such an expression-dependent effect only holds for glioblastoma specimens 
(data not shown).
Characteristic genetic aberrations in gliomas do not drive PTP expression
Strikingly, for 80 out of the 91 PTP genes a pattern emerged showing lower transcript 
levels in the glioblastoma samples as compared to lower grade gliomas (Figure 1a-
b). This raises the question whether general PTP profiles are influenced by char-
acteristic genetic alterations associated with lower grade glioma (frequently IDH-
mutant) or glioblastoma (e.g. EGFR amplification; PTEN deletion) or rather reflect 
the tumor pathogenesis, including cell of origin. To test this, U-251 MG glioblastoma 
cells were lentivirally transduced to over-express EGFR or EGFRvIII. Phosphoryla-
tion of EGFR and EGFRvIII was readily detected in the transduced cells and was 
effectively blocked by treatment with the EGFR inhibitor Gefitinib (Figure 5a). The 
increased EGFR signaling, however, did not influence expression levels of three 
representative PTPs (DUSP16, PTPRG and PTPRT; Figure 5c) that displayed the 
grade-related expression pattern as observed for the majority of the PTP cohort 
(Figure 1a-b). 
PTEN-inactivating deletions or mutations represent another common aberration in 
primary glioblastoma samples and could potentially explain the pattern observed 
on the PTP transcripts. To genocopy PTEN loss, the PTEN WT glioblastoma cell 
line LN-229 was subjected to CRISPR/Cas9-mediated genome editing and resulting 
clones were inspected for PTEN levels and activity, respectively, as witnessed by 
PTEN and phospho-AKT levels under low-serum conditions (Figure 5b). Although 
we successfully generated PTEN-deficient LN-229 derivates and appropriate con-
trols, no significant changes in expression levels were observed for the three repre-
sentative reporter PTPs that were tested (Figure 5d). 
We also monitored epigenetic effects due to the oncometabolite 2-hydroxyglutarate 
(2-HG) that is produced in lower grade gliomas and secondary glioblastomas as a 
result of the characteristic IDH1R132H mutation and inhibits DNA and histone dem-
ethylation. Tumor-relevant levels of 2-HG were added for 48 hrs to U-251 MG (IDH1 
wild type) glioblastoma cells and potential changes in DUSP16, PTPRG and PTPRT 
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expression levels were monitored. Addition of 2-HG significantly reduced the mRNA 
levels for two out of the three PTPs measured (Figure 5e). These results are in line 
with epigenetic regulation of DUSP16 and PTPRG but do not explain the generally 
higher PTP mRNA levels in IDH-mutant low-grade gliomas. Preliminary RNAseq 
data from WT or IDH1 R132H-containing glioblastoma xenografts also do not point 
to a difference in amount of transcripts reads for DUSP16, PTPRG and PTPRT de-
pending on the IDH status (WPJL, unpublished data). Collectively, these data make 
it rather unlikely that genetic alterations characterizing lower grade glioma and glio-
blastoma subgroups are major determinants of the general PTP expression pattern 
observed (Figure 1a,b).
Figure 2, Bourgonje et al. 
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Figure 2: Immunohistochemical analysis of PTPRZ1, MTMR4 and DUSP26 expression in normal brain 
and glioma tissue. Representative images of formalin-fixed paraffin-embedded specimens stained with 
antisera against PTPRZ1 (a), MTMR4 (b) or DUSP26 (c). For PTPRZ1 and MTMR4 antisera, immu-
nostainings in (i) normal brain tissue, (ii) negative or low intensity tumor areas and (iii) high intensity tumor 
areas are provided. For anti- DUSP26 a low staining example is shown in (iii). d Trichotome (PTPRZ1, 
MTMR4) and dichotome (DUSP26) analysis of PTP immunopositivity in lower grade and high grade 
specimens. Percentages reflect the proportion of samples in the respective bin. 
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Figure 2, Bourgonje et al. 
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Figure 3: RNA-seq reveals PTP expression differences in lower grade and high grade glioblastoma. a-g) 
Dot plots showing the mean estimated fraction of transcripts per million as calculated in RSEM; (hori-
zontal black bars) and standard deviation for the indicated PTP in lower grade glioma  (triangles) or high 
grade glioblastoma (dots) tumor samples as extracted from two RNA-seq datasets in the TCGA database. 
Asterisks indicate significance levels (***p<0.001) as determined by two-tailed Student’s t-test. 
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Figure 4, Bourgonje et al. 
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Figure 4: Transcript levels of several PTPs correlate with patient survival probability. a-g) Kaplan-Meier 
analysis of glioma patient survival data according to low (red) and high (blue) PTP mRNA expression, 
obtained from microarray analyses on 524 glioma samples as present in the REMBRANDT repository. 
Insets show histograms of PTP expression distribution with the vertical black line indicating the cutoff 
point (taken at the median expression level) between low and high expressing samples. Asterisks indi-
cate significance levels (***p<0.001) calculated using the log-rank test in the Project Betastasis online 
representation tool.
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Overexpression of DUSP26 or PTPRT in E98 glioblastoma cells results in reduced 
tumorigenicity
DUSP26 and PTPRT are the most down-regulated PTPs in gliomas with highest 
grade malignancy and both show a pronounced correlation with survival probability 
(Figures 1,3,4). To test direct effects of expression on  cell behavior we overex-
pressed these PTPs in the E98 glioblastoma model [11, 21, 27, 33] and monitored 
effects on cell growth and migration (Figure 6). To facilitate tracking of success-
fully transduced E98 cells, lentiviral expression vectors were used that also carry 
a tagRFP fluorescent reporter. DUSP26 and PTPRT Protein expression of virus 
producing HEK293FT was visualized using immunoblotting [see Additional file 5]. 
Successful overexpression of DUSP26 and PTPRT in E98 cells was confirmed by 
qPCR (Figure 6a,b) and E98 cell proliferation capacity was investigated using EdU 
labeling of S-phase cells. Increased DUSP26 or PTPRT levels led to reduced EdU 
incorporation as compared to empty-vector controls (Figure 6c-d). This suppression 
EV
-c
trl
EG
FR
 W
T
EG
FR
vI
II
U251
IB:
EGFR
IB:
GAPDH
a b
pa
re
nt
al
cr
is
pr
 c
trl
cr
is
pr
 P
TE
N
 d
el
.
Figure 5, Bourgonje et al.
EV
-c
trl
EG
FR
 W
T
EG
FR
vI
II
EV
-c
trl
EG
FR
 W
T
EG
FR
vI
II
DMSO 1μM Gefitinib
IB:pY
LN229
IB:PTEN
     +
IB:Tubulin
1/32
1/16
1/8
1/4
1/2
0
2
4
8
16
32 DUSP16
PTPRG
PTPRT
 DMSO 1 µM Gefitinib
 f
o
ld
 c
h
an
g
e 
co
m
pa
re
d
 t
o
 
U
25
1 
EV
-c
tr
l
1/8
1/4
1/2
0
2
4
8
16
32 DUSP16
PTPRG
PTPRT
 f
o
ld
 c
h
an
g
e 
co
m
pa
re
d
 t
o
 
LN
22
9 
C
R
IS
P
R
 c
tr
l
2-HG 4mM
1/8
1/4
1/2
0
2
4
8
16
32 DUSP16
PTPRG
PTPRT
* *
 f
o
ld
 c
h
an
g
e 
co
m
pa
re
d
 t
o
 
U
25
1 
un
tr
ea
te
d
IB:p-AKT 
Ser473
PTEN
pAKT
0.5%FCS
1/16 1/16
c d
IB:
GAPDH
e
 CRISPR PTEN del.
Figure 5: Characteristic mutations for lower/high grade gliomas exert no overt effect on PTP expres-
sion patterns. a) Immunoblot of lysates from U-251 MG glioblastoma cells expressing wild-type EGFR, 
EGFRvIII or empty vector (EV) control. Cells were treated with the EGFR inhibitor Gefitinib (or DMSO 
as solvent control) for 48h before being lysed. Immunostaining (IB) was with antibodies against EGFR, 
phosphotyrosine (pY) or GAPDH (as loading control). b) Immunoblot analysis for PTEN and Ser473-
phosphorylated AKT levels in parental and (PTEN-targeted) CRISPR/Cas9-treated LN-229 cells. Lysates 
were prepared following 8 hrs of serum starvation (0.5%FCS), and Tubulin immunostaining served as 
loading control. c-e) Analysis of (ACTB-normalized) DUSP16, PTPRG and PTPRT transcript levels, as 
determined by qPCR, in cell models mimicking EGFR hyperactivity (c), PTEN deficiency (d) or mutant 
IDH1-mediated 2-HG exposure (e). Bars indicate mean with SEM, asterisk represents significance level 
(* p<0.05).
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of proliferation in the E98 high grade glioma model following overexpression of these 
two PTPs is in line with the observed positive correlation with patient survival data.
To also monitor potential DUSP26 or PTPRT effects on glioblastoma cell migration, 
we turned to a previously established spheroid outgrowth assay [4, 28]. Homoge-
neously-sized spheroids of lentivirally transduced E98 cells, generated using the 
hanging-drop method, were placed on a layer of mouse astrocytes and the migra-
tory performance of outgrowing fluorescent E98 cells was calculated as the change 
in radius of the spheroid over 24 hrs. As compared to GFP-expressing control cells, 
the expression of either PTPRT or DUSP26 significantly reduced migration of E98 
cells from the spheroid edge (Figure 6e-f). DUSP26 and PTPRT thus impinge on 
both growth and motility of glioblastoma cells. Collectively, these data underscore 
their involvement as tumor suppressors in glioma, in line with the mRNA profiling 
data (Figures 1,3,4). 
Discussion:
Diffuse gliomas are invariably fatal tumors, with most glioblastoma patients surviving 
only up to 15 months after diagnosis [3], stressing the need for more effective treat-
ment modalities. In this study we focused on the protein tyrosine phosphatase gene 
family as alternative entry points for treatment strategies. Seven out of ninety-one 
investigated PTPs displayed significantly different mRNA expression levels when 
comparing lower and high grade gliomas. Furthermore, for four out of these seven, 
expression levels correlated with patient survival probability, underscoring their role 
in tumor behavior. Importantly, overexpression of the two PTPs that showed the larg-
est expression difference in our qPCR and in silico analyses, DUSP26 and PTPRT, 
resulted in reduced glioblastoma cell proliferation and migration, supportive of a tu-
mor suppressive role.
In general, PTP expression levels in lower grade gliomas resembled those in nor-
mal brain tissue whereas levels in glioblastomas were generally lower. This overall 
reduction in PTP expression with increasing grade may relate to differences in the 
cell type of origin. Alternatively, it may be imposed by characteristic genetic altera-
tions acquired during glioma development. We found that experimental introduction 
of EGFR hyperactivity, or of PTEN inactivation, in a glioblastoma cell line had no 
effect on overall PTP expression patterns. Furthermore, the transcriptional impact of 
2-HG on PTP expression in IDH1 wildtype glioblastoma cells was at best opposite to 
the expected, and not able to tone down PTP mRNA levels to those in lower grade 
gliomas or normal brain tissue. These findings suggest that other differences in tu-
mor pathogenesis between lower and high grade tumors is the major determinant 
for the PTP expression pattern. The overall reduced PTP levels in glioblastomas as 
compared to histologically normal brain and lower grade tumor levels, points to PTP 
agonists as a potential option for glioblastoma treatment. 
In our screening rationale, stringent criteria led to a selection of seven PTPs that 
differed significantly in their expression between glioblastomas and lower grade glio-
mas. Our data revealing that PTEN expression was low in high grade gliomas con-
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Figure 6: DUSP26 and PTPRT suppress glioblastoma cell growth and motility. a) DUSP26 and b) PTPRT 
mRNA levels in lentivirally transduced E98 cells were determined by qRT-PCR. Expression, normalized to 
ACT-B, is given as fold change of that in GFP control cells. c) Transduced E98 cells were grown on cover-
slips for 48 hrs, pulse-labeled with EdU for 1 hr, fixed, and EdU incorporation was visualized. Representa-
tive images of DAPI, EdU and tagRFP positivity are depicted. d) Percentage of EdU-positive nuclei among 
DAPI-stained cells was determined (n>3). Error bars indicate SD and asterisks reflect confidence levels 
(ANOVA; ** p<0.01; *** p<0.001). e) Spheroids of transduced E98 cells on a confluent mouse astrocyte 
layer were incubated for 24h before being fixed. Representative images of tagRFP-expressing spheroids 
with outgrowing cells are shown for the respective constructs. f) The average radius increase (in pixels) 
due to migrating cells was calculated per spheroid from the data in e), and plotted as gray data points 
on top of the box plot for the mean with standard deviation. Asterisks indicate significance (*** p<0.001; 
Kruskal-Wallis one way analysis of variance p<0.0001).
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cords with literature data on PTEN inactivation or absence in over one-third of high 
grade gliomas, resulting in increased proliferation and survival through activation of 
the PI3K/AKT pathway [10, 34]. PTPRM has also been proposed as a glial tumor 
suppressor (e.g. [19, 32]) and is consistently down-regulated in high grade samples 
in our screen. Together with its subfamily members PTPRU and PTPRK, they are 
amongst the most frequently mutated PTPs in a number of cancer types [16, 19, 20, 
32, 35]. Some PTPs that had previously been implicated in primary glioblastoma 
etiology [19] were not selected by our screen, although some only just failed to reach 
our criteria (e.g. PTPN11, encoding SHP2). This may reflect that such PTPs could 
govern processes equally important to lower grade and high grade tumors.
We found that PTPRZ1 expression is higher in lower grade tumors than in high 
grade tumors, but in online RNA-seq data the inverse was observed. This apparent 
discrepancy may result from histopathological differences in the tumor collections. 
In the RNA-seq dataset, a third of the lower grade samples represent astrocytomas 
while in our sample cohort lower grade tumors consisted mostly of oligodendroglial 
neoplasms with 1p/19q co-deletion. PTPRZ1 is highly expressed in oligodendrocyte 
precursor cells and is involved in normal oligodendrocyte development [36, 37], thus 
providing rationale for the high PTPRZ1 expression in our sample cohort. Irrespec-
tive, PTPRZ1 expression is consistently up-regulated in all glioma specimens. We 
and others have shown that the encoded transmembrane PTP acts as an oncogene 
in gliomas [21, 38, 39] and, interestingly, two HLA-presented peptides derived from 
PTPRZ’s extracellular part are included in an experimental glioma vaccine that is 
currently explored in phase II clinical trials [40]. 
We additionally identified PTPRT, DUSP26, PTPRN2 and MTMR4 in our screen for 
glioma-relevant PTPs. PTPRT belongs to the same cell adhesion molecule-like PTP 
subfamily as PTPRM, PTPRU and PTPRK. Although compelling evidence has put 
forward PTPRT as a colon cancer susceptibility gene [20, 41–43], thus far no reports 
have linked PTPRT to gliomas. PTPRT mRNA levels are quite low in normal brain 
tissue and lower grade gliomas but are still on average 40-fold higher than those 
in high grade glioblastomas. In line with a tumor suppressive role, we found that 
PTPRT overexpression significantly suppressed glioblastoma cell proliferation and 
migration. The finding that the closely related PTPRT and PTPRM show distinct ex-
pression patterns in lower versus high grade gliomas (PTPRU just failed to reach the 
criteria in the first cohort) and correlate with patient survival, warrants further studies 
on their role in glioma-associated signaling pathways. 
DUSP26 represents a dual-specificity phosphatase, i.e. it is able to dephosphoryl-
ate not only phosphotyrosines but also phospho-serine and -threonine residues in 
substrate proteins. In neuroblastoma cells DUSP26 dephosphorylates and inhibits 
the tumor suppressor p53 [44]. Furthermore, DUSP26 amplification has been found 
in thyroid cancer, and DUSP26 knockdown impeded growth of anaplastic thyroid 
cancer cells [45]. Collectively, this indicates that DUSP26 acts as an oncogene, and 
contrasts with our observation of low DUSP26 levels in glioblastomas in comparison 
with lower grade glioma samples and normal brain tissue. Importantly, we found that 
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DUSP26 overexpression in E98 glioblastoma cells resulted in decreased growth 
and motility. Other investigators also reported on down-regulated DUSP26 levels in 
glioblastoma [46] and Tanuma and colleagues additionally provided evidence that 
DUSP26 facilitates catenin/cadherin delivery to cell-cell junction sites, hence cell-
cell adhesiveness [47]. It is becoming increasingly clear that diffuse glioma cells form 
functional networks via cell-cell contacts [48] and in such a context DUSP26 protein 
may indeed have tumor suppressive activity. Together with PTPRM and PTPRT, 
DUSP26 therefore holds promise for therapeutic intervention.
Intriguingly, PTPRN2 and MTMR4 both encode PTPs that, like PTEN, have phos-
phoinositides as substrates. PTPRN2 preferentially dephosphorylates phosphati-
dylinositol 4,5-bisphosphate (PI(4,5)P) [49] and MTMR4 prefers phosphatidylinositol 
3-phosphate (PI(3)P) [50]. Whereas the tumor suppressive impact of PTEN’s phos-
pholipid phosphatase activity is beyond doubt [51], only limited and contradicting 
data exist regarding PTPRN2 involvement in cancer. The hypermethylation of the 
PTPRN2 promoter region in glioblastomas and lung adenocarcinomas [52, 53] sug-
gests tumor suppressor roles. In contrast, high PTPRN2 expression has been re-
ported to correlate with poor clinical outcomes in breast cancer cases [54]. Further-
more, experimental down-regulation of PTPRN2 in metastatic breast cancer cells 
inhibited migratory potential and yielded smaller tumors in vivo [55], rather pointing 
to oncogenic potential. The tumor biological impact of PTPRN2 and MTMR4 may 
thus be context-dependent, and how these PTPs feed into glioma biology needs 
further investigation.
Taken together, our study – to our knowledge the first comprehensive PTP mRNA 
profiling in diffuse gliomas – highlights seven PTPs (DUSP26, MTMR4, PTEN, 
PTPRM, PTPRN2, PTPRT and PTPRZ1) of which expression decreases with in-
creasing malignancy. Largest expression differences between lower grade and high 
grade diffuse gliomas were found for DUSP26 and PTPRT. Their expression cor-
related with patient survival probability, and overexpression inhibited glioblastoma 
cell growth and motility. Together with PTPs that impinge upon cellular contacts 
(DUSP26, \PTPRZ1) and phospholipid signaling (DMTMR4, PTEN and PTPRN2) 
they provide novel cues to explore and design glioma treatment options. 
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Supplementary material
Online resource 1 : Molecular diagnosis data of glioma tumors samples.
# sample grade 1p 19q IDH1 mut EGFR EGFRvIII PTEN
1 II loss loss Yesz normal normal normal
2 II loss loss Yes normal normal normal
3 II normal normal Yes normal normal normal
4 II ND ND Yes ND ND ND
5 II loss loss No normal normal normal
6 II loss loss Yes normal normal normal
7 II loss loss Yes normal normal normal
8 II loss loss Yes normal normal normal
9 II loss partial gain Yes normal normal gain
10 II loss loss No normal normal normal
11 II loss loss Yes normal normal normal
12 II loss loss ND ND ND ND
13 II loss loss ND ND ND ND
14 II ND ND Yes ND ND ND
15 II normal normal ND normal normal normal
16 II loss loss Yes normal normal normal
17 II loss loss Yes normal normal normal
18 II ND ND ND ND ND ND
19 II loss loss Yes normal normal normal
20 III normal normal Yes normal normal loss
21 III loss loss Yes normal normal normal
22 III loss loss Yes normal normal normal
23 III loss loss Yes normal normal normal
24 III ND ND Yes ND ND ND
25 III ND ND Yes ND ND ND
26 III normal normal ND HCA variant loss
27 III ND ND Yes ND ND ND
28 III loss loss Yes normal normal normal
29 III loss loss Yes HCA normal normal
30 III ND ND No gain normal normal
31 III ND ND Yes normal normal loss
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32 III loss loss Yes normal normal normal
33 III loss loss Yes normal normal normal
34 III loss loss Yes normal normal normal
35 IV normal normal No normal normal loss
36 IV normal normal No gain normal loss
37 IV normal normal No gain normal loss
38 IV partial loss 
1p36
loss No HCA variant loss
39 IV normal partial gain No HCA variant loss
40 IV normal normal No gain normal normal
41 IV partial loss normal No HCA variant loss
42 IV loss partial loss No HCA variant loss
43 IV ND ND No ND ND ND
44 IV loss partial loss No HCA normal loss
45 IV partial loss partial gain No HCA normal HD
46 IV normal gain No HCA normal normal
47 IV partial loss partial gain/par-
tial loss
No HCA other normal
48 IV loss normal No HCA variant loss
49 IV ND ND No HCA normal normal
50 IV ND ND No ND ND ND
51 IV ND ND No ND ND ND
52 IV loss gain No HCA variant loss
53 IV ND ND No gain normal loss
54 IV ND ND No gain normal loss
55 IV ND ND No normal normal normal
56 IV ND ND No ND ND ND
57 IV ND ND No gain normal loss
58 IV ND ND No normal normal normal
59 IV ND ND No HCA variant loss
60 IV normal gain No HCA normal loss
61 IV normal gain No HCA normal loss
62 IV ND ND No HCA normal normal
63 IV normal partial loss 
19pter-q24 
No normal normal normal
64 IV normal normal No ND ND ND
65 IV normal normal No HCA variant HD
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66 IV ND ND No ND ND ND
67 IV ND ND No ND ND ND
68 IV normal normal No normal normal normal
69 IV normal partial gain No gain normal loss
70 IV normal normal No HCA variant normal
71 IV normal normal No gain normal loss
72 IV normal normal No gain normal loss
73 IV partial gain partial gain No normal normal normal
74 IV normal normal Yes normal normal normal
75 IV normal normal No gain normal normal
76 IV normal normal No HCA normal normal
77 IV normal normal No gain normal loss
78 IV normal normal No HCA variant normal
79 IV normal gain Yes normal normal normal
80 IV normal normal No normal normal loss
81 IV ND ND No normal normal normal
82 IV ND ND No ND ND ND
83 IV partial gain 
4-14
partial loss 19-21 No normal normal normal
Molecular diagnosis data as it is known for gliomas tumors samples used in the 
qPCR screen. 1p19q, EGFR, EGFRvIII and PTEN status were judged by MLPA 
data and IDH status was reviewed using specific antibody staining and subsequent 
sequencing by the diagnostic department of the Radboudumc. ND=not determined, 
HCA= high copy amplification and HD= homozygous deletion.
Online Resource 2: ΔΔCt values of 1st cohort of diffuse glioma samples run 
on 91 validated primer sets.
1st cohort
Lower grade (II-III) glioblastoma (IV) lower grade vs 
glioblastoma
Meets 
criteria
avg sem n avg sem n p-value diff
ACP1 -3.25155 0.557863 14 -4.39231 0.318133 18 0.0708 1.140767
CDC14A -1.97436 0.525319 13 -3.21579 0.232678 19 0.022413 1.24143
CDC14B -1.21846 0.356338 13 -2.00965 0.298728 19 0.100029 0.791188
CDC25A -3.74155 0.474555 14 -4.13338 0.311585 20 0.476282 0.391827
CDC25B 1.379778 0.408468 15 0.923728 0.353846 19 0.40357 0.45605
CDC25C -9.52429 0.682148 14 -9.82289 0.290424 19 0.660844 0.298609
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CDKN3 2.389936 0.749589 13 1.151574 0.507078 18 0.166087 1.238362
DUSP01 0.556218 0.34075 13 0.585046 0.328256 18 0.952823 0.028828
DUSP02 -2.98639 0.862621 12 -4.4164 0.423927 19 0.10918 1.430015
DUSP03 -1.30583 0.214426 12 -2.33185 0.200181 18 0.002029 1.026019
DUSP04 -5.37845 0.756125 14 -6.00535 0.332932 19 0.41193 0.626898
DUSP05 -7.65548 0.524687 14 -8.2555 0.507834 20 0.42939 0.600024
DUSP06 2.755972 0.804182 12 -0.02509 0.356631 18 0.001413 2.781065 *
DUSP07 -0.85692 0.354814 13 -2.68548 0.211657 19 5.34E-05 1.828559 *
DUSP08 -1.28789 0.657521 15 -0.75222 0.8871 21 0.655473 0.535667
DUSP09 -1.97403 0.721805 12 -4.23675 0.688777 21 0.041527 2.262718 *
DUSP10 -1.11405 0.490657 14 -1.25037 0.445964 18 0.83911 0.136323
DUSP11 2.601515 0.619086 11 0.71912 0.200357 18 0.001793 1.882395 *
DUSP12 3.363077 0.59329 13 1.331272 0.241018 19 0.001208 2.031805 *
DUSP14 0.100385 0.595505 13 -0.38833 0.316979 18 0.442054 0.488718
DUSP16 0.42 0.371427 12 -0.95948 0.232409 16 0.002816 1.379479
DUSP18 -7.36107 0.630275 14 -7.02454 0.680874 18 0.72621 0.336534
DUSP19 -1.73538 0.334111 13 -3.36325 0.285807 20 0.000944 1.627865 *
DUSP22 -0.54744 0.252797 13 -1.092 0.360588 20 0.277898 0.544564
DUSP23 -0.37472 0.603368 12 -0.42046 0.228557 18 0.935895 0.045741
DUSP26 -0.03712 0.4471 13 -2.90769 0.497295 18 0.000298 2.87057 *
EPM2A -0.56929 0.684909 13 -2.17883 0.943768 20 0.224354 1.609538
MTM01 -0.0859 0.322624 13 -2.01318 0.259416 16 6.59E-05 1.92728 *
MTMR02 0.261154 0.362867 13 -0.17798 0.425436 19 0.467465 0.439136
MTMR03 -0.79205 0.253864 13 -1.23658 0.40893 20 0.424227 0.444532
MTMR04 0.199487 0.338745 13 -1.93224 0.378075 19 0.000415 2.131724 *
MTMR06 -0.56295 0.324275 13 -1.86691 0.242742 17 0.002719 1.303963
MTMR07 -2.23744 0.656055 13 -5.07514 0.672648 18 0.006574 2.837703 *
MTMR08 -0.62607 0.772293 14 -1.16489 0.759163 15 0.623044 0.538817
MTMR09 -0.4891 0.335848 13 -1.79842 0.208855 19 0.0015 1.309318
MTMR10 -1.09679 0.443789 13 -3.19627 0.5258 19 0.007746 2.099477 *
MTMR11 -2.90958 0.688153 12 -0.33809 1.935293 17 0.290677 2.571495
MTMR12 -0.90917 0.235381 12 -2.69671 0.277676 18 9.09E-05 1.787546 *
PTEN 0.768889 0.499919 12 -1.66537 0.277297 18 8.33E-05 2.434259 *
PTP4A1 3.006474 0.810708 13 -0.19241 0.273705 18 0.000216 3.198882 *
PTP4A2 -0.78353 0.373092 13 -2.11523 0.335218 18 0.013505 1.331706
PTP4A3 -0.21481 0.236823 13 -0.84301 0.461602 18 0.288683 0.628202
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PTPDC1 -2.08103 0.286822 13 -2.16983 0.379175 20 0.866917 0.088808
PTPMT1 0.092692 0.344434 13 -2.12579 0.525013 19 0.003419 2.218482 *
PTPN01 -1.12356 0.817924 12 -1.57782 0.678055 18 0.673202 0.454262
PTPN02 -1.49834 0.722416 12 -1.41565 0.360869 18 0.911153 0.082694
PTPN03 -4.25103 0.513095 15 -5.42329 0.521144 20 0.126875 1.172266
PTPN04 0.014509 0.249476 15 -2.0019 0.263667 21 6.04E-06 2.016413 *
PTPN05 -3.60516 0.642601 15 -6.47111 0.664014 21 0.005054 2.865948 *
PTPN06 0.803166 0.360692 12 0.174028 0.429042 18 0.30635 0.629138
PTPN07 -0.33067 0.692397 15 1.00307 0.517463 19 0.124999 1.333742
PTPN09 0.692678 0.144811 15 -0.95554 0.532223 20 0.013224 1.64822 *
PTPN11 1.474958 0.61778 12 -1.29421 0.409221 19 0.000528 2.769169 *
PTPN12 1.07932 0.182015 15 1.142125 0.485565 20 0.915045 0.062805
PTPN13 0.075712 0.237878 14 -0.83688 0.371977 20 0.070904 0.912587
PTPN14 -0.47522 0.453636 15 -1.04804 0.378208 20 0.336503 0.572819
PTPN18 0.651222 0.608698 15 0.062083 0.515059 18 0.462405 0.589139
PTPN21 -0.38167 0.298817 14 -0.53204 0.21877 20 0.680202 0.150375
PTPN22 -1.56313 0.611956 12 -1.53804 0.588186 17 0.977191 0.025086
PTPN23 0.159583 0.685866 12 -1.62132 0.240633 19 0.007511 1.780899 *
PTPRA -0.46128 0.341797 15 -1.3556 0.208479 21 0.024257 0.894317
PTPRB 0.550536 0.31794 14 -1.29079 0.264417 20 9.54E-05 1.841327 *
PTPRC 0.971488 0.542533 14 0.644405 0.377564 21 0.612553 0.327083
PTPRD 1.396488 0.254753 14 -0.65576 0.270189 18 7.58E-06 2.052252 *
PTPRE 1.025893 0.511706 14 -1.16558 0.247028 21 0.000159 2.191468 *
PTPRF -0.39993 0.299968 12 -1.3413 0.345972 18 0.065208 0.941366
PTPRG 0.375495 0.298564 13 -0.0102 0.546258 21 0.603925 0.385694
PTPRH -3.6776 0.782694 13 -2.76467 0.503051 20 0.310795 0.912936
PTPRJ 0.449366 0.369573 13 -1.29037 0.358437 18 0.002528 1.739736 *
PTPRK 0.435372 0.508261 14 -0.27196 0.315817 20 0.221788 0.707331
PTPRM -1.24503 0.333427 16 -2.8186 0.244773 22 0.000406 1.573564 *
PTPRN -1.26161 0.812509 14 -3.52429 0.631556 20 0.033011 2.262683 *
PTPRN2 -0.27096 0.35539 15 -2.91737 0.383316 20 2.44E-05 2.646413 *
PTPRO -1.40913 0.48252 13 -3.4707 0.412299 19 0.003014 2.061574 *
PTPRQ -3.59416 0.701952 12 -2.34721 0.65876 20 0.226981 1.246948
PTPRR -2.34379 0.420771 12 -2.82475 0.383227 20 0.423885 0.480958
PTPRS 0.609453 0.287494 14 -1.04475 0.297355 20 0.000532 1.654203 *
PTPRT -0.18173 0.558499 13 -5.37245 0.681148 18 5.32E-06 5.190727 *
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PTPRU -1.70976 0.525682 15 -3.11982 0.401263 19 0.037412 1.410069
PTPRZ1 3.064411 0.22548 12 1.164667 0.415288 20 0.002179 1.899744 *
RNGTT -0.71197 0.43516 12 -2.55412 0.1851 18 0.000146 1.842151 *
SBF1 -4.17682 0.334524 11 -4.873 0.295629 20 0.149577 0.696182
SBF2 0.592087 0.416762 12 -1.31384 0.196047 18 8.39E-05 1.90593 *
SSH1 -0.26894 0.303309 12 -1.09356 0.159327 18 0.013914 0.824626
SSH2 0.33569 0.436566 13 -1.46745 0.209653 18 0.00034 1.803143 *
SSH3 -2.29922 0.471247 12 -0.75587 0.397372 21 0.021172 1.543347 *
STYX 0.095482 0.510495 13 -1.5102 0.315042 17 0.009073 1.605678 *
STYXL1 0.109339 0.375299 12 -0.44214 0.409861 21 0.375752 0.551482
TENC1 -2.42665 0.331074 13 -2.79392 0.408297 20 0.526917 0.367266
TNS1 -3.5168 0.326485 13 -4.57775 0.346491 20 0.043818 1.060949
TNS3 -0.71594 0.42453 12 -1.8937 0.223498 18 0.012332 1.177765
The relative expression of PTPs compared to histologically normal brain tumor in 
different malignancy grades lower (grade II-III) vs high grade (grade IV) diffuse glio-
mas. PTPs are arranged alphabetically. Avg ( average ΔΔ Ct
  across samples for a 
single PTP). sem (standard error of the mean of the samples in avg,  n (number of 
samples tested in the first cohort per group). This varies per PTP because expres-
sion of some PTPs is so low that only a high amount of RNA and cDNA will show a 
reliable ΔΔCt value. P-value (statistically tested using Student t-test, calculated be-
tween lower-grade and high-grade glioma samples from the previous columns). diff 
(absolute difference in ΔΔCt  between lower grade and high grade glioma samples). 
A candidate is defined as p<0.05 and |ΔΔCt|> 1.5.
Online Resource 3: ΔΔCt values of 2nd cohort of diffuse glioma samples run 
on 36 validated primer sets judged as candidates in the 1st cohort.
2nd cohort
Lower grade(II-III) glioblastoma (IV) Lower grade vs 
glioblastoma
Meets
criteria
avg sem n avg sem n p-value diff
DUSP06 2.856667 0.745139 14 1.805132 0.379352 19 0.184901 1.051535
DUSP07 -1.5205 0.225323 15 -2.06682 0.303028 16 0.162969 0.546323
DUSP09 0.047143 0.70536 14 -1.56267 0.745825 15 0.129664 1.60981
DUSP11 0.291369 0.867016 14 0.799389 0.302442 15 0.574262 0.50802
DUSP12 2.259679 0.73258 13 1.908194 0.366295 17 0.64878 0.351486
DUSP19 -0.14333 0.520413 12 -1.60921 0.361781 16 0.024477 1.465873
DUSP26 2.110476 0.642162 14 -0.51627 0.684359 16 0.009745 2.62675 *
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MTM01 -1.97095 0.596229 14 -0.70724 0.353405 16 0.070845 1.263713
MTMR04 -0.83115 0.38667 13 -2.47217 0.582182 15 0.031626 1.641013 *
MTMR07 -2.06826 0.725815 12 -3.12036 0.581401 16 0.262851 1.052101
MTMR10 -2.23991 0.435974 14 -2.25299 0.352138 17 0.981319 0.013083
MTMR12 -2.52821 0.403529 13 -1.92574 0.344054 18 0.26547 0.602464
PTEN 3.210539 0.737889 17 0.695708 0.494792 20 0.006336 2.514831 *
PTP4A1 3.113462 0.778614 13 2.745602 0.364403 18 0.643235 0.36786
PTPMT1 -0.85323 0.505893 16 -1.75818 0.729131 16 0.316014 0.904948
PTPN04 -0.13468 0.398514 14 -0.00946 0.397168 20 0.830616 0.125224
PTPN05 -2.5195 0.644852 12 -3.65596 0.763076 20 0.313182 1.136462
PTPN09 2.52591 0.525052 14 1.414042 0.300955 20 0.058452 1.111869
PTPN11 1.157402 0.782 13 -0.11224 0.246148 19 0.083074 1.269639
PTPN23 2.092238 0.735329 15 1.29297 0.790034 17 0.468531 0.799268
PTPRB -0.09375 0.40724 12 -0.10176 0.567361 18 0.991804 0.008009
PTPRD 0.815 0.424222 16 -0.02468 0.328476 18 0.12312 0.839676
PTPRE 1.91 0.397673 12 0.980219 0.44406 19 0.159192 0.929781
PTPRJ -0.0585 0.412693 13 0.552807 0.467766 19 0.36297 0.611303
PTPRM 0.241506 0.318901 15 -1.35033 0.630703 15 0.032326 1.591839 *
PTPRN -0.30016 0.501415 13 -1.51421 0.622846 18 0.163595 1.214054
PTPRN2 0.950112 0.521216 15 -0.98242 0.586004 20 0.023605 1.932529 *
PTPRO -0.13803 0.623377 15 -1.74478 0.477837 15 0.050289 1.606745
PTPRS 0.297587 0.370615 13 -0.76538 0.378555 20 0.065821 1.062962
PTPRT 2.566557 0.990977 16 -3.89536 0.613803 16 5.02E-06 6.461921 *
PTPRZ1 4.233353 0.560277 14 0.890044 0.432969 19 3.81E-05 3.343309 *
RNGTT -1.48855 0.355342 16 -1.65495 0.210277 18 0.681791 0.1664
SBF2 -0.12773 0.404277 15 -0.73711 0.205654 17 0.174211 0.609375
SSH2 0.062055 0.614237 13 -0.75294 0.3962 15 0.262849 0.815
SSH3 1.368139 0.582929 12 2.801444 0.545805 15 0.086337 1.433306
STYX 0.321298 0.60187 14 -0.25267 0.67783 15 0.534154 0.573965
The relative expression of PTPs compared to histologically normal brain tumor in 
different malignancy grades lower (grade II-III) vs high grade (grade IV) diffuse glio-
mas. PTPs are arranged alphabetically. Avg ( average ΔΔ Ct
  across samples for a 
single PTP). sem (standard error of the mean of the samples in avg,  n (number of 
samples tested in the second cohort per group. P-value (statistically tested using 
Student t-test, calculated between lower grade and high grade glioma samples from 
the previous columns). diff (absolute difference in ΔΔCt  between lower-grade and 
high-grade glioma samples). A candidate is defined as p<0.05 and |ΔΔCt|> 1.5.
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Online Resource 4, Bourgonje et al.
PTPRT
Online resource 4
Immunohistochemical staining for PTPRT on formalin-fixed paraffin-embedded ma-
terials. Three different samples stained with antiserum against PTPRT: i) histologi-
cally normal brain tissue; ii) glioma sample; iii) HEK293FT cells transfected with a 
PTPRT expression construct.
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Online resource 5
HEK293FT cells expressing lentiviral constructs for DUSP26 and PTPRT. a) Fluorescent 
images of HEK293FT cells expressing DUSP26, PTPRT, or GFP as a control, under a 
PGK promoter. Expression constructs also contained a CMV promoter-driven cassette 
for tagRFP, allowing assessment of transfection efficiency. b) Immunoblot of lysates 
from HEK293FT cells transfected with lentiviral expression constructs for DUSP26, 
PTPRT or GFP control, stained with antisera against DUSP26, PTPRT and Tubulin.
Online Resource 5, Bourgonje et al. 
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Chapter 4
Intracellular and extracellular domains of protein tyrosine phos-
phatase PTPRZ-B differentially regulate glioma cell growth and 
motility
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Abstract
Gliomas are primary brain tumors for which surgical resection and radiotherapy is 
difficult because of the diffuse infiltrative growth of the tumor into the brain paren-
chyma. For development of alternative, drug-based, therapies more insight in the 
molecular processes that steer this typical growth and morphodynamic behavior of 
glioma cells is needed. Protein tyrosine phosphatase PTPRZ-B is a transmembrane 
signaling molecule that is found to be strongly up-regulated in glioma specimens. 
We assessed the contribution of PTPRZ-B protein domains to tumor cell growth 
and migration, via lentiviral knock-down and over-expression using clinically relevant 
glioma xenografts and their derived cell models. PTPRZ-B knock-down resulted in 
reduced migration and proliferation of glioma cells in vitro and also inhibited tumor 
growth in vivo. Interestingly, expression of only the PTPRZ-B extracellular segment 
was sufficient to rescue the in vitro migratory phenotype that resulted from PTPRZ-
B knock-down. In contrast, PTPRZ-B knock-down effects on proliferation could be 
reverted only after re-expression of PTPRZ-B variants that contained its C-terminal 
PDZ binding domain. Thus, distinct domains of PTPRZ-B are differentially required 
for migration and proliferation of glioma cells, respectively. PTPRZ-B signaling path-
ways therefore represent attractive therapeutic entry points to combat these tumors.
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Introduction
Diffuse gliomas comprise a heterogeneous group of glial brain tumors that share 
high migratory potential, as evidenced by diffuse infiltration in the surrounding brain 
parenchyma along white matter tracts and blood vessels [1]. This phenotype se-
verely reduces efficacy of conventional therapeutic strategies, i.e. surgery and radio-
therapy [2]. A hallmark of the highly malignant WHO-grade-IV gliomas, with a very 
dismal prognosis of less than 15 months [3], is the additional local occurrence of an-
giogenesis. This angiogenesis has been combated using specific inhibitors in phase 
III trials, but thus far therapeutic survival benefit is lacking because the approach 
leaves the diffuse infiltrative component unaffected or even increases diffuse growth 
[4-6]. Additional treatment modalities aiming at diffuse tumor cells that escape sur-
gery and radio-chemotherapy, hence knowledge about the molecular mechanisms 
that underpin glioma cell migration and proliferation in the brain parenchyma, are 
therefore urgently needed.
Aberrant phosphotyrosine-based signaling is a hallmark of cancer, and gliomas are 
no exception; tyrosine kinase membrane receptors like EGFR, ERBB2, PDGFRA, 
MET and VEGFR2 have been implicated in glioma growth, angiogenesis and cell 
motility [7]. A role for the counter-acting protein tyrosine phosphatase (PTP) enzyme 
family [8, 9] is much less studied. There is compelling evidence that PTPs influence 
cell migration [10], especially during neuronal development [8, 9]. Several PTPs 
have been linked to carcinoma development [11, 12] and their involvement in glioma 
biology is gradually being uncovered [13]. PTEN, for example, is inactivated or ab-
sent in one-third of high-grade gliomas, resulting in increased PI3K-mediated cell 
proliferation and survival [7, 14]. For multiple additional PTPs the contribution to gli-
oma etiology, especially the diffuse infiltration in the neuropil, requires further study. 
Within the receptor-type PTP (RPTP) subfamily there is a number of transmembrane 
enzymes that resemble cell adhesion molecules, having extracellular domains that 
might engage in interactions with neighboring cells or extracellular matrix compo-
nents [8-10]. These characteristics make RPTP genes, including PTPRZ1, potential-
ly important regulators of cell motility and growth. PTPRZ1 encodes three isoforms 
(PTPRZ-A, PTPRZ-B and phosphacan) that share a carbonic anhydrase-like (CAH) 
and a fibronectin type III (FNIII) domain at the protein’s N-terminus [15]. Further-
more, a spacer with chondroitin sulfate proteoglycan attachment sites is present in 
isoforms PTPRZ-A and phosphacan. PTPRZ-B lacks most of this spacer, resulting 
in a smaller extracellular part. PTPRZ-A and PTPRZ-B have identical intracellular 
parts consisting of a catalytically active membrane-proximal and an inactive mem-
brane-distal PTP domain. The phosphacan isoform lacks these PTP domains and 
represents a secreted protein [15]. Several PTPRZ-interacting proteins have been 
identified. For instance, the extracellular ligand pleotrophin binds to and inactivates 
PTPRZ, thereby increasing the phosphorylation of intracellular substrates β-catenin 
[16], Fyn [17], β-adducin [18] and Alk [19]. Additional interaction partners include 
contactin-1, which binds to the CAH domain [20], and tenascin-C and -R that bind 
to the FNIII domain [21]. It is thought that these proteins form complexes with the 
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extracellular matrix [22] to induce and facilitate migration.
PTPRZ expression, in particular PTPRZ-B [23], is up-regulated in glioma tumor 
specimens [24-26]. PTPRZ1 knock-down in glioblastoma cell lines reduced cell mi-
gration [25] and tumor growth [27], and PTPRZ overexpression enhanced cell mi-
gration [24]. However, these cell models produce circumscribed tumors that lack 
the highly invasive phenotype when grown orthotopically [28]. Furthermore, PTPRZ 
protein domains that steer glioma cell behavior still need to be uncovered. Here we 
investigated the role of PTPRZ and its protein domains, exploiting glioma models 
that faithfully recapitulate diffuse infiltrative growth in vivo [28-30]. Lentivirus-mediat-
ed knock-down and subsequent rescue experiments revealed that PTPRZ-mediated 
effects on migration rely exclusively on its extracellular domain, whereas impact on 
proliferation depends on the intracellular carboxyl-terminal PDZ domain binding site. 
These findings identify PTPRZ as a dual entry point for glioma therapy development.
Materials and methods
Experimental details on cell lines and antibodies used, plasmid construction, lenti-
viral transduction, immuno-blotting, -precipitation and –histochemical procedures, 
peptide microarray analysis, and statistical analyses are provided as supplementary 
material.
Cell proliferation and viability assays
E98 cells were grown on collagen I-coated (10 µg/cm2; Invitrogen) coverslips to 
60-80% confluency, and incubated for 1hr with culture medium containing BrdU (50 
μM; Life Technologies, #B23151). Cells were then washed three times with PBS and 
fixated in 2% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB: 46 mM NaH2 
PO4; 354 mM Na2HPO4, pH 7.4). Subsequently, coverslips were washed with PBS 
and quenched with 50 mM NH4Cl in PBS. Cells were blocked and permeabilized 
for 1hr in blocking buffer (5% Normal Goat Serum and 0.1% Triton X-100 in PBS) 
and then incubated for 2.5hrs with anti-BrdU, anti-Ki67 or anti-cleaved Caspase 3 
antibodies in blocking buffer with added DNAseI (100 ng/mL; Roche) and MgCl2 (2.5 
mM) at 37 °C. Bound antibodies were detected with goat-anti-mouse Alexa 488 and 
goat-anti-rabbit Alexa 647 secondary antibodies in PBS. Coverslips were mounted 
on microscope slides in DAPI-containing Mowiol (Sigma-Aldrich) and images were 
collected on a Leica DMRA Fluorescence microscope, equipped with a DFC340 FX 
CCD camera, using 40x and 63x objectives. DAPI- and BrdU-positive nuclei and 
cleaved Caspase 3-positive cells were counted using FIJI software [44].
For proliferation assays, stably transduced E98 cells were seeded in triplicate in 
a 96-well microtiter plate (10,000 cells/well), and cultured in 10% FCS-containing 
DMEM. At various time points, cells were washed with PBS and fixed using 10% 
trichloroacetic acid for 1hr at 4 °C, washed with water and afterwards frozen until all 
time points were collected. Cells were then stained with 1% Sulforhodamine B (SRB; 
Sigma-Aldrich) in 1% acetic acid for 20 minutes. Plates were subsequently washed 
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with 1% acetic acid and dried at 60 °C for 3 hrs. Protein-bound SRB was then dis-
solved in 10 mM Tris (pH 10.5) and absorption was measured at 510 nm using a 
micro-plate reader (Bio-Rad). Lentivirally transduced E434 spheroids were seeded 
in a 96-well imaging plate (BD Biosciences, #353219) and allowed to settle over-
night. The next day, images were taken using a BD Pathway 855 high-content bio-
imager (BD Biosciences). Fluorescent images (TagRFP or EGFP-based) were taken 
longitudinally at days 4, 6 and 8 and the average increase in spheroid area was 
calculated automatically using FIJI software. After images had been taken on the 
fourth day, half of the medium was replenished and spheroid growth was continued.
2D and 3D migration assays
E98 spheroids were generated by the hanging-drop method. In brief, 0.7 mL methyl-
cellulose (12 mg/mL; Sigma, M6385) was added to 4.3 mL E98 cell suspension in 
DMEM supplemented with 10% FCS (500,000 cells total) and 25 µL drops were 
seeded in a dry culture dish. The dish was then inverted and incubated overnight at 
37 °C in the presence of 5% CO2. The next day, individual spheroids were seeded in 
a 96-well imaging culture dish (BD Falcon, #353219) coated with Matrigel (30 μg/mL 
PBS; BD Biosciences, #356237) and further incubated in DMEM with 10% FCS, at 
37 °C and 5% CO2. For E434, cultured spheroids were directly plated onto Matrigel-
coated wells containing B27-supplemented neurobasal medium. After 24 hrs, wells 
were washed with PBS and cells were fixed with 2% PFA in 0.1 M PB, followed by 
DAPI staining. Fluorescent images were collected on a high-content microscope 
(Leica DMI6000B) extended with a motorized x-y scanning stage (Leica EL6000 illu-
mination source), and FIJI software [44] was used to automatically quantify spheroid 
outgrowth. Briefly, cells which migrated from the spheroids were selected, coordi-
nates of each individual cell were determined, and distance from the spheroid border 
was calculated using the coordinates and radius of the spheroid. For each experi-
ment the average cell migration distance across all spheroids (n>31) was calculated.
Cell cultures in solidified Matrigel/Agarose matrices were prepared as follows. 10 
μL Matrigel and 5 μL 2% agarose (Seaplaque Agarose; Lonza #50101 in PBS) were 
mixed with 35 μL 10% FCS-containing DMEM and 50 µL of Matrigel/agarose mix 
was added to the wells of a 96-well microtiter plate which was placed on ice. One 
minute later, 50 µL cell suspension (50,000 cells) was mixed resulting in a 3D en-
vironment containing cells. Cells were imaged overnight with 10-min intervals on a 
time lapse system (Nikon Diaphot 300 with Hamamatsu C8484-05G CCD Camera, 
Okolab 4 well CO2 stage incubator and Okolab 2D time lapse software) at 37 °C and 
5% CO2 with a 10x objective. Cells were manually tracked for at least 2 hrs using 
the FIJI plug-in [44].
Intracerebral injection of spheroid-derived cells
All animal experiments were approved by the local Animal Experimental Commit-
tee of the Radboud University Medical Center. Athymic female BALB/c nu/nu mice 
(18–25 gram, age 6–8 weeks) were kept under specified pathogen-free conditions 
and received food and water ad libitum. E98 and E434 cells were grown as sphe-
roids in supplemented neurobasal medium for at least two weeks prior to orthotopic 
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injection [29]. A 20 μL cell suspension (107 cells/mL in PBS) containing a mixture 
of shSCR/GFP and shPTPRZ1/TagRFP labeled cells was injected per animal (n=5 
and 4 for E98 and E434 cells, respectively). Prior to injection, the ratio of GFP- and 
TagRFP-positive cells was determined using an EVOS fluorescence imaging sys-
tem (AMG) and FIJI Software. Animals were closely monitored and sacrificed when 
signs of tumor burden (especially weight loss and neurological dysfunction) were 
observed. Brains were harvested, and parts were either formalin-fixed and paraffin-
embedded (FFPE) or snap-frozen in liquid nitrogen, and stored for (immuno)histo-
chemical analysis.
Results
Modulation of PTPRZ-B expression levels in glioblastoma cells
In line with previous reports [24-26], high PTPRZ1 expression levels are detectable 
in glioma tumors (data not shown) and in human xenograft-derived cells in culture 
(Fig. 1). The two well-characterized glioma xenograft lines E98 and E434 [28] differ 
in their in vitro culture regimen; anaplastic oligodendroglioma-derived E434 cells 
only propagate under neurosphere growth conditions, using serum-free neurobasal 
medium [31], whereas glioblastoma-derived E98 cells additionally grow in standard 
DMEM/10%FCS as an adherent monolayer (Fig 1A). To assess PTPRZ influence on 
glioma growth and migration, lentiviral vectors for PTPRZ-B expression and PTPRZ1 
shRNA-mediated knock-down (targeting all three isoforms) were generated (sup-
plementary Fig. S1). We introduced a silent mutation in the PTPRZ-B open reading 
frame to create an shRNA-insensitive lentiviral PTPRZ-B expression construct and 
used this throughout for validation and rescue purposes. Following lentiviral trans-
duction of E98 and E434 cells with PTPRZ1 shRNA, a five- to twenty-fold reduction 
of PTPRZ1 transcript levels (Fig. 1B,C) and a five- to ten-fold drop in PTPRZ-B 
protein content (Fig. 1D,E) was obtained. As for C6 glioma cells [23], it is the short 
transmembrane variant PTPRZ-B that was detected in E98 and E434 lysates (Fig. 
1D,E). Use of the lentiviral PTPRZ-B expression vector resulted in PTPRZ-B protein 
levels that were one to three times that of the endogenous protein, also in presence 
of PTPRZ1 shRNA (Fig. 1D).
PTPRZ-B stimulates glioma cell growth in vitro
PTPRZ-B over-expression and knock-down effects on E98 and E434 cell prolifera-
tion was assessed via direct measurement of cell content and via BrdU incorporation. 
Sulforhodamine B (SRB) proliferation assays revealed that PTPRZ1 knock-down 
significantly inhibited growth of adherent E98 cells, as illustrated by an increased cell 
doubling time (Fig. 2A). Accordingly, BrdU pulse-labeling showed a significant reduc-
tion of the percentage of S-phase cells in shPTPRZ1-transduced samples (p<0.05). 
PTPRZ-B over-expression did not significantly affect E98 proliferation, in agreement 
with the modest increase in PTPRZ-B levels on immunoblot. Nevertheless, PTPRZ1 
knock-down effects were fully rescued by PTPRZ-B re-expression (Fig. 2B). 
To investigate whether observed PTPRZ1 knock-down effects are on the level of 
cell viability, apoptosis or cell cycle progression, BrdU pulse-labeled cells were im-
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munostained for BrdU, for the G1-S-G2-M marker Ki-67 and for cleaved Caspase-3. 
The percentage of apoptotic cells was less than 1% for all conditions (data not 
shown) and, with the exception of PTPRZ1 knock-down cells, approximately 20% 
of cells ended up BrdU-positive. Intriguingly, always half of the cells stained positive 
for Ki-67, even among shPTPRZ1-tranduced cells of which 10% is in S-phase (Fig. 
2B-C). This suggests that the growth impairment upon PTPRZ1 knock-down reflects 
increased duration of cell cycle time. 
Knock-down of PTPRZ1 also resulted in significantly delayed growth in E434 cells. 
Since these cells can only be propagated as spheroids, we measured proliferation 
capacity by means of the spheroid diameter (Fig 2D-E). Fluorescent protein sig-
nals in the lentivirally transduced cells were used to image spheroid size over time. 
Whereas shSCR-transduced E434 spheroids showed clear signs of growth, 
shPTPRZ1-transduced spheroids only increased a little in size.
Figure 1, Bourgonje et al. 
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Figure 1: PTPRZ1 expression or knock-down in E98 and E434 cells. A) Fluorescent images of glioma 
cells containing shSCR or shPTPRZ1 knock-down constructs carrying GFP or TagRFP fluorescent report-
ers, respectively. E98 cells were DAPI counterstained. B) PTPRZ1 mRNA levels in lentivirally transduced 
E98 cells were determined by qRT-PCR. Expression, normalized to β-actin, is given as percentage of that 
in control shRNA-expressing (shSCR) cells. EV; empty vector control. C) Normalized PTPRZ1 mRNA lev-
els in lentivirally transduced E434 spheroids, determined by qRT-PCR. D) E98 cells were lentivirally trans-
duced with expression constructs for PTPRZ-B protein or EV and/or PTPRZ1 or control (SCR) shRNAs. 
After three days, lysates were analyzed on immunoblots using PTPRZ-B (upper) and GAPDH (lower) 
antibodies. Normalized PTPRZ-B levels, relative to that in shSCR control lysates, are depicted in between 
the blot images. Molecular weight indications (in kDa) are on the left. E) Immunoblot analysis (as in D) of 
E434 lysates 72 hrs after lentiviral transduction with the indicated constructs.
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PTPRZ-B facilitates migration of E98 and E434 glioma cells 
We next investigated whether PTPRZ1 influence on cell migration [24, 25] is repre-
sented in our glioma models. Following PTPRZ1 knock-down, migration of individual 
E98 cells in a 3D Matrigel/agarose environment was significantly reduced (p<0.001), 
an effect that was rescued by expression of the shRNA-insensitive PTPRZ-B tran-
script in knock-down cells (Fig. 3A-B). To confirm this in a different setting, we gen-
erated transduced E98 spheroids using the hanging-drop method. Resulting homo-
geneously sized E98 spheroids were subsequently placed on a thin Matrigel layer 
for 24 hours and migratory performance of outgrowing cells, expressed as distance 
travelled from the edge of the spheroid [32], was calculated semi-automatically. 
Again, PTPRZ1 knock-down cells migrated significantly less (p<0.05) than scram-
bled controls, and restoration of PTPRZ-B levels rescued this phenotype (Fig. 3C-
D). Of note, PTPRZ-B over-expression by itself did not alter E98 motility. In a similar 
fashion, outgrowth of lentivirally transduced E434 spheroids was inhibited by PTPRZ 
Figure 2: PTPRZ1 knock-down impairs glioma cell growth. A) E98 cells expressing shSCR or shPTPRZ1 
knock-down constructs and non-transduced (E98nt) controls were cultured in microtiter plates, total cell 
mass was determined at various time points, and population doubling times were calculated from re-
sulting curves. Error bars indicate SD, asterisk indicates p<0.05 (Student t-test, n=3). B) Transduced 
E98 cells were grown on coverslips and labeled with BrdU for 1 hr. Percentage of BrdU-positive nuclei 
among DAPI-stained cells was determined (n>3). Error bars indicate SD. Asterisks reflect confidence 
levels (ANOVA; * p<0.05; ** p<0.01; n.s., not significant). C) Representative images from (B), showing 
DAPI and BrdU (arrowheads) positivity. D) Transduced E434 cells were seeded into a 96-well plate and 
images were collected at indicated time points. Increase in spheroid size relative to day 1 is depicted. Er-
ror bars indicate SEM and asterisks indicate significance levels (* p<0.05; ** p<0.01). Repeated measure 
ANOVA: p<0.0014. E) Representative images from (C), exploiting TagRFP and GFP autofluorescence in 
shRNA vectors.
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Figure 3, Bourgonje et al. 
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Figure 3: PTPRZ1 knock-down reduces glioma cell migration. A-B) E98 cells were lentivirally transduced 
with indicated protein (PTPRZ-B), EV control or shRNA (shPTPRZ1 or shSCR control) expression vec-
tors, and seeded in an agarose/Matrigel 3D matrix. A) Migration paths were recorded overnight and 
analyzed by single-cell tracking. B) Averaged migration speeds (arbitrary units, AU) of individual cells, 
normalized to shSCR (n>30), are shown (gray points). Box-plot whiskers represent minimum and maxi-
mum. Asterisks indicate significance (*** p<0.001; n.s., not significant; Kruskal-Wallis p<0.0001). C) E98 
spheroids were seeded on a Matrigel layer and fixed and DAPI-stained 24hrs later. Two representative 
images are shown. D) Pixel distance from the spheroid border was calculate for individual cells and per 
spheroid (n>32) average outgrowth was plotted (grey data points). Box-plot whiskers represent minimum 
and maximum. Asterisks indicate significance (*** p<0.001; n.s., not significant; non-parametric ANOVA: 
Kruskal-Wallis p<0.0001). E) Representative pictures of transduced E434 spheroids, fixed and DAPI-
stained, after 24hrs on Matrigel. F) Mean pixel distance that cells traveled from the spheroid border was 
calculated, and averages per spheroid (n>53) are plotted (grey data points). Box-plot whiskers represent 
minimum and maximum, and asterisks indicate significance (***p<0.001). 
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knock-down (p<0.05; Figure 3E-F). Interestingly, whereas outgrowing E98 cells pre-
sented as scattered, amoeboid-like migrating cells, the migrating E434 cells largely 
remained interconnected, suggestive of collective migration [33]. Taken together, the 
reduced migration in vitro due to PTPRZ1 knock-down, which was rescued following 
PTPRZ-B re-expression, corroborates a stimulatory role for PTPRZ-B in cell motility.
PTPRZ1 knock-down impairs glioma cell growth in mouse brain 
To investigate how these PTPRZ-B knock-down effects translate to in vivo tumor be-
havior, we co-injected intracerebrally shPTPRZ1- and shSCR-expressing E98 cells 
that were tagged with TagRFP and EGFP fluorescent marker proteins, respectively. 
When cultured under serum conditions, E98 cells grow to compact non-diffuse tu-
mors upon orthotopic injection, but when cultured as spheroids they display diffuse 
infiltrative properties (our unpublished results). Stably transduced E98 cells were 
therefore grown as spheroids in serum-free neurobasal medium for at least two 
weeks prior to injection. E434 cells exclusively grow as spheroids in neurobasal me-
dium and were directly injected after dissociation. ShPTPRZ1/TagRFP and shSCR/
EGFP spheroids were processed to single cell suspensions and a 1:1 mixture of 
both cell types was injected intracerebrally in immunodeficient mice. Animals were 
sacrificed when symptoms of tumor burden appeared, and brains were examined for 
the distribution of EGFP- and TagRFP-containing cells (Fig. 4). EGFP-positive con-
trol cells greatly outnumbered the TagRFP-expressing PTPRZ1 knock-down cells in 
the tumors (p<0.01), in accordance with the low in vitro proliferation rate of the 
PTPRZ1 knock-down. The ratio of knock-down versus control cells did not signifi-
cantly differ between compact and diffuse infiltrative tumor regions (Fig4A). Collec-
tively, in vitro and in vivo data demonstrate a significant reduction of tumor growth 
upon PTPRZ1 knock-down, prompting us to address the molecular mechanisms by 
which PTPRZ-B impacts on glioma cell behavior.
The PTPRZ-B PDZ binding domain mediates growth stimulatory signals
PTPRZ-B may exert its stimulatory effect on E98 glioma proliferation in multiple 
ways, potentially involving extracellular CAH, FNIII and chondroitin sulfate-contain-
ing domains or intracellularly the two PTP domains and the C-terminal PDZ do-
main target site (Fig. 5A). Because the PTPRZ-B knock-down phenotype in E98-
shPTPRZ1 cells could be rescued with an shRNA-insensitive full-length expression 
construct (Figs. 2-3), we tested the contribution of the individual PTPRZ-B protein 
domains using this assay. Three different shRNA-resistant PTPRZ-B cDNA versions 
were generated (Fig. 5A). In PTPRZ-B ecto-VSV the transmembrane and intracel-
lular PTPRZ-B segments were replaced by a VSV-G epitope tag, effectively leading 
to the secretion of a C-terminally tagged PTPRZ-B extracellular domain (Fig. 5B). 
PTPRZ-B C/S represents a cysteine-to-serine catalytically inactive mutant, and in 
PTPRZ-B-VSV the ‘SLVCOOH’ PDZ domain target site is blocked by a C-terminal 
VSV-G tag. Expression of all constructs was readily detected in E98-shPTPRZ1 cells 
(Fig 5B-C).
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BrdU pulse-labeling experiments revealed that reduction in percentage of cells 
in S-phase, due to knock-down of endogenous PTPRZ, was fully rescued by full-
length PTPRZ-B and the inactive PTPRZ-B C/S mutant. Expression of PTPRZ-B 
ecto-VSV or PTPRZ-B-VSV did not rescue the knock-down phenotype (Fig. 5D-E). 
Thus,PTPRZ-B impacts on cell cycle progression through mechanisms that are in-
dependent of PTPRZ-B phosphatase activity and require interactions with the PT-
PRZ PDZ domain target site.
Extracellular PTPRZ-B interactions impact on glioma cell migration
Rescuing abilities of PTPRZ-B variants were also assessed in the spheroid migra-
tion assay. Migratory impairment due to PTPRZ1 knock-down in E98-shPTPRZ1 
cells was effectively rescued upon re-expression of full-length PTPRZ-B, PTPRZ-B 
C/S and, importantly, also by PTPRZ-B ecto-VSV (Fig. 6A-B). Moreover, purified 
VSV-tagged PTPRZ-B ectodomains, isolated from conditioned medium of transfect-
ed HEK-293FT cells, also rescued the PTPRZ knock-down effect on E98 cell migra-
tion (Fig. 6C). Contactin-1 has been put forward as a membrane-anchored PTPRZ 
Figure 4, Bourgonje et al. 
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Figure 4: PTPRZ1 knock-down impairs glioma growth in vivo. Suspensions of E98 or E434 cells express-
ing PTPRZ1 shRNA and TagRFP (shPTPRZ1/TagRFP+) or control shRNA and EGFP (shSCR/EGFP+) 
were mixed and injected intracerebrally in immunodeficient mice. TagRFP+/EGFP+ ratios were calcu-
lated using fluorescent images. A) For E98 this resulted 3-4 weeks later in compact (top panel) and 
diffuse infiltrative (bottom panel) tumor areas. Representative areas, immunohistochemically stained for 
TagRFP or EGFP and haematoxylin-counterstained, of one out of three animals are shown. B) E434 
glioma tumor-bearing mice were processed 9 weeks post-injection. Representative pictures of one out 
of two animals are shown. For E434 a 50% transduction efficiency after two consecutive transduction 
rounds was achieved resulting in also non-transduced cells being injected. C) Quantification of TagRFP+/
EGFP+ ratios in E98 xenografts, as determined for five different tumor areas per animal, averaged and 
compared to the ratio pre-injection. Error bar represents SD. One-sample Student’s t-test yielded p<0.01 
(**). D) Quantification of TagRFP+/EGFP+ ratios in E434 xenografts and pre-injection mixture. Error bar 
indicates SD.
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Figure 5: The PTPRZ-B C-terminus is required to rescue the proliferation phenotype in E98 PTPRZ1 
knock-down cells. A) Schematic representation of PTPRZ-B variants used in the study. CAH, carbonic 
anhydrase-like; FNIII, fibronectin type-III; CS, chondroitin sulfate chain; TM, transmembrane region; PD1, 
phosphatase domain 1; PD2, inactive phosphatase domain 2; VSV, C-terminal VSV-G epitope tag. C/S 
indicates the mutation of the catalytic site cysteine to serine that renders PD1 inactive. B) Conditioned 
medium from E98 cells expr ssing PTPRZ-B ecto-VSV or from empty vector (EV) control cells was sub-
jected to immunoprecipitation using anti-VSV monoclonal antibody and subsequent immunoblot analysis 
using rabbit antiserum against VSV. Size markers (in kDa) are indicated on the left. Arrowhead on the right 
indicates the chondroitin sulfated PTPRZ-B extracellular part. C) E98 shPTPRZ1 cells were transduced 
with the indicated expression constructs and 72 hrs later lysates were prepared and analyzed on Western 
blots using PTPRZ-B antiserum. GAPDH staining served as loading control and E98 shSCR lysate was 
included for comparison. D) E98 shPTPRZ1 cells were seeded on collagen-coated glass coverslips and 
hours later, transduced with the indicated expression constructs. Three days after transduction cells were 
labeled with BrdU, fixed and stained. Fluorescent images were taken and the percentage of BrdU-positive 
nuclei among DAPI-stained cells was determined (n>3). Error bars indicate SD. Confidence levels, as 
determined by ANOVA, are represented by asterisks (* p<0.05; n.s., not significant). The dashed line 
indicates the percentage in E98 shSCR cells as obtained in comparable experiments. E) Percentage of 
BrdU-positive nuclei in DAPI-stained E98 or E98 shPTPRZ1 cells following transduction with the indicated 
constructs (n=3). Error bars indicate SD. Confidence levels, as determined by ANOVA, are represented 
by an asterisk (* p<0.05; n.s., not significant).
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ligand, binding to the CAH domain and impacting on cell migration [22]. In line with 
this, endogenous contactin-1 from E98 cells indeed bound to PTPRZ-B ecto-VSV 
that was preloaded onto anti-VSV antibody-coupled beads (Fig. 6D), underscoring 
PTPRZ-B – contactin-1 interplay in E98 glioma cells.
Our results did not disclose PTPRZ phosphatase activity as a regulator of glioma cell 
migration and proliferation. It is reasonable to assume, however, that the phosphoty-
rosine-controlled activity of cellular kinases is affected following PTPRZ1 knockdown 
in E98 cells. A comparison of E98-SCR and E98-shPTPRZ1 cell extracts in a tyrosine 
kinase microarray activity assay [34] revealed that PTPRZ1 knock-down cells dis-
played reduced activity, most notably towards PDGFRB- and MET-derived peptides 
(Supplementary Fig. S2). We previously reported on the importance of MET for E98 
cell migration [32]. Immunoblot analyses confirmed that in shPTPRZ1-expressing 
E98 cell lysates MET tyrosine phosphorylation was reduced four-fold (Fig. 6E). Addi-
tionally, PTPRZ1 knock-down also resulted in lower MET protein levels, suggesting 
that PTPRZ-B regulates MET transcription, synthesis or degradation. Interestingly, 
PTPRZ1 knock-down effects on MET are partly alleviated by PTPRZ-B ecto-VSV 
expression (Fig. 6F). Taken together, results demonstrate a dual oncogenic role for 
PTPRZ1 in glioma cells. The PTPRZ-B intracellular PDZ domain binding site is re-
quired to orchestrate a submembranous complex that boosts cell proliferation, while 
the extracellular portion binds receptors and adhesion molecules on nearby cells 
and stimulates migration.
Discussion:
Effective treatment of glioma patients requires that also tumor cells that diffusely 
spread out into the brain parenchyma are therapeutically addressed. In the cur-
rent study we assessed the contributions of different PTPRZ-B domains to glioma 
cell migration and proliferation using models that faithfully recapitulate infiltrative 
tumor growth. We show that PTPRZ1 knock-down in E98 glioblastoma and E434 
oligodendroglioma cells results in impaired growth and motility in vitro and reduced 
tumor growth in vivo, also in diffuse infiltrative tumor areas. Furthermore, our rescue 
experiments disclose a dyad functionality for this RPTP. The intracellular PTPRZ-B 
C-terminal PDZ domain binding site, and not its enzymatic PTP activity, turned out 
essential for effects on cell proliferation. Conversely, the PTPRZ-B extracellular moi-
ety, which in part resembles the naturally occurring phosphacan isoform, impacted 
on cell migration. 
PTPRZ1 is upregulated in gliomas, which likely contributes to enhanced tumor cell 
migration [24-26]. A role for PTPRZ in proliferation was less clear. Reduction of tu-
mor growth as well as absence of growth effects have been reported for PTPRZ1 
knock-down experiments [25, 27]. Administration of soluble PTPRZ ectodomain is 
known to inhibit proliferation of oligodendroglial precursor cells [35]. In our study, 
the PTPRZ-B ectodomain did not affect the reduction of E98 cells in S-phase that 
resulted from PTPRZ1 knock-down. Addition of wild-type or enzymatically inactive 
PTPRZ-B did suffice to rescue proliferation impairment, but a C-terminally tagged 
version did not. If PTPRZ phosphatase activity would have been crucial for glioma 
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Figure 6: The PTPRZ-B ectodomain stimulates glioma migration. A) E98 or E98 shPTPRZ1 cells were 
lentivirally transduced with indicated constructs. Three days later spheroids were generated and the next 
day seeded on a thin Matrigel layer. After being cultured for another 24 hrs cells were fixed and stained 
with DAPI. Pictures were collected and two representative images are shown. B) Using these images 
the migration, in arbitrary units, was calculated per spheroid (light grey data points) as the average dis-
tance cells traveled from the spheroid border using FIJI-based software. Box-plot whiskers represent 
minimum and maximum values. Significance levels are indicated by asterisks (* p<0.05; ** p<0.01; *** 
p<0.001; Kruskal-Wallis p<0.0001). C) Using the above set-up, spheroid migration was also determined 
following addition of immunopurified PTPRZ-B ecto-VSV to E98 shPTPRZ1 cells (shPTPRZ1 +PTPRZ-B 
ecto-VSV protein) during the 24 hrs of culturing on Matrigel. Kruskal-Wallis p<0.003. D) PTPRZ-B ecto-
VSV was immunopurified, using mouse anti-VSV monoclonal antibody-coupled beads, from conditioned 
medium (CM) of HEK-293FT cells transfected with PTPRZ-B ecto-VSV (ecto-VSV) or empty vector (EV) 
expression plasmids (left panel). Subsequently, beads were incubated with E98 whole cell lysates and co-
purifying proteins were analyzed on western blots using Contactin-1 antiserum (right panel). E) Lysates of 
E98 cells, that were transduced with indicated shRNA constructs and blasticidin-selected, were prepared 
and analyzed on immunoblots. Size markers (kDa) are indicated on the left. Upper panels: PTPRZ-B 
immunostaining, using GAPDH as loading control. Middle and lower panels: blots were probed with an-
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cell proliferation, expression of an inactive ‘substrate protection’ mutant in PTPRZ1 
knock-down cells might act dominant-negative and worsen the effect. On the con-
trary, proliferation rescue by the catalytically dead PTPRZ-B mutant and not by the 
C-terminally tagged version rather implicates PTPRZ-B’s C-terminal protein interac-
tion potential as important for signaling complexes that steer glioma proliferation.
Multiple PDZ-containing proteins have been reported to bind to the PTPRZ C-ter-
minus; PSD95 [36], MAGI-3 [37], MAGI-1, GOPC, Mupp1, Synj2bp, Snta1, Sntb1 
and Veli-3 [38]. This opens up several mechanisms by which PTPRZ may influence 
proliferation. For instance, tyrosine kinase ErbB4 auto-activation is suppressed by 
PSD95 through PDZ domain-mediated interactions with both the enzyme PTPRZ 
and the substrate ErbB4 [39]. Likewise, PTPRZ and its substrate β-catenin form a 
complex through MAGI-1 [38, 40]. However, current findings argue against an enzy-
matic role for PTPRZ in such PDZ-based complexes and rather point to a scaffolding 
role. By clustering proteins submembranously in glioma cells, PTPRZ might contrib-
ute to efficient funneling of growth stimulatory signals towards the cell’s interior. 
In both our glioblastoma and anaplastic oligodendroglioma model, the PTPRZ ec-
todomain did not impinge on proliferation but rather was instrumental for migration. 
Also in U87-MG glioblastoma cells, PTPRZ positively influenced adherence and 
migration [24] and an antibody targeting the PTPRZ extracellular region delayed 
U87-MG compact tumor formation in vivo [41]. PTPRZ ectodomain binding partners 
include extracellular matrix components like pleiotropin, tenascin-C and tenascin-
R, and cell surface molecules [35] like contactin-1 [20, 21]. Extracellular binding of 
PTPRZ and contactin-1 is hypothesized to recruit additional proteins, such as tenas-
cins, to the complex [22]. In oligodendroglial precursors this inhibits proliferation 
and triggers differentiation towards myelinating cells. In our glioma models, PTPRZ-
contactin-1 interactions apparently lead to migratory responses. This difference may 
result from separate PTPRZ-mediated interactions in either system or, alternatively, 
by absence or presence of facilitator proteins involved. Contactin-1, tenascin-C and 
tenascin-R have adhesion and migration effects in glioma cells [21, 24, 25, 41, 42]. 
Recently we showed that MET inhibition by cabozantinib effectively stops E98 cell 
migration [32]. Here, migration impairment in E98-shPTPRZ1 cells co-incided with 
reduced MET activity. For a candidate substrate, rather increased phosphorylation 
levels are expected upon knock-down of PTPRZ, and thus far MET does not meet 
PTPRZ substrate criteria [43]. Together with ErbB and PDGFR family members, 
tisera against MET (middle) and Y1234-1235-phosphorylated MET (lower) while tubulin staining served 
as control. Representative images are shown. On the right, the quantification (n>3) of normalized signal 
intensities (arbitrary units) is given. Error bars indicate SD and asterisks reflect significance based on 
one-sample Student t-test (** p<0.01). F) E98 shPTPRZ1 cells were transduced with indicated constructs 
and 72 hrs later whole cell lysates were prepared and analyzed as described under (E). E98 shSCR cell 
lysate was included for comparison. Representative images are shown on the left and quantification (n>3) 
of normalized signal intensities (arbitrary units) is given on the right. Dashed lines indicate removal of in-
between lanes from the depicted blots. Error bars indicate SD and asterisks reflect significance (* p<0.05, 
Student t-test).
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MET represents one of the oncogenic drivers in glioma tumor biology [7]. Whereas 
E98 cells displayed a scattered, single-cell migration pattern in spheroid outgrowth 
experiments, E434 cells showed a more collective migratory behavior. This may 
reflect MET signaling differences in the two models, bearing in mind ‘scatter factor 
receptor’ as alternative name for MET. In our in vivo experiments we were unable to 
assess PTPRZ-B’s migratory role on tumor formation because this was blurred by 
effects on cell proliferation. Current findings now provide a basis to experimentally 
separate both type of effects through independent targeting of PTPRZ-B intracellular 
and extracellular binding potential. Further knowledge on PTPRZ intracellular and 
extracellular signaling involvement will strengthen its candidacy as a therapeutic 
target in gliomas.
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Supplementary material
Cell lines and antibodies
Generation and maintenance of orthotopic glioma xenograft models E98 (glioblas-
toma) and E434 (anaplastic Oligodendroglioma) have been described previously 
(28).  E98 and E434 orthotopic xenograft-derived cells were cultured as spheroids in 
neurobasal medium supplemented with B27 Supplement, 2 mM L-glutamin, 2 μg/mL 
Heparin, 1% penicillin/streptomycin (all Gibco), 20 ng/mL EGF and basic-FGF (both 
PromoCell) (32). Regular passaging of spheroids was done by gentle mechanical 
dissociation. In addition, E98 cells were grown as adherent cultures in DMEM sup-
plemented with 10% FCS, and passaged using trypsinisation (30). E434 cells cannot 
be propagated under these conditions.
Antibodies used were as follows: for Western Blotting: mouse anti-PTPRZ (1:1000; 
BD Biosciences, #610179), mouse anti-VSV (IP: 5μl; P5D4 (45)), mouse anti-tubulin 
(1:5000; DSHB, University of Iowa, E7), rabbit anti-MET (1:2000; Cell Signaling Tech-
nology, #8198), rabbit anti-pMET (1:2000; Cell Signaling Technology, #3027), rab-
bit anti-GAPDH (1:5000; Cell Signaling Technology #2118), rabbit anti-Contactin-1 
(1:2000) (22), for immunohistochemistry mouse anti-BrdU (1:50; Sigma-ALDRICH, 
#2531), rabbit- ki67 (1:200 Clone SP6; Thermo Scientific #Rm-9106) rabbit-cleaved 
caspase 3 (1:200; Cell Signaling Technology, #9661) rabbit anti-GFP (1:1000) (46), 
and rabbit anti-TagRFP (1:500; Evrogen, AB233). As secondary antibodies, IRDye 
680- or 800-conjugated goat anti-mouse and goat anti-rabbit antibodies (1:20.000; 
LI-COR Bioscience), Alexa Fluor 488 goat-anti-mouse and Alexa Fluor 647 goat-an-
ti-rabbit antibodies (1:300; Alexa) or biotinylated goat-anti-rabbit IgGs (1:200; Dako) 
were used.
Plasmid constructs
The plasmid pLenti6/BLOCK-iT-DEST (Invitrogen) was adapted to also contain CMV 
promoter-driven TagRFP or EGFP expression cassettes. Briefly, the CMV-TagRFP 
cassette was PCR-amplified from pTagRFP-C (Evrogen) using oligonucleotide set 
1 (all oligonucleotide sequences are listed in Supplementary Table 1), digested with 
XbaI and XhoI, and ligated into XbaI/XhoI-digested pLenti6/BLOCK-iT-DEST. Like-
wise, the CMV-driven EGFP expression cassette was amplified from pEGFP-N2 
(Clontech) using oligonucleotide set 2, digested with XbaI and ligated in the XbaI-lin-
earized pLenti6/BLOCK-iT-DEST. For over-expression purposes, the mouse phos-
phoglycerate kinase (PGK) promoter was inserted upstream of the attR1 recom-
bination site in these pLenti6/Block-it-DEST-TagRFP and -EGFP variants. Briefly, 
oligonucleotide set 3 was used to amplify the pLenti6.2/V5-DEST (Invitrogen) PGK 
fragment and the ClaI digested amplicon was ligated to produce plasmids pLenti6/
PGK-DEST-TagRFP and pLenti6/PGK-DEST-EGFP. To create knock-down con-
structs, shPTPRZ1 (set 4) and shSCR (set 5) oligonucleotide heteroduplexes were 
ligated in pENTR/U6 vector and subsequently Gateway-cloned into pLenti6/Block-
iT-DEST-TagRFP (for shPTPRZ1) and pLenti6/Block-iT-DEST-EGFP (for shSCR) 
according to the manufacturer’s protocols (Invitrogen). 
A pENTR/U6 derivative was customized by inserting oligonucleotide heteroduplex 
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set 6 between the unique SalI-XbaI sites, rendering pENTR/NotI-XhoII. To clone 
PTPRZ-B cDNA (Refseq NM_001206838.1), we first tailored pENTR/NotI-XhoI by 
inserting an SstII site-containing linker (set 7) in the unique HindIII site. The open 
reading frame of PTPRZ-B was produced by reverse-transcriptase PCR using oligo-
nucleotide set 8 and E98 total RNA as template. The SstII and NotI digested cDNA 
was subsequently inserted into the SstII site-containing pENTR/NotI-XhoI variant, 
resulting in plasmid pENTR-wtPTPRZ-B. A shPTPRZ1-resistant PTPRZ-B version 
(further indicated as pENTR-PTPRZ-B) was created via introduction of a silent C-T 
mutation at nucleotide position 1861 (numbering according to NM_001206838) in 
the shPTPRZ1 recognition site, using oligonucleotide set 9 and the Quickchange 
site-directed mutagenesis kit (Stratagene) according to manufacturer’s instructions. 
PTPRZ-B cDNA was subsequently adjusted via site-directed mutagenesis to encode 
an enzymatically inactive PTPRZ-B C/S mutant (GC to CG, at positions 3613-3614) 
using oligonucleotide set 10 and the afore-mentioned protocol. Furthermore, a C-ter-
minally VSV-tagged full-length PTPRZ-B variant was generated by first generating 
a KpnI site (AGTTTAA to GGTA, pos. 4757-4763) using oligonucleotide set 11, and 
subsequently introducing oligonucleotide heteroduplex set 12, encoding an in-frame 
C-terminal VSV-G epitope tag (flanked by KpnI sites). To enable expression of the 
PTPRZ-B ecto-domain only, first a KpnI site was created at the codon preceding the 
PTPRZ-B transmembrane-encoding region (AGTTATA to GGTA, pos. 2726-2732) 
using oligonucleotide set 13 in the mutagenesis protocol. Subsequent ClaI digestion 
and re-ligation resulted in removal of residues 776-1448 comprising the PTPRZ in-
tracellular domains. Finally, the new KpnI site was used to insert the VSV-G epitope 
tag-encoding heteroduplex 12. All resulting pENTR-PTPRZ-B plasmid variants were 
sequence-verified before being used in Gateway LR cloning reactions with pLenti6/
PGK-DEST-TagRFP as destination vector. Also using Gateway cloning, the empty 
pENTR/NotI-XhoI vector served to generate pLenti6/PGK-EV-TagRFP as empty 
vector control.
Lentiviral transduction of glioblastoma cells and spheroids
Lentiviruses were produced using HEK-293FT cells according to the manufacturer’s 
instructions (Invitrogen). Briefly, 95% confluent 10cm culture dishes with HEK-293FT 
cells were transfected overnight, using JetPRIME reagent (Westburg) and the ap-
propriate plasmid cocktail. The next day, medium was refreshed and 48-72 hrs later 
virus-containing medium was harvested, passed through a 0.45 µm pore size fil-
ter and stored at -80 °C. E98 Glioma cells or E434 spheroids were transduced by 
adding virus-containing medium to the cultures, at a 1:2 to 1:5 virus to medium 
ratio. After an overnight incubation, cells were superinfected with virus to increase 
the percentage of transduced cells. Routinely, this led to 80-100% transduction ef-
ficiency for E98 cells and 40-80% for the spheroid E434 cultures. Stably transduced 
E98 cells were selected by adding Blasticidin (2 µg/mL; Invitrogen). For rescue ex-
periments, cells were first transduced twice with shPTPRZ1-expressing lentiviruses. 
Several days later, two or three rounds of transduction with PGK promoter-driven 
rescue constructs were performed and cells were subjected to the proliferation and 
migration assays 72 hrs later. 
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Real-time quantitative RT-PCR
Total RNA was isolated using RNA-Bee (Tel-Test Inc. cs104B) using standard trizol-
chloroform extraction methods, and concentrations were measured spectrophoto-
metrically. Reverse transcriptase reactions were performed using Iscripttm cDNA 
synthesis kit (Bio-Rad) according to the supplier’s specifications. Specificity and ef-
ficacy of real-time quantitative PCR primer pairs for PTPRZ1 and β-actin (Qiagen) 
have been verified previously by Schmidt et al. (47). Reactions, containing 3 μL of 
cDNA, 1 µL of the pre-mixed primer pair, 5 μL of SYBR Green PCR master mix (Bio-
Rad) and 1 µL MQ, were run on a CFX96tm Real Time system using the C1000tm 
Thermal Cycler (Bio-rad). Reactions were initialized at 95 °C for 15 minutes and then 
cycled 40 times at 95 °C for 15 s and 60 °C for 40 s. After the last cycle, a dissocia-
tion curve was recorded between 60 °C and 95 °C with and increment of 0.5 °C. The 
amount of PTPRZ1 RNA was determined relative to ACTB levels using the delta Ct 
method (48).
Immunoblotting and immunoprecipitation 
Cells were washed with cold PBS and scraped in ice-cold lysis buffer (50 mM Tris-
HCl, pH 7.5; 150 mM NaCl; 1% Triton X-100 (Serva); 1 mM PMSF; 100 mM NaF; 
2 mM Na3VO4; 20 mM Na4P2O7; complete protease inhibitor cocktail, Roche, 
#13006200 (1 tablet in 1.5 mL MQ, 20 μl solution per mL lysis buffer)). Samples 
were either further processed for immunoprecipitation (see below) or added to 2x 
SDS sample buffer (60 mM Tris-HCl, pH 6.8; 2% SDS; 100 mM dithiothreitol; 0.001% 
bromophenol blue; 10% glycerol) and heated at 95 °C for 5 min. Protein samples 
were size-separated using SDS-PAGE on 8% gels and electro-blotted onto PVDF 
membrane (Immobilon-FL, #IPFL00010) according to standard protocols. Mem-
branes were blocked using 1% BSA in TBST (10 mM Tris-HCl, pH 8.0; 150 mM 
NaCl; 0.1% Tween-20 (Sigma-Aldrich)) for 1 hr at RT, and subsequently incubated 
with primary antibodies in 1% BSA in TBST, overnight at 4 °C. Membranes were then 
washed three times for 10 min in TBST and subsequently incubated with the appro-
priate secondary antibodies for 1 hr at RT in the dark. Blots were analyzed using the 
Odyssey imaging system (LI-COR Biosciences). Immunoblot images were analyzed 
quantitatively using standard FIJI software.
To visualize PTPRZ-B ecto-VSV in E98 conditioned medium, immunoprecipitation 
was performed. 30 μl ProtG sepharose beads (GE Healthcare, #17-0618-01) were 
incubated with mouse-VSV antibody overnight at 4 °C. Beads were washed 5 times 
with TBS and incubated with E98 conditioned medium overnight at 4 °C. Beads were 
washed 5 times with TBS and suspended in SDS sample buffer. After centrifuga-
tion, the supernatant was used for gel loading and blotted as described above. For 
purification purposes PTPRZ-B ecto-VSV was produced in HEK-293FT cells trans-
fected with pLenti6/PGK-PTPRZ-B ecto-VSV-TagRFP, using JetPRIME according to 
the manufacturer instructions. The secreted PTPRZ-B ectodomain was purified from 
conditioned medium via immunoprecipitation using mouse anti-VSV bound to ProtG 
sepharose beads, as described above. VSV-tagged proteins were eluted from the 
beads using excess VSV peptide (49). 
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For co-immunoprecipitation, mouse anti-VSV was coupled to ProtG sepharose 
beads by overnight rotation at 4 °C in TBS. After 5 subsequent washes with TBS, 
conditioned medium from HEK293FT cells transfected with either pLenti6/PGK-EV-
TagRFP or pLenti6/PGK-PTPRZ-B ecto-VSV-TagRFP was added to the beads al-
lowing coupling to VSV overnight at 4 °C. After 5 washes, E98 cell lysates (prepared 
as described above) were added to the beads and were incubated overnight at 4 °C. 
The next day, beads were washed 5 times with TBS before being taken up in 2x SDS 
sample buffer. Samples were processed for immunoblotting as described above.
Immunohistochemistry
FFPE sections of 4 μm were subjected to immunohistochemical stainings according 
to standard procedures (29). In brief, sections were de-paraffinized in xylene and 
rehydrated in PBS. Endogenous peroxidases were blocked in 3% H2O2 in PBS, fol-
lowed by epitope retrieval (10 min boiling in 10 mM sodium citrate, pH 6.0). Slides 
were then washed twice in PBS, blocked in 20% normal serum (from the species 
in which the secondary antibody was raised) in PBA (1% BSA in PBS) for 20 min, 
and incubated overnight at 4 °C with primary antibodies in PBA. After 3 PBS wash-
es, sections were incubated with biotinylated secondary antibodies in PBA for 1hr 
at room temperature. Slides were washed 3x with PBS and signals were then en-
hanced by incubation with Avidin/Biotin complexes (Vector Laboratories, #PK-6100), 
both 1:100 in PBA for 45 min, followed by 3 PBS washes and visualization of specific 
signals using 3,3′-diaminobenzidine (Bright-DAB, ImmunoLogic, #B04). All sections 
were counterstained with haematoxylin and mounted in Quick-D Mounting medium 
(Klinipath BV, #7280). 
Quantification of immunodetected EGFP and TagRFP signals was done using KS400 
software (Carl Zeiss AG) and a custom-written macro. Sections of FFPE brains with 
orthotopic glioma xenografts were included in the analysis (n=3 and 2 for E98 and 
E434, respectively) and at least five non-overlapping microscopic fields (magnifica-
tion x200) were measured per immunostaining for each animal. The TagRFP- or 
GFP-positive area per tumor field was divided by the total tumor area as determined 
via nuclear DAPI staining, and average values per animal were determined and 
used to calculate TagRFP/GFP ratios. Ratios were compared to those prior to injec-
tion using the one-sample Student’s t-test.
Peptide microarray analysis
E98 cells stably expressing shSCR/GFP and shPTPRZ1/TagRFP constructs were 
grown to 80% confluency in 6-well plates (4 wells per sample). Cells were washed 
twice with ice-cold PBS prior to lysis with M-PER Mammalian Extraction Reagent 
supplemented with protease and phosphatase inhibitor cocktails (Thermo Scientific) 
for 30 min at 4 °C. Lysates were centrifuged (15 min, 14,000 rpm, 4 °C), and super-
natants were snap frozen in liquid nitrogen and stored at -80 °C. Protein concentra-
tions were determined using the BCA protein assay (Thermo Scientific). Kinase ac-
tivity measurements were performed in quadruplicate on Tyrosine kinase PamChip 
arrays on a PamStation 12 instrument (PamGene International BV) essentially as 
described (35). Sample input was 5 µg per array. A Student’s t-Test was used to 
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identify the peptides that are significantly (p<0.05) different between the treatments.
Statictical analysis:
Statistical analysis was performed using GraphPad Prism 5 or PamGene’s propri-
etary BioNavigator software. For two conditions the Student t-test was applied. For 
other conditions ANOVA, repeated measure ANOVA or non-parametric Kruskal-
Wallis with post-hoc tests were performed. When all experimental conditions were 
included, Tukey’s multiple comparison test was used. In contrast, when comparisons 
were made to a single “control” experimental condition the Dunn’s post-hoc test was 
applied.
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Supplementary Figure S1: Plasmid maps of constructs used to create lentiviral vectors for glioma cell 
transduction. A) Schematic overview of the expression construct that is generated in an LR Gateway clon-
ing reaction, using pLenti6/PGK-DEST-tagRFP and the appropriate cDNA-containing pENTR plasmid (in 
this case full-length PTPRZ-B). B) Schematic overview of the scrambled control knock-down construct 
that resulted from an LR Gateway reaction involving the pLenti6/Blocki-iT-DEST variant (with added fluo-
rescent protein expression cassette) and the pENTR/U6 plasmid with inserted oligonucleotide heterodu-
plex for shSCR production. Long terminal repeat (LTR) regions, attR1 and attR2 Gateway recombination 
sites, and the CMV promoter-driven TagRFP and EGFP expression cassettes as well as the SV40 early 
promoter-driven Blasticidin selection cassette are indicated.
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Supplementary figure S2, Bourgonje et al. 
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Supplementary Figure S2: Kinase activity profiling of E98 cells stably expressing shSCR/GFP and shPT-
PRZ1/TagRFP constructs. A) Heatmap representation of the mean signals (n=4) for 144 different pep-
tides on the Tyrosine Kinase PamChip® Array upon incubation with lysates from shSCR or shPTPRZ1-
expressing E98 cells. The order of peptide signal depiction (top, highest signal in red; bottom, lowest 
signal in blue) was determined by that in the shSCR sample. B) List of 37 peptides that were significantly 
differentially phosphorylated by shSCR- and shPTPRZ1-expressing E98 lysates. The ID column contains 
the protein name and first and last amino acid position of the peptide. Corresponding UniProt accession 
numbers are shown in the second column, and column ‘Tyr’ lists the positions of the phosphorylatable 
tyrosines in the peptide. The final column is a color-coded representation of the lower signals obtained 
with shPTPRZ1 E98 extracts as compared to the scrambled control.
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Supplementary Table S1: Oligonucleotide sequences used in generating 
plasmid constructs. 
Oligonucleotide (set) Sequence
1: CMV-TagRFP Fw
Rv
5’- GGCTCGAGTAGTTATTAATAGTAATC -3’
5’- CCTCTAGATCAATTAAGTTTGTGCCCC -3’
2: CMV-EFGP Fw
Rv
5’- GGCGCTCTAGATAGzTTATTAATAGTAATCAATTACG -3’
5’- GGCGCTCTAGATTACTTGTACAGCTCGTCCATG -3’
3: PGK promoter Fw
Rv
5’- GGCATCGATCTCGAGCTACCGGGTAGGGGAGGCGC -3’
5’- GCCGCATCGATGTCGAAAGGCCCGGAGATG -3’
4: shPTPRZ1 Fw
Rv
5’- CACCGGAAGTGAATTCTCTGGAAAGCGAACTTTCCAGAGAATTCACTTCC -3’
5’- AAAAGGAAGTGAATTCTCTzGGAAAGTTCGCTTTCCAGAGAATTCACTTCC -3’
5: shSCR Fw
Rv
5’- CACCGTCAAACTGCTTACTCTAGACGAATCTAGATGTAAGCAGTTTGAC -3’
5’- AAAAGTCAAACTGCTTACATCTAGATTCGTCTAGATGTAAGCAGTTGAC -3’
6: NotI-XhoI adapter Fw
Rv
5’- TCGACGCGGCCGCGAATTCCCGGGATCCACCGGTCTCGAGAAGCTTATCG 
ATACCGT -3’
5’- CTAGACGGTATCGATAAGCTTCTCGAGACCGGTGGATCCCGGGAATTCGC 
GGCCGCG -3’
7: SstI linker 5’- AGCTGACCGCGGTC -3’
8: PTPRZ-B cDNA Fw
Rv
5’- GCGCGCGGCCGCCCACTCTGAGAAGCAGAGGAG -3’
5’- GCGCCCGCGGGTGTTAAACTAAAGACTCTAAG -3’
9: PPRZ-B rescue mut. Fw
Rv
5’- CAAGAGGAAGTGAATTTTCTGzGAAAGGGTGATG -3’
5’- CATCACCCTTTCCAGAAAATTCACTTCCTCTTG -3’
10: PTPRZ-B C/S, mut Fw
Rv
5’- CCTGTTGTCGTCCACTCGAGTGCTGGAGTTGG -3’
5’- CCAACTCCAGCACTCGAGTGGACGACAACAGG -3’
11: PTPRZ-B, mut Fw
Rv
5’- GCTGAGAGCTTAGAGTCTTTGGTACCCGCGGTCAGCTTATCGAT -3’
5’- ATCGATAAGCTGACCGCGGGTACCAAAGACTCTAAGCTCTCAGC -3’
12: KpnI VSV-stop, mut Fw
Rv
5’- CTTATACAGACATAGAGATGAACCGACTTGGAAAGTAGGTAC -3’
5’- CTACTTTCCAAGTCGGTTCATCTCTATGTCTGTATAAGGTAC -3’
13: PTPRZ-B ectodo-
main, mut
Fw
Rv
5’- GTTGGAATCCGAGAAGAAGGCGGTACCCCTTGTGATCGTGTCAGC -3’
5’- GCTGACACGATCACAAGGGGTACCGCCTTCTTCTCGGATTCCAAC -3’
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PTPN13 AS A CANDIDATE ANCHORING PROTEIN IN THE PTPRZ-B 
INTERACTOME IN GLIOMA
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Abstract
Glioblastoma cells rapidly proliferate and migrate diffusely into the healthy brain pa-
renchyma, complicating surgical resection and radiation therapy. The prognosis for 
glioma patients following treatment is generally poor, with a median survival time 
of less than 15 months. Glioblastoma cells express high levels of the receptor-type 
protein tyrosine phosphatase PTPRZ-B and we previously demonstrated that the 
intracellular domain of PTPRZ-B is facilitating their proliferation. Here, we set out to 
study the proteins that interact with the intracellular segment (RZi) of PTPRZ-B us-
ing immune pull-down experiments and proximity labeling strategies. We found that 
PTPN13, a PDZ domain-containing submembranous protein tyrosine phosphatase, 
interacts with the C-terminus of PTPRZ-B. Knockdown of PTP13 resulted in reduced 
glioblastoma cell proliferation, and in addition triggered cell death and conspicuous 
cell fusion events resulting in multinuclear cells reminiscent of giant cell glioblasto-
mas. Further studies regarding the PTPRZ-B and PTPN13 interactome in glioblas-
toma may ultimately provide novel therapeutic targets for these tumors. 
PTPN13 as a candidate anchoring protein in the PTPRZ-B interactome in glioma
129
5
Introduction
Diffuse gliomas represent the most common primary brain tumors among humans, 
with an incidence of 3-5 per 100,000 people each year. Arising from glial cells or their 
precursors, the tumors are notorious for their highly infiltrative nature, explaining 
their devastating effect and the relatively short life expectancy of patients after diag-
nosis. Gliomas are classified into several distinct subtypes based on WHO criteria 
[37], of which high-grade astrocytomas (named glioblastomas) are the most malig-
nant. Although research over the last decades has helped to reveal many molecular 
etiological features of gliomas, a significant improvement in patient survival is still 
lacking [56]. Current efforts in the field are therefore strongly concentrated on find-
ing new druggable targets and the development of alternative treatment strategies. 
As in other cancer types, glioblastoma cell growth relies on the activation of onco-
genic signaling pathways and loss of tumor-suppressive mechanisms due to ge-
netic mutations [8, 26, 30, 43]. In the vast majority of glioblastomas this involves 
aberrancies in growth factor signaling pathways (notably receptor tyrosine kinases 
PDGFRA, MET, EGFR and the autoactive deletion variant EGFRvIII) leading to high 
levels of phosphotyrosine-mediated signaling [8, 44, 46]. Phosphotyrosine levels 
are, however, not controlled by protein tyrosine kinases only. The protein tyrosine 
phosphatase (PTP) class of enzymes play an equally important role (e.g. [43]).  Tar-
geted anti-tumor strategies nowadays mostly focus on protein tyrosine kinases be-
cause of their direct role in signaling and their better druggability. Almost no atten-
tion is currently spent on the role of counteracting PTPs. This situation may need 
change, as evidence for PTP relevance for tumor biology is growing. This is perhaps 
best illustrated by the family member PTEN, a tumor suppressor that is lost in about 
one-third of primary (IDH-WT) glioblastomas [8]. PTEN’s activity directly impinges 
on PI3K signaling [11]. Earlier, in our in-depth analysis of PTP family member ex-
pression in diffuse glioma subtypes, we obtained evidence that the levels of three 
additional PTPs - DUSP26, PTPRM and PTPRT – have prognostic value for patient 
outcome. Also, multiple studies revealed that gene PTPRZ1 is highly up-regulated 
in all glioma types [7, 42, 57] and PTPRZ1-targeted knock-down or PTPRZ blocking 
antibodies demonstrated that this PTP regulates glioma cell migration and prolifera-
tion [18, 23, 42, 57]. 
Here we will focus on the pathobiological relevance of this latter PTP family member. 
Gene PTPRZ1 is mainly expressed in brain and is important for neuronal develop-
ment [29, 35]. PTPRZ1 encodes three protein isoforms that all consist of an extracel-
lular N-terminal carbonic anhydrase domain followed by a fibronectin type III repeat 
and a chondroitin sulfate attachment region [45]. Isoform PTPRZ-S is a secreted 
extracellular protein, whereas the other two isoforms (PTPRZ-A and PTPRZ-B) 
are single-pass transmembrane proteins that differ in the size of their chondroitin 
sulfate attachment region but further have identical intracellular parts, which es-
sentially consist of two phosphatase domains and a C-terminal tail that ends in 
the amino acid sequence –SLVCOOH and represents a PSD95/Dlg1/ZO-1 (PDZ)-
binding motif [3, 34, 38]. PTPRZ isoforms interact extracellularly with a wide range 
of ligands and substrates. For example, binding of the ligand pleiotrophin induces 
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homo-dimerization of the transmembrane PTPRZ-B isoforms, and resulting steri-
cal hindrance keeps the PTP from dephosphorylating its downstream targets that 
include β-catenin, β-adducin, FYN and ALK [41, 47–49]. Protein interaction screens 
yielded two membrane-associated guanylate kinases, PSD95 and MAGI1, that bind 
to the PTPRZ-B C-terminus by means of their PDZ domains [22, 25, 31]. 
PDZ domains are globular (80–90 amino acids) protein-protein interaction modules 
that play roles in protein targeting and complex assembly [36].  In the canonical bind-
ing mode, PDZ domains interact with C-terminal binding motifs. Specificity is hereby 
mainly determined by the ultimate and antepenultimate amino acid residues of the 
target proteins. In the case of PTPRZ this entails the three C-terminal amino acids 
SLV. Also examples of internal PDZ-binding motif recognition exist. PSD95 contains 
three such PDZ domains of which the second one binds PTPRZ-B [31].  It is thought 
that this scaffolding mediates clustering of PTPRZ-B and by simultaneous binding 
to Erbb4 is instrumental in dephosphorylation of this growth factor receptor [21]. 
Another known substrate of PTPRZ-B is MAGI1 [41]. MAGI1 is a submembranous 
anchoring protein for β-catenin [16] with six PDZ-domains, of which domain two 
binds the PTPRZ-B C-terminus [22].
In previous experiments we have shown that the PTPRZ-B extracellular part is in-
volved in migratory behavior of glioma cells whereas its intracellular moiety supports 
proliferation [6]. Here, we used the entire intracellular segment of PTPRZ-B in glioma 
cells for non-biased partner protein identification methodology (Bio-ID) as well as for 
testing of candidate interactors, in order to unravel how PTPRZ-B impacts on cell 
cycle behavior. We identified its family member PTPN13 as a new PTPRZ-B interac-
tor that is important for gliobastoma cell survival.
Materials and methods
Construction of plasmids:
The plasmids pENTR-EGFP [7], pENTR-NotI/XhoI [6], pENTR-PTPRZ-B and 
pENTR-PTPRZ-B-VSV (with coding sequence modifications that render them re-
sistant to shRNA mediated knockdown [6]), PSD-95-pTagRFP (Addgene plasmid # 
52671; a gift from Johannes Hell), pCDNA3-PTP-BL [14] and pCMV5-HA-PTPN13 
[27] have all been described elsewhere. 
For the construction of the pCDNA3-GFP-RZi-(VSV) expression vectors the follow-
ing 3-point ligation strategy was used. The GFP-encoding fragment was amplified 
using forward  (5’-GCGGAATTCATGGTGAGCAAGGGCGAGGAGCTG-3’) and 
reverse (5’-CGCGGATCCCTTGTACAGCTCGTCCATGCCG-3’) primers that con-
tained EcoRI and BamHI sites (underlined), respectively, using pENTR-EGFP as 
template. The cDNA fragments encoding the intracellular PTPRZ-B part, with (RZi-
VSV) or without (RZi) the VSV-G epitope tag, were PCR-amplified from pENTR-PT-
PRZ-B and pENTR-PTPRZ-B-VSV, respectively, with use of primers that introduced 
5’ BamHI and 3’ XhoI sites (underlined): 5’-GCGGGATCCAGGAAATGCTTC-
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CACACTGCACACT-3’ as forward primer and 5’-GCCCGGCGCCTCGAGTTAAAC-
TAAAGACTCTAAG-3’ or 5’-CGCCTCGAGCTACTTTCCAAGTCGGTTCATCTCT-3’ 
as reverse primer. Three-point ligation of  EcoRI-XhoI-digested vector pENTR-NotI/
XhoI with the EcoRI-BamHI GFP-encoding and BamHI-XhoI RZi(-VSV)-encoding 
segments yielded pENTR-GFP-RZi and pENTR-GFP-RZi-VSV, respectively. Next, 
inserts in these entry clones were subsequently transferred into pcDNA-DEST by 
use of Gateway recombination reactions with Clonase II to produce expression plas-
mids pCDNA3-GFP-RZi(-VSV), per manufacturer’s instructions (Invitrogen).   
For construction of an expression vector encoding the biotinylating enzyme biotin 
ligase (BirA*), alone or as fusion product with PTPRZ’s intracellular domains, the 
pcDNA3.1 mycBioID plasmid a gift from Kyle Roux (Addgene plasmid # 35700) [51], 
was used as a template. BirA*-encoding cDNA was generated using PCR with prim-
ers Fw: 5’-GGCCGCGGCCGCGCTAGCCACCATGGAACAAAAACTCAT-3’ and rev: 
5’-GGCCGGATCCTTACTTCTCTGCGCTTCTCAGGGAGATTT-3’. The resulting 
fragment was NotI and BamHI digested (sites are underlined in primer sequences) 
and ligated into NotI / BamHI digested pENTR-NotI/XhoI, resulting in pENTR-BirA*. 
Similarly the amplified NotI-BamHI BirA* fragment was introduced in pENTR-GFP-
RZi(VSV), effectively replacing the GFP cDNA.
pDONR223-MAGI1 was a gift from William Hahn & David Root (Addgene plasmid # 
23523) [28]. MAGI1 was amplified using PCR to introduce flanking EcoRI and KpnI 
sites (fw 5’-GCCGCGAATTCACCATGTCCAAAGTGATC-3’: rev 5’- AAGGTACCTG-
GATACTGAGGTCGGTGC-3’). GFP-RZi in pENTR-GFP-RZi-VSV was substituted 
by  MAGI1 by exchanging EcoR1/KpnI inserts, creating a MAGI1-VSV reading frame. 
Resulting pENTR clones were used in Gateway recombination reactions with 
pCDNA3.1-DEST or pLenti6.2/V5-DEST (both Invitrogen) as recipients, using Clon-
ase II (Invitrogen #11791) essentially as described above.
For shRNA-mediated knockdown of PTPN13 in glioma cells, we converted the 
shRNA-expression cassette from retroviral vector pSuperRetro into a Gateway-
compatible plasmid to facilitate Lentiviral transduction. First, forward (5’- GCGGTC-
GACGAATTCGAACGCTGACGTC-3’) and reverse (5’-GCGTCTAGACGGTATCGA-
TAAGCTTAGATC-3’) primers were used to PCR-amplify nucleotide region 1429-1673 
from plasmid pRS (retroviral pRETRO-SUPER RNA interference vector [9]) and to 
introduce flanking SalI and XbaI restriction sites (underlined). The resulting amplicon, 
containing the H1 promoter-based shRNA-expression cassette, was inserted into the 
SalI-XbaI-digested pENTR/U6 (invitrogen) plasmid backbone in between the att re-
combination sites, yielding vector pENTR/H1. To generate pENTR/H1shPTPN13-1 
and pENTR/H1shPTPN13-2 appropriate oligonucleotide heteroduplexes (of 5′-gatcc-
ccAGACCAAAGCCACTGTTAAttcaagagaTTAACAGTGGCTTTGGTCTtttttggaaa-3′ 
with 5′-agcttttccaaaaaAGACCAAAGCCACTGTTAAtctcttgaaTTAACAGTGGCTTTG-
GTCTggg-3′  and 5′-gatccccGCCAGGCTATTCGAGATCGttcaagagaCGATCTC-
GAATAGCCTGGCtttttggaaa-3′ with 5′-agcttttccaaaaaGCCAGGCTATTCGAGA-
TCGtctcttgaaCGATCTCGAATAGCCTGGCggg-3′, respectively) were ligated into 
the BglII and HindIII digested pENTR/H1 vector. Subsequently, Gateway-type re-
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combination reactions into pLenti6/BLOCK-it-DEST-TagRFP [6] were used to gener-
ate plasmids for production of lentiviruses containing shRNA as well as fluorescent 
marker protein expression cassettes. PTPRZ1-directed shRNA constructs and the 
non-targeting knockdown control (shSCR) have been described previously [6]. 
Cell lines, culturing, transfection and lentivirus production:
HEK 293FT cells were purchased from Invitrogen. The xenograft-derived glioblas-
toma cell model E98 has been described elsewhere [13]. Cells were cultured in high 
glucose Dulbecco’s Modified Eagle Medium (Life Technologies; cat.no.11960-044) 
supplemented with 10% Fetal Bovine Serum (PAA laboratories; Cat.no. A15-101), 
4 mM glutamine and 1 mM pyruvate (Life Technologies), at 37 °C in a humidified 
incubator under 7.5% CO2. Expression plasmids were transfected into HEK293FT 
cells using JetPRIME reagent (Westburg), according to the manufacturers’ instruc-
tions. Generation of lentiviruses has been described previously [6]. Briefly, lentiviral 
plasmids with supporting packaging plasmids were transfected into HEK293FT cells 
using JetPRIME reagent and medium was replaced after 8 hours. After 48 hours, 
medium containing lentivirus was harvested for infection of E98 cells.
For BioID experiments, cells were incubated for 16 hours with 50 μM Biotin (Sigma 
#B4501) in the culture medium . Afterwards, excess biotin was removed  by washing 
cells three times for five minutes with with biotin-free medium .
Affinity-purification and immunoblotting:
Cell lysates for GFP- or HA-tagged immunoprecipitation were prepared using Su-
crose buffer (10 mM Tris-HCl, pH 7.5; 2 mM MgCl2; 3 mM CaCl2; 300 mM Sucrose; 
1 mM PMSF; 2 mM Na3VO4; 10 mM NaP2O7; complete protease inhibitor cocktail, 
Roche, #13006200 (1 tablet in 1.5 mL MQ, 20 μl solution per mL lysis buffer)) or 
MPER (30 mM Tris-HCl, pH 7.5; 25 mM Bicine buffer, pH 7.5; 50 mM NaCl; and pro-
tease and phosphatase inhibitors as described above and 0.1% CHAPS). Cells were 
scraped in ice-cold buffer and passed through a 0.5 µm needle to shear the cells. 
Lysates were incubated on ice for 30 min with regular mixing, after which they were 
centrifuged at 20,000 g at 4°C for 10 min. Supernatant was collected and stored 
at -20 oC until use. For immunoprecipitation of GFP-tagged fusion protein-contain-
ing complexes, anti-GFP antibody-coated magnetic beads were used (chromotek 
GFP-Trap®_MA). For immunoprecipitation of HA-tagged fusion proteins and their 
associated proteins, 30 μl ProtG sepharose beads (GE Healthcare, #17-0618-01) 
that were pre-loaded with anti-HA antibody (12CA5) [17] were used. All beads were 
incubated with cleared lysates either overnight (sepharose beads) at 4°C, or at RT 
for one hour (GFP magnetic beads). Beads with bound proteins were washed five 
times with lysis buffer and finally transferred into a new tube.
For BioID experiments the cells were scraped in Triton buffer (50 mM Tris-HCl, pH 
7.5; 150 mM NaCl; 1% Triton X-100 (Serva); and protease- and phosphatase in-
hibitors as described above). Lysates were incubated on ice for 30 min and mixed 
regularly, after which they were centrifuged at 20,000 g at 4oC for 10 min. Super-
natant was collected and the pellet discarded. For pulldown of biotinylated proteins, 
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MyOne Streptavidin T1 Dynabeads (Thermo scientific) were incubated with lysate at 
RT for one hour and further processed as described above. Affinity purification was 
performed as described [50]. Biotinylated protein-containing beads were washed 
five times with PBS.  Subsequent on-bead digestion, in-gel digestion and mass-
spectrometric analysis was performed as described [55].
Immunoblotting:
Protein lysates and immunoprecipitates were processed by adding 2x SDS sample 
buffer (60 mM Tris-HCl, pH 6.8; 2% SDS; 100 mM dithiothreitol; 0.001% bromophe-
nol blue; 10% glycerol) and heating the lysates at 95 °C for 5 min. Proteins were 
size-separated using SDS-PAGE on 8% PAA gels according to standard protocols. 
In case of BioID experiments, commercial 4-12% gradient gels (BOLT Thermo fisher 
scientific #NW04122) were used according to manufacturer’s instruction. 
Gels were electro-blotted onto PVDF membrane (Immobilon-FL, #IPFL00010). Mem-
branes were blocked using 5% BSA in PBST (PBS; 0.1% Tween-20 (Sigma-Aldrich)) 
for 1 hr at RT, and subsequently incubated with primary antibodies or streptavidin- 
IR-Dye800 in 5% BSA-containing PBST, overnight at 4 °C. Membranes were then 
washed three times for 10 min in PBST and either stored until imaged (in the case of 
conjugated streptavidin- IR-Dye800) or subsequently incubated with the appropriate 
secondary antibodies for 1 hr at RT in the dark. Immuno-fluorescent signals were 
visualized using the Odyssey imaging system (LI-COR Biosciences) and images 
were analyzed using Image Studio Light (Li-COR Biosciences).
Antibodies used were as follows: mouse anti-PTPRZ (1:1000; BD Biosciences, 
#610179), rabbit anti-VSV (1:20.000; LifeSpan Biosciences), mouse anti-tubulin 
(1:5000; DSHB, University of Iowa, E7), rabbit anti-GAPDH (1:5000; Cell Signal-
ing Technology #2118), mouse anti-GFP (1:1000; Santa Cruz, JO511), rabbit anti-
TagRFP (1:500; Evrogen, AB233), mouse anti-PSD95 (1:5000; NeuroMab), rab-
bit anti-PTPN13 (1:1000; Santa Cruz, H300), rabbit anti-Myc (1:1000; Santa-Cruz 
#sc789), rabbit anti-HA (12CA5) [17], and rabbit anti-LYAR (1:1000; Invitrogen 
#PA5-44683) antibodies. As secondary antibodies, IRDye 680- or 800-conjugated 
goat anti-mouse or goat anti-rabbit antibodies (1:20,000; LI-COR Bioscience) were 
used. IRDye 800-conjugated streptavidin (1:1000; LI-COR Biosciences) were used 
to visualize biotinylated proteins. 
Proliferation assay: 
E98 cells were transduced with shRNA-expressing lentiviruses according to the pro-
tocol described in [6] and grown to 60-80% confluency on collagen I-coated (10 µg/
cm2 ; Invitrogen) coverslips. Cells were then incubated for 1 hr in culture medium 
containing 10 μM EdU (5-ethynyl-2’- deoxyuridine), incorporation of which was visu-
alized on fixed cells using the click-iT® EdU Imaging kit (Thermo Fisher Scientific, 
#C10086) following the manufacturers’ instruction. Coverslips were mounted on mi-
croscope slides in DAPI-containing Mowiol (Sigma-Aldrich) and images were col-
lected using a 20x objective on a Leica DMI6000B Fluorescence microscope that 
was equipped with a motorized x-y scanning stage and Leica EL6000 illumination 
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source. DAPI- and EdU-positive nuclei were counted automatically using FIJI soft-
ware [53].
Results
Association of the PTPRZ-B C-terminus with PDZ domain-containing proteins
Our previous work revealed a signaling role for the C-terminal PDZ binding motif in 
PTRZ-B in the regulation of glioma cell proliferation. Disrupting this SLV sequence 
motif by fusion with a VSV-G epitope sequence eliminated its effects on cell prolifera-
tion [6].  Here we set out to study how the structure and domain topology of the entire 
PTRZ-B intracellular segment  (further referred to as RZi) is involved in regulating 
proliferation. Therefore, to identify proteins that are capable of interacting and thus 
might have a role in the observed signaling, we constructed a series of vectors en-
coding tagged variants of the RZi segment (Fig. 1A) and used these in subsequent 
affinity purification experiments. Addition of an N-terminal GFP tag to RZi would en-
able purification of stable protein complexes on GFP-Trap beads, whereas use of an 
N-terminal Myc-BirA* tag that catalyzes the promiscuous biotinylation of vicinal pro-
teins in the cell (a method known as Bio-ID [50]) should enable their purification over 
streptavidin beads. Both types of RZi fusion proteins were properly expressed in 
HEK 293FT cells, as revealed by immunoblot analyses, also when PTPRZ-Bs PDZ 
binding motif was altered by C-terminally adding the VSV-G epitope tag (Fig. 1B,C). 
First, to verify that addition of the VSV tag to the SLV sequence motif in RZi in-
deed prohibits interactions with PDZ domain proteins, we co-transfected HEK 293FT 
cells with pcDNA3-type expression plasmids encoding the two GFP-RZi variants 
and RFP-tagged PSD95 (PSD95-tagRFP) or VSV-tagged MAGI1 (MAGI1-VSV), two 
known PTPRZ-B interactors [22, 31]. Using anti-GFP-coated magnetic beads, these 
interactors were both efficiently co-purified with RZi. When GFP-RZi-VSV was used 
as a bait no interaction was detectable (Fig 2A and B), corroborating previous ob-
servations. 
Screening for interactors of the PTPRZ-B intracellular part using BioID
The mutant biotin ligase BirA* biotinylates lysines in any protein within a radius of 
10nm [32]. To identify RZi-mediated interactions in a proper physiological setting, 
we chose to explore this BioID approach in glioma cells. Prior to the in-cell vicinity 
labeling approach we verified whether expression of N-terminal BirA* fusions of RZi 
indeed results in biotinylation of known interactors. To this end, HEK 293FT cells 
were co-transfected with expression plasmids for PSD95 or MAGI1, and either BirA*, 
BirA*-RZi or BirA*-RZi-VSV. After addition of biotin to the cells and subsequent lysis, 
protein biotinylation was analyzed following SDS-PAGE and blotting. Indeed PSD95 
and MAGI1 were found to be preferentially biotinylated by BirA*-RZi as compared 
to BirA*-RZi-VSV (Fig 3A,B). This demonstrates that BirA* addition renders a func-
tional bait which can even biotinylate interactors that bind at the PDZ-binding motif 
at the other end of RZi, but only when this C-terminal motif is freely available and 
not blocked by the VSV-tag. Biotinylation of RZi partners that bind elsewhere, not at 
sites located an entire length span of the protein away from the BirA domain, should 
thus also be possible.
PTPN13 as a candidate anchoring protein in the PTPRZ-B interactome in glioma
135
5
As a next step, E98 glioblastoma cells were lentivirally transduced with expression 
constructs for BirA*, BirA*-RZi or BirA*-RZi-VSV. Stably transduced cell lines were 
exposed overnight to biotin, lysed and proteins in the lysates were subjected to affin-
ity purification using streptavidin magnetic beads. Captured proteins were then sub-
Figure 1, Bourgonje et al. 
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Figure 1: Structure and expression of tagged intracellular PTPRZ-B protein segments
A. Schematic overview of PTPRZ-B protein variants encoded by the various constructs used in this study. 
Next to the full-length protein, intracellular PTPRZ-B (RZi) domains fused with either the GFP protein 
or the BirA* enzyme are depicted. Also the versions in which the C-terminal PDZ-binding motif (SLV) is 
blocked by an added VSV tag are shown. CA, carbonic anhydrase; CS, chondroitin sulphate attachment 
region; FNIII, fibronectin type III repeat; Myc, c-myc-derived decapeptide epitope tag bound to BirA; PTP, 
protein tyrosine phosphatases catalytic domain; PTP*, inactive membrane-distal PTP domain; TM, single-
pass transmembrane domain. Dashed lines represent the cell membrane, and grey curves on the CS 
segment indicate chondroitin sulphate additions. B. Expression of GFP-tagged constructs in HEK293FT 
cells. Lysates of transfected cells expressing GFP-RZi or GFP-RZi-VSV were analyzed on immunoblot 
(IB) using GFP and VSV antisera. C. BirA*-expressing HEK 293FT cells were provided with biotin and 
lysates were analyzed on blots using PTPRZ antiserum and streptavidin for staining. IB: immunoblot. 
Protein size markers (in kDa) are indicated on the right.
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5 jected to mass spectrometric (Supplementary Fig. S1 and Table S1) and immunoblot (Fig. 3C,D) analyses. The different BirA* variants were all properly expressed and 
active, as witnessed by the biotin incorporation in most notably the recombinant pro-
tein itself and by visualization of the Myc-tag on the myc-BirA*-tagged proteins (Fig. 
3C). Mass spectrometric analysis, however, revealed overall low peptide counts. 
Only a single protein, called LYAR, was found enriched in the fraction that originated 
from BirA*-RZi expressing cells, compared to that from BirA*-RZi-VSV transduced 
cells (Supplementary Fig. S1). This zinc finger protein could, however, not be de-
tected in the streptavidin-purified sample on immunoblot (Fig. 3D). Likewise, en-
dogenous PSD95 – that might have served as appropriate control – was also not 
appreciably biotinylated (Fig. 3D), leaving the evidence for interaction inconclusive 
and the nature of glioblastoma partners for domains of the intracellular segment of 
PTPRZ-B as yet enigmatic.
PDZ-domain containing protein PTPN13 binds to the PTPRZ-B C-terminus
The PTPRZ-B C-terminal SLV amino acid sequence represents a canonical class 
I PDZ domain binding site (-S/TxVCOOH)[4].  PSD95 and MAGI1 not only bind to 
PTPRZ-B but in fact to multiple proteins carrying class I C-terminal sequences, in-
cluding the glioma tumor suppressor PTEN [54]. PTPRZ-Bs’ RZi segment may thus 
well represent a bait for other proteins that bind class I PDZ domain targets. Follow-
Figure 2, Bourgonje et al. 
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Figure 2: Verification of intracellular interaction between the C-terminal PDZ binding motif of PTPRZ and 
known partners PSD95 and MAGI1
A. GFP-containing protein complexes were affinity-purified (IP) from lysates of HEK 293FT cells express-
ing tRFP-PSD95 and GFP-RZi variants using GFP-antibody-coupled magnetic beads and analyzed on 
Western blots (IB). Presence of co-purifying partner proteins in input cell lysates before and after immune-
capture (IP) was probed by Western blot analysis using anti-PSD95. VSV serum was used to visualize 
GFP-RZi -VSV variant. Migration positions of full-length and cleaved PSD95 are indicated to the right of 
the upper pane in kDa. B. Similarly, whole cell lysates of HEK293FT cells expressing MAGI1-VSV in pres-
ence or absence of GFP-RZi and GFP-RZi-VSV fusion proteins were analyzed. Western blot pictures of 
products in the input lysates before, and purified proteins after capture on GFP-immune magnetic-beads 
stained by anti-VSV and anti-GFP antisera are shown. Migration positions of MAGI1-VSV and GFP-RZi-
VSV (both stained with anti-VSV) are shown to the right of the upper panel in kDa. 
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Figure 3: Identification of binding partners of intracellular PTPRZ using BioID
Biotinylated proteins in whole cell lysates of HEK293FT cells transfected with an expression vector encod-
ing PSD95-tagRFP (panel A) or MAGI1-VSV (panel B)and different cDNA3 plasmids encoding BirA* and 
BirA* fusion proteins size-separated on a gradient gel and analyzed on Western blots by staining with 
conjugated streptavidin (Strept.). Migration positions of biotinylated input proteins are indicated to the left 
of both panels. C. E98 cells were transduced with lentiviruses encoding BirA* control or BirA-RZi (+ or 
-VSV) fusion proteins as indicated and exposed to medium with or without biotin before lysis. Proteins 
in these lysates were size-separated on a gradient gel and analyzed by Western blotting and staining 
with conjugated streptavidin or with (IB) anti-c-Myc, anti-PTPRZ or anti-VSV antibodies, respectively. D. 
Lysates of E98 cells used in C. were harvested in large quantities and used for Western blot and mass-
spectrometry analyses. Proteins stained with anti-PSD95 and anti-LYAR sera in samples of the whole 
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ing this line of reasoning, we identified PTPN13, a submembranous PTP harbor-
ing five PDZ domains, as  a protein that binds to class I PDZ binding motifs [4]. In 
particular PTPN13’s implication in glioblastoma cell survival [19] triggered our inter-
est and made us investigate whether PTPN13 could also be a candidate PTPRZ-B 
interacting protein. Indeed, PTPN13 was efficiently co-precipitated using GFP-RZi 
as a bait in transfected HEK293FT lysates and this did not occur if GFP-RZi-VSV 
was used (Fig. 4A). Vice versa, upon pull-down of HA-tagged human PTPN13 us-
ing anti-HA-coated beads, GFP-RZi but not GFP-RZi-VSV was efficiently co-purified 
(Fig. 4B). Collectively, these findings put forward PTPN13 as a potential PTPRZ-B 
interactor.
Membrane localization is crucial for PTPRZ-B effects on glioblastoma proliferation
In a previous study, we found that the reduction of E98 cell proliferation due to 
PTPRZ1 knockdown could only be reversed by re-expression of shRNA-resistant 
full-length PTPRZ-B but not when its PDZ binding motif was blocked [6]. To test 
whether the truncated intracellular segment of the protein (RZi) is also capable of 
rescuing the proliferative impairment of E98 cells with reduced PTPRZ1 expres-
sion, cells were transduced with two different lentiviruses; one for shRNA mediating 
knockdown of endogenous PTPRZ-B production and the other for expressing the 
shRNA resistant GFP-tagged RZi variants (Fig. 5A). One to two days later, the prolif-
eration capacity of the resulting E98 cells was determined using a 1h EdU incorpora-
tion as a readout (Fig. 5B). Knockdown of PTPRZ1 reduced E98 cell proliferation by 
a factor of two and  this effect could not be rescued or partially reverted by expres-
sion of GFP-RZi, GFP-RZi-VSV, or by the GFP moiety as a control. Since expression 
of full length PTPRZ does rescue proliferation in PTPRZ-knock down cells  [6], this 
shows that not only availability of a functional PDZ binding domain, but also proper 
membrane anchoring of the intracellular segment in PTPRZ-B is required to facilitate 
its effects on glioma proliferation. The above findings are in line with existence of a 
submembranous interaction niche for the PTPRZ-B C-terminus, a subcellular com-
partment that is also harboring PTPN13 (see e.g. [5, 15]).
PTPN13 knockdown impinges on proliferation and viability of glioblastoma cells
Based on the fact that transmembrane PTPRZ-B regulates E98 cell proliferation 
and that this role may possibly be exerted in conjunction with the submembranous 
protein PTPN13, we also wished to address the role of this latter PTP in these cells. 
To this end we lentivirally transduced the glioblastoma cells with shRNA expres-
sion constructs targeting PTPN13 (shPTPN13-1 and shPTPN13-2) or with a non-
targeting control (shSCR). Both PTPN13-targeted shRNAs caused a firm reduction 
of PTPN13 protein levels and had profound effects on E98 cell survival (Fig. 6A-B). 
EdU incorporation revealed a significant reduction of the percentage of S-phase 
cells upon shPTPN13-2 expression (Fig. 6C). For shPTPN13-1 this was not evident 
but the outcome may have been obscured by the reduction in the amount of cells as 
lysate (input) and proteins mixtures obtained after purification on streptavidin dynabeads (AP: strept.) are 
shown. Migration positions of full-length and cleaved PSD95 and LYAR are indicated to the left of the top 
and bottom panels, respectively.  Molecular weight calibration sizes (in kDa) are indicated to the right of 
each panel 
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measured by nuclear coverage (Fig. 6B). Strikingly, upon PTPN13 knockdown with 
either shRNA the E98 glioblastoma cells tended to fuse, resulting in the production 
of giant multi-nucleated cells. Application of shPTPN13-2 resulted in a more modest 
phenotype, with cells containing up to 10 nuclei, whereas shPTPN13-1 express-
ing cells occasionally contained over 50 nuclei (Fig. 6D-E). Time-lapse recordings 
(data not shown) revealed that most multi-nucleated cells die shortly after fusion, 
thus explaining the dramatic reduction in cell numbers. The ones that did survive, 
however, formed giant multinucleated cells. Importantly, E98 cells that received the 
non-targeting control shRNA displayed no such cell fusion events (Fig. 6D-E).
Discussion
We have previously shown that the intracellular part of PTPRZ-B impinges on glio-
blastoma cell proliferation [6]. In the current study, we searched for relevant partner 
proteins that bind to PTPRZ-B intracellular domains using immunoprecipitation and 
proximity labeling strategies. PDZ domain-mediated binding to RZi was detected for 
known (PSD95 and MAGI1) as well as predicted (PTPN13) interaction partners when 
using ectopic expression systems and dedicated lysis buffers. BioID in-cell vicinity 
labeling of endogenous interaction partners in E98 glioblastoma cells did, however, 
not reveal additional potential proteins, presumably because the RZi moiety lacks 
the proper guidance signals for transmembrane localization, and proper embedding 
in the cell membrane is required for its functional recognition. Intriguingly, like for 
PTPRZ-B the shRNA-mediated knockdown of PTPN13 in E98 cells caused a reduc-
tion in cell proliferation. Additionally, PTPN13 knockdown caused extensive cell fu-
sion and cell death, phenomena that are not observed upon PTPRZ-B knockdown. 
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Figure 4:  PTPN13 binds to the PDZ-binding domain of PTPRZ-B.
A. HEK 293FT cells were co-transfected with cDNA plasmids encoding mouse PTPN13 or GFP- RZi(-
VSV) fusion proteins. Presence of these protein products in whole lysate protein mixtures (input) or co-
purified proteins captured on anti-GFP magnetic beads (IP:GFP) was revealed by Western blot analysis 
(IB) using antisera against PTPN13 and GFP. Protein sizes (in kDa) are indicated on the right. B. Similarly, 
HEK 293FT cells expressing GFP-RZi variants and catalytically inactive (C/S) HA-tagged human PTPN13 
were lysed (input) and HA-containing protein complexes were immunopurified (IP:HA) and analyzed on 
blot using GFP and PTPN13 antisera. Size markers (in kDa) are depicted on the right.
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The observation that PTPRZ-B knockdown affects E98 glioblastoma cell prolifera-
tion and that the intracellular part of PTPRZ-B is essential for this effect [6] points to 
involvement of interacting proteins, including the known PTPRZ interactors PSD95 
and MAGI1. The bridge function of PSD95 and MAGI1 between PTPRZ and its 
targets (Erbb4 and β-catenin [21] [17, 41], combined with those targets having links 
Figure 5, Bourgonje et al. 
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Figure 5: A cytosolic intracellular PTPRZ-B fragment is unable to rescue PTPRZ1 knockdown effects.
A. E98 cells were transduced with a knockdown construct targeting PTPRZ-B (shPTPRZ) or a non-tar-
geting control (shSCR) as well as with expression constructs for GFP or GFP-RZi fusion variants. Lysates 
were prepared and analyzed on immunoblot (IB). Knockdown efficacy (indicated below the GAPDH im-
age) was determined by ratioing endogenous PTPRZ-B (upper) and GAPDH (lower) immunosignals and 
normalizing relative to the shSCR control. Ectopic expression of GFP variants was visualized on blot us-
ing GFP antibody. Difference in GFP levels between the shSCR- and the shPTPRZ-expressing samples 
are due to the CMV promoter-controlled GFP marker in the shSCR construct versus tagRFP as reporter in 
the shPTPRZ constructs. Amount of GFP fusion products relative to endogenous PTPRZ was assessed 
using VSV and PTPRZ antibodies and depicted below the lower PTPRZ image. Size markers (in kDa) 
are on the right. Bracket indicates different migration speeds of PTPRZ due to post-translational modifica-
tions. B. Transduced E98 cells were grown on coverslips and labeled with EdU for 1 hr. Percentage of 
EdU-positive nuclei among DAPI-stained cells was determined (n=3). Error bars indicate SD, n.s. means 
not significant, * indicates p-value < 0.05.
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Figure 6: PTPN13 knockdown results in reduced proliferation, survival and increased cell fusion in glio-
blastoma cells.
A. E98 cells were lentivirally transduced with different shRNAs against PTPN13 or a scrambled control. 
After three days cell lysates were analyzed on immunoblots using PTPN13 (upper) and tubulin (lower) 
antibodies to determine knockdown efficiency relative to that in shSCR control (depicted below the im-
ages). Sizes in kDa are depicted on the right. B. E98 cells were transduced as described under A. One 
week later cells were fixed and the cumulative nuclear area was measured by DAPI staining (n=3). C. 
E98 glioblastoma cells were lentivirally transduced with the indicated constructs and grown on coverslips 
before being labeled with EdU for 1 hr. Percentage of EdU-positive nuclei among DAPI-stained cells 
was determined (n=3). Error bars indicate SD and * indicates p-value < 0.05. D. E98 cells expressing 
the indicated shRNA constructs (as well as the linked tagRFP reporter) were grown on coverslips and 
the number of nuclei within one cell membrane as defined by tagRFP and DAPI fluorescence was deter-
mined and binned. E. Fluorescent images depicting cell coverage and cell fusion. Representative images 
are shown. Note that shSCR cells co-express a GFP reporter whereas shPTPN13 constructs carry the 
tagRFP reporter cassette.  
Figure 6, Bourgonje et al. 
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with cancer (eg. [17, 56]), depicts an appealing mechanistic framework for explain-
ing an analogous proliferation-stimulatory role for PTPRZ-B.  PDZ domain-mediated 
interactions are notoriously detergent-sensitive and may not be the only mecha-
nism involved in partner binding. Therefore we explored the proximity-dependent 
BioID strategy to identify  additional binding partners for the intracellular segment of 
PTPRZ-B with impact on glioma cell proliferation. One should bear in mind that the 
promiscuous BirA biotin ligase mutant (BirA*) used in BioID experiments works only 
optimally within a relatively small confined space with ~10 nm radius. Moreover, it 
is able to intra-molecularly biotinylate itself and may dimerize [12], tendencies that 
might complicate proper subcellular localization of the bait and labeling of asso-
ciating proteins. Also GFP tagging may affect a protein’s tendency to oligomerize 
[14]. Full-length PTPRZ-B is a type-I transmembrane receptor that becomes enzy-
matically inactive following ligand-induced dimerization [24, 40]. Any superimposed 
multimerization effect caused by tagging with BirA or GFP as used here may thus 
evoke abnormal sterical hindrance effects and thereby prevent binding and dephos-
phorylation of interacting substrates. We thus must realize that our strategy to dis-
close protein interactions by introducing N-terminal BirA* or GFP tags to the RZi 
segment may have affected its binding to interactors. Nevertheless, both GFP- and 
BirA*-tagged RZi specifically bound to known interactors in transfected HEK 293FT 
cells. Of note, the over-expressed partner proteins also encounter BirA* by chance, 
explaining background signals in control experiments and underscoring the need for 
physiological protein levels to obtain meaningful results.  
Our current functional rescue experiment suggests that not only accessibility of the 
intracellular PTPRZ-B C-terminus is essential in supporting glioblastoma cell prolif-
eration but that also proper membrane anchoring is important. Earlier we demon-
strated that expressing only the ectodomain of PTPRZ-B cannot rescue glioblastoma 
proliferation upon PTPRZ1 knockdown [6], and here we now show that a cytosolic 
version of the PTPRZ-B intracellular domain is not sufficient either. Also the possibil-
ity that relevant endogenous partner proteins are only present in sufficient amounts 
in the submembranous area of the cell needs further attention. Indeed, preferred 
localization of PSD95 and MAGI1 complexes containing Erbb4 and/or β-catenin [10] 
in the vicinity of the membrane has already been demonstrated. Finally, also addi-
tional measures may be needed to make cells fully devoid of competing endogenous 
PTPRZ-B. Thus, to reveal interactions shRNA inhibition strategies as used here, 
or even complete CRISPR-Cas9-mediated knockout of the PTPRZ-B gene may be 
necessary. 
Intriguingly, also the newly identified PTPRZ-B interactor PTPN13 is a submem-
branous protein. This non-receptor-type PTP with five PDZ domains is capable of 
binding a multitude of proteins that are instrumental in cell growth and differentiation 
[1]. For example, PTPN13 downregulates the cell surface expression of the FAS re-
ceptor, and thus the cells’ sensitivity to FAS-induced cell death [20], by binding to the 
FAS C-terminus via its second PDZ domain [4]. Since PTPRZ-B ends in the exact 
same amino acid sequence as FAS (SLV) we expect the PDZ2 domain of PTPN13 
to mediate the interaction with its enzyme family member PTPRZ-B as well. 
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A new striking finding in this study was that PTPN13 knockdown in glioblastoma cells 
not only impacted on cell viability but also triggered cell fusion. Massive mulitinucle-
ated cell bodies were formed within a few hours. The phenomenon was not observed 
upon PTPRZ-B knockdown. This points at an interesting effects of PTPN13 in cell 
fusion events. In line with this, Sardina and coworkers [52] reported increased num-
bers of polyploid cells following PTPN13 silencing in megakaryocyte differentiation, 
a phenotype also observed following β-catenin knock-down. Whether β-catenin is 
also mediating the PTPN13 silencing effect in our study and whether or not the 
PTPN13-related cell fusion phenomenon is key in the development of giant cell glio-
blastoma, a distinct tumor variant characterized by multinucleated giant cells with 
abundant cytoplasm [33], requires further study.
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General Discussion
Glioblastoma, the most malignant form of glioma, is a devastating brain tumor aris-
ing from glial cells or their precursors. After diagnosis patients with this type of tumor 
face an average life expectancy of only 15 months with treatment [77]. Therefore, 
new insights that ultimately result in improved median survival or better quality of 
life are desperately needed. At the molecular level much progress has been made 
and key mutations that deregulate signaling and metabolic pathways in glioma have 
been mapped [13]. Cellular processes such as proliferation, differentiation, migra-
tion, and survival are normally tightly controlled by multiple -often opposing- forces 
that collectively determine whether the pertinent cellular response is activating or 
inhibiting. Cell fate in tissue homeostasis and growth is mostly regulated by signal 
cascades involving protein tyrosine kinases (TKs) and their enzymatic counterparts, 
the protein tyrosine phosphatases (PTPs). The balance between activities of these 
two enzyme classes is pivotal in maintaining cell and tissue homeostasis.
In the research described in this thesis we have investigated the expression levels 
of PTP family members in glioma and have studied the significance of the TK c-MET 
and the PTP PTPRZ-B in particular. Presence of a mutated and amplified MET gene 
in patient-derived E98 glioblastoma cells [58] allowed us to test the efficacy of a TK 
inhibitory compound for c-MET and VEGFR2, both in vitro and in vivo (Chapter 2). 
Using glioma patient samples and online databases we were able to show that in 
general PTPs display low expression levels in gliomas as compared to healthy tis-
sue and that levels decrease with increasing malignancy (Chapter 3). An exception 
is formed by the PTPRZ1 gene which, alike many other oncogenes in tumors, is 
highly expressed in gliomas. Our in vitro and in vivo experiments revealed that the 
PTPRZ-B extracellular part contributes to the migratory phenotype whereas its in-
tracellular domains are responsible for proliferative signals in glioma cells (Chapter 
4). We subsequently launched an attempt to uncover the PTPRZ-B binding partners 
involved in specifying glioma’s typical features and found that the PDZ domain-con-
taining PTPN13 is a potential candidate that regulates glioma cell survival (Chapter 
5). Here I will present some intriguing findings regarding the glioblastoma cell model 
E98 that I gathered over the years and that may have bearing for future studies. Ad-
ditionally, I will elaborate on the potential role of PTPs in gliomas, and new insights 
and treatment strategies that build on the reversibility of phosphotyrosine growth 
signals will be discussed.
Cancer stem cell-like properties of E98 glioblastoma cells
For many experiments described in this thesis the human patient-derived E98 glio-
blastoma cell model was used. Genetic characteristics of E98 cells, including an 
amplification and auto-activating mutation of MET as well as a deletion of PTEN, 
have been documented [20, 58]. E98 cells that are cultured as adherent cells under 
standard serum-containing conditions will give rise to compact tumors upon ortho-
topic injection in mice. Importantly, when cultured in neurobasal medium (essentially 
serum-free, but with selective growth factors added) E98 cells grow as neurospheres 
in vitro and display the clinically relevant diffuse migratory phenotype in vivo [20]. In-
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triguingly, E98 cells display doubling times of 35-40 hours in vitro but appear highly 
proliferative in vivo [12, 20]. Upon in vitro labeling of cells in S-phase for an hour, 
using either BrdU or EdU, around 20% of the cells were found positive (Chapter 4). 
Still, half of the E98 cells entered the cell cycle, as visualized by Ki67 immunostain-
ing or by using the live cell cycle reporter Fucci [67]. The latter was introduced in the 
E98 cells by lentiviral transduction of a home-made bicistronic construct encoding 
the ubiquitination-based cell cycle indicator components Cdt1-Kusabira-Orange2 
and Geminin-Azami-Green1 that differentially label G1 and S/G2/M cells with orange 
and green fluorescence, respectively (Krause et al., manuscript in preparation). The 
remaining 50% of non-cycling cells appear senescent, as judged from senescence-
associated beta-galactosidase staining (Fig. 1A). Whether this bifurcation in cell fate 
specification is due to artificial in vitro cultivation conditions, is currently not known 
(see also discussion below).
As mentioned earlier (Chapter 1), tumors are composed of a related but heterogene-
ous population of cancer cells [72] and ample studies have shown that their cells are 
able to undergo switches in functional state (e.g. [42, 62, 76]). Therefore we separat-
ed the cycling and the apparently senescent fractions of the population of E98 cells, 
based on the fluorescent Fucci reporter-positivity of these cells, prior to monitoring 
their behavior in proliferation and migration assays. Using the spheroid migration 
assay [12] the non-cycling cells demonstrated a migratory potential that sharply con-
trasted with the hardly moving proliferative cells (Figure 1C). Furthermore, when cul-
tured for several passages, the Fucci-positive subset gradually reverted back to an 
E98 cell population with only half of the cells in cycle. Conversely, within the highly 
migratory non-cycling population an increasing number of E98 cells re-entered the 
cell cycle over time (Figure 1D). Apparently, E98 cells in culture switch between cy-
cling and dormant states and consequently the non-cycling cells are not senescent 
or permanently terminally differentiated. A similar plasticity may be envisioned for the 
E98 cells when a switch is made from adherent to neurosphere conditions; only the 
latter regime allows the reproducible generation of diffusely outgrowing tumors upon 
orthotopic injection in mouse brains [12, 20, 57]. 
The above phenomena are reminiscent of the situation for stem cells in physiologi-
cal conditions in that the majority is dormant and only a small fraction of cells, once 
activated when needed, will start cycling [47]. Also for tumors in vivo, the concept of 
stem cell-like cancer cells is appealing as it can explain why some cells are resistant 
to therapy and why tumor recurrence is inevitable in case of incomplete resection 
(e.g [76]). Progeny of stem cell-like cancer cells accumulate independent mutations 
and undergo clonal selection, leaving some subclones to become dominant inside 
the tumor and/or its metastases. Selection due to radio- or pharmaco-therapy may 
eliminate some populations but other subclones may prove resistant to the therapy 
and will prevail [11]. Importantly, because of their semi-dormant state especially the 
stem-cell like cancer cells display a different, usually reduced, sensitivity towards 
conventional cancer treatments. Also in glioblastoma a small population of tumor 
cells displays stem cell-like properties as seen in adult neural stem cells. These 
so-called glioma stem cells, or glioma initiating cells, show expression of stemness 
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markers such as Nestin, Bmi-1, Olig2 and Sox2 [24]. The identification of such tu-
mor-founding cells is important and discoveries of ways to target them specifically 
may hold great promise to reduce tumor recurrence and increase the overall patient 
survival.
Figure 1, Bourgonje et al. 
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Fig 1: E98 shows some characteristics of stem cell-like cancer cells.
A) E98 cells, grown as neurospheres in neurobasal medium (left) or adherent in serum-containing me-
dium (right), were stained for senescence-associated β-Galactosidase (Promo Kine #PK-CA577-K320). 
B) E98 cells, lentivirally transduced with a bicistronic version of the Fucci cell cycle reporter, were FACS 
sorted to separate GFP- (green) or mOrange-positive (red), cycling (Fucci+ sorted) cells from non-cyling 
(Fucci-sorted) cells. Subsequently, the cells were grown as spheroids, using the hanging drop method, 
and seeded in matrigel-coated 96 wells plates. Spheroids were cultured for another 24 hours, after which 
the cells were fixed, counterstained with DAPI (purple) and microscopically examined to monitor migra-
tion from the spheroid. Representative images are shown. C) FACS-sorted Fucci- and Fucci+ populations 
were cultured on glass slides in serum-containing medium and imaged at day 1 and day 24 after sorting. 
Pictures represent an overlay of mOrange (red) and brightfield images taken at the indicated time points.
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Stem cell-like properties of cells overexpressing c-MET
In glioblastoma, recurrent tumors often display a mesenchymal profile [78]. This 
could mean that the original tumor already contained a minority of cells with a mes-
enchymal signature. These cells may be inherently resistant to therapy and have the 
ability to expand and create a recurrence. Such a recurrence may happen even if 
the predominant clones before were classical, proneural or neural [11]. Interestingly, 
c-MET is a ‘signature gene’ for glioblastoma’s specifically those with a mesenchymal 
signature [78] and cells thereof with upregulated c-MET levels retain a stem cell-like 
phenotype upon isolation and culture [7, 41, 49]. Remaining low c-MET-expressing 
cells from the same tumor do not show these stem cell-like properties [41]. Fur-
thermore, when ‘high c-MET’ cells are cultured in serum-containing differentiation 
medium, c-MET is downregulated [7], suggestive of a link between c-MET levels 
and stem cell characteristics in glioma cells. As mentioned above, cancer stem cells 
have been found to be more resistant to therapy because of their relative dormancy 
[19]. This bears clinical relevance since radiotherapy leads to upregulation of c-MET 
expression through the ATM/NF-κB pathway [6] Furthermore,  pharmacological in-
hibition of c-MET sensitizes cells to radiotherapy [41]. Thus, two possible models 
on how c-MET levels may correlate with radioresistance may be postulated. Either 
subclones that are already high in c-MET and better resistant to radiotherapy will 
become more dominant following radiotherapy and will give rise to the recurrence, 
or low-c-MET subclones upregulate c-MET in order to become resistant (reviewed 
in [11]).
Amplification or overexpression of c-MET is often associated with loss of the tumor 
suppressor PTEN [11]. PTEN-loss may contribute to the invasive phenotype ob-
served with glioma cells overexpressing c-MET as both c-MET and PTEN have ef-
fects on the PI3K pathway (e.g [17, 60]). Where c-MET has an activating role leading 
to cell survival, PTEN has an inhibitory role in the P13K pathway. Overexpression 
of c-MET in a PTEN deleted/ mutated cell might further the damage done by over-
activation of the PI3K pathway. The reverse is also true, c-MET amplified cells which 
undergo PTEN deletion might have a growth advantage because the PI3K pathway 
is further activated. Simultaneous inhibition of c-MET and inhibition of mTOR (which 
is normally inhibited by PTEN), resulted in greater reduction of migration and prolif-
eration than either compound alone [48], indeed suggesting a link between PTEN 
and c-MET downstream effectors. 
Interaction of c-MET and PTPRZ
Another PTP which c-MET may interact with is PTPRZ. In chapter 4 we show that 
PTPRZ has an effect on c-MET phosphorylation. We found that knock-down of 
PTPRZ-B levels in glioblastoma cells resulted in reduced cell migration and a re-
duction of phospho-MET levels. Reintroducing PTPRZ-B’s extracellular domain into 
these cells normalized migration behavior as well as increased MET phosphotyrosine 
levels [12]. How the two proteins interact is currently unclear. There is no evidence 
that c-MET is a direct substrate for PTPRZ-B and in fact the catalytic domain of 
PTPRZ was not required for restoration of phospho-MET levels in our rescue experi-
ment. Furthermore, PTPRZ-B knock-down should rather result in an increase, and 
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not a decrease, in phosphotyrosine levels of its substrates. Thus it is likely that the 
connection involves other protein intermediates. Interestingly, PTPRZ has recently 
been implicated as a marker of stem cell-like glioma tumor cells, in a similar way as 
c-MET [32]. Authors found that paracrine stimulation of these cells with macrophage-
derived-pleiotrophin via PTPRZ played a crucial role in their maintenance [70]. Fur-
thermore, pharmacological inhibition of PTPRZ or its family member PTPRG, 
resulted in a reduction in stemness markers [32]. Thus there may be interplay be-
tween c-MET and PTPRZ in the poising of stemness. Studying their interaction in the 
context of stem-cell like tumor cells, may yield insight that will become beneficial in 
combatting these hard to target cells.
To determine whether PTPRZ and c-MET may participate in the same signaling 
complex on the cell surface one could turn to proximity ligation assays [26]. In this 
technique antibodies directed against two proteins of interest are exploited to bring 
conjugated oligonucleotides in close enough proximity to allow rolling circle ampli-
fication and subsequent detection. One may also probe via immune-pull down and 
complex purification whether the kinase-phosphatase pair is part of the same com-
plex, but own experience (Chapter 5) showed that the success of such experiments 
is critically dependent on the composition of lysis and purification buffers.  Ideally, 
one would like to also identify the unknown additional interactors in such a c-MET 
/ PTPRZ-B assembly. Tandem affinity purification followed by mass spectrometry 
(TAP-MS) then comes to mind. In this technique bait proteins are tagged twice to 
enable sequential purification steps of prey interactors thereby reducing background 
signals [43]. Again, like with immunoprecipitation, the challenge remains to keep 
the protein complex intact during lysis and purification steps. Two recent methods 
now circumvent this problem by making use of the enzyme APEX2 or BirA*. Both 
are engineered enzymes that generate highly reactive biotin-phenoxyl and biotinoyl-
5-AMP radicals, respectively [46, 66]. The covalent coupling of these radicals to vici-
nal proteins allows for later purification using high-affinity avidin-based beads. Both 
methods require the expression of a fusion product of the protein of interest with the 
APEX2 or BirA* enzyme. As is evident from the experiments in chapters 4 and 5, 
inclusion of such labeling tags in itself could hamper the binding of partner proteins 
to the complex. For example, our addition of the VSV epitope tag to the PTPRZ-B 
C-terminus, at that time for immunoprecipitation purposes, presumably blocked the 
binding of PDZ domain–containing proteins required to affect the proliferation of glio-
blastoma cells.  Also the distance between the APEX2 or BirA tag and the actual site 
of interaction – and thus bait topology– may be a factor that determines success with 
this methodology for interactor protein identification
The interaction between c-MET and PTPRZ-B does not only occur at the protein 
level. In about 10% of glioblastoma’s, due to translocation events involving introns 3 
or 8 of PTPRZ1 and intron 1 of MET, there is even a covalent link between PTPRZ 
and c-MET. The resulting fusion transcripts encode primary proteins that consist of 
various lengths of the extracellular domain of PTPRZ-B followed by the entire c-MET 
open reading frame [9, 18]. The fusion proteins contain only a small part of the extra-
cellular domain of PTPRZ-B and, due to proteolytical processing during intracellular 
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transport, the mature protein on the cell surface ends up being identical to c-MET 
[18]. Thus in view of the short stretch of PTP-derived amino acids sequence in the 
premature fusion protein, PTPRZ-B binding partners will have no bearing for ‘fused 
c-MET’ regulation. However, during their journey in the cell the various PTPRZ-c-
MET fusions appear less well protected from HGF-independent activation and con-
sequently display overall elevated phosphotyrosine levels. Furthermore, the promo-
tor switch from MET’s own promotor to that of PTPRZ1 considerably upregulates 
the expression level of c-MET [18]. Indeed, this is compliant with our finding that, 
PTPRZ1 is strongly expressed in glial tumors as compared to normal tissue (Chap-
ter 3). This combination of enhanced expression and increased ligand-independent 
phosphorylation of c-MET, induced by the fusion to PTPRZ1, may well explain the 
oncogenicity of the translocation event. It seems appealing, therefore, to specifi-
cally target the fusion transcripts using therapeutic oligonucleotides, as proposed 
for treatments of neurodegenerative diseases like Huntington’s Disease and Amyo-
trophic Lateral Sclerosis [23]. 
Interactions of PTPRZ-B with PDZ-containing proteins.
We studied the role of PTPRZ-B in glioblastoma proliferation and migration and not-
ed that its extracellular part, possibly involving c-MET, is mediating migratory signals 
whereas the proliferative effects are provided by the intracellular part (Chapter 4). 
More specially, the PTPRZ-B C-terminal PDZ binding motif appeared crucial for the 
latter process and thus a collection of potential binding partners and interacting pro-
teins deserves further discussion (Fig.2)
Postsynaptic density protein 95 (PSD95) is part of the membrane-associated gua-
nylate kinases family (MAGUK) and contains three PDZ domains, an SH3 domain 
and a guanylate kinase domain. First discovered in yeast two hybrid screens, it is 
the second PDZ domain of PSD95 that binds to the PTPRZ-B C-terminus [44]. Using 
either its first or second PDZ domain PSD95 can also bind to ErbB4.  Thus, PSD95 
can simultaneously bind both ErbB4 and PTPRZ-B, facilitating the dephosphoryla-
tion of ErbB4 by PTPRZ-B, but it can also facilitate ErbB4 homo-dimerization and 
subsequent auto-activation [29]. PDZ domain-containing proteins thus may regulate 
phosphotyrosine-mediated signals through the organization of RTK/RPTP clusters. 
It also implies that in cell systems, overexpression of components of such a regula-
tory cluster will not be without consequence. High amounts of PTPRZ-B, as in glio-
blastoma cells, could cause a decrease in ErbB4 phosphorylation in two ways. Both 
sequestering PSD95 and preventing PDZ-mediated ErbB4-ErbB4 homodimer for-
mation as well as direct dephosphorylation of Erbb4 could be involved. Like its family 
member ErbB1 (EGFR), ErbB4 uses PI3K and Ras signaling pathways. However, 
whereas EGFR leads to increased proliferation and survival, the prolonged activa-
tion by ErbB4 leads to an inhibitory effect of these pathways on proliferation, survival 
and differentiation in brain maintenance and development (reviewed in [40]). It is 
tempting to speculate that the high PTPRZ-B levels in glioma hamper this ErbB4-
mediated inhibition of proliferation as part of their tumor-promoting effect. 
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Both PTPRZ-B and ErbB4 can also bind to MAGI2, and possibly MAGI1 and MAGI3, 
in a similar manner as to PSD95 [16]. MAGI proteins also belong to the MAGUK family 
of PDZ domain-containing submembranous anchoring proteins, and a MAGI/ErbB4/
PTPRZ-B complex may serve similar purposes as described above for PSD95. Al-
ternatively, PSD95 and MAGI members could compete for binding to ErbB4 and 
PTPRZ-B, and direct them to specific subcellular niches to exert their signaling ef-
fects. In addition, MAGI1 represents a PTPRZ-B substrate as it is dephosphorylated 
on Y373 and Y858 following binding [30]. MAGI3 is not a substrate itself but being a 
Apoptosis
proliferation
PDZ domain 
containing proteins
PDZ binding motif 
containing proteins
Protein-protein interactions
Dephosphorylation
Synthetic Lethal pair
Cellular process they regulate
Fig. 2 Schematic representation of PDZ mediated interactions of PTPRZ and PTEN.
PTPRZ-B and PTEN can interact with a wide range of PDZ-containing proteins and associate and regu-
late many other PDZ-binding site containing proteins. In the text we elaborate on the relation between 
these proteins. The figure is meant to illustrate how complex the PDZ-interactions are and how many 
proteins would be affected if one of these proteins would be altered in expression or structure. Lines in-
dicate protein-protein interactions - in this case the interaction of a PDZ-domain containing protein with a 
PDZ-binding-site containing protein. Furthermore, the enzymatic activity of PTPRZ is displayed, whereby 
several targets are dephosphorylated in reactions mediated via its PDZ-interactions. Also effects of sev-
eral targets are depicted, giving clues as to how these interactions regulate cellular functions.
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scaffolding protein it can provide PTPRZ-B access to substrates like the phospho-
protein p130 in glioma cells [2]. Likewise, MAGI1 might facilitate the dephospho-
rylation of β-catenin by PTPRZ-B [56] by using its fifth PDZ domain for β-catenin 
and PDZ domain 2 for PTPRZ-B anchoring [22, 33]. Of note, β-catenin levels are 
often upregulated in cancers and result in the transcription of proliferation-associat-
ed genes [52]. Moreover, tyrosine-phosphorylated β-catenin increases Wnt signal-
ing and tumorigenesis. Since an increase in PTPRZ-B would be expected to result 
in more dephosphorylated β-catenin in the presence of abundant MAGI1, halting 
β-catenin nuclear activation and stabilizing cadherin-mediated cell adhesions, we 
reason that the MAGI-dependent link with β-catenin does not represent PTPRZ-B’s 
tumorigenic contribution in glioma. 
PTEN and PTPRZ-B share a large part of their PDZ-mediated inter-
actome.
Interestingly, the C-terminus of PTEN is bound by many of the same PDZ domain-
containing proteins as those that bind to PTPRZ-B, including PSD95, MAGI1 and 
PTPN13 [71] (fig.2). Recently, a large bioinformatics screen using yeast and human 
interaction databases led to the suggestion of thousands of potential synthetic lethal 
gene pairs (meaning inactivation of one gene will not kill the cell because the other 
will compensate, but inhibiting both genes will kill the cell) and the combination 
PTPRZ1 - PTEN was present in their top 20% [74]. This triggered us to perform 
a pilot experiment using the LN229 PTEN wildtype and PTEN deficient isogenic 
cell lines that were generated using CRIPSR/Cas9 technology (Chapter 3). Upon 
PTPRZ-B knock-down (using the lentiviral shRNA constructs described in Chapter 4) 
the PTEN proficient cells demonstrated a mild reduction in survival and growth, but 
cells that lack PTEN showed a drastic decrease in proliferation and survival. This is 
in line with a synthetic lethal interaction of PTEN and PTPRZ1 in these glioblastoma 
cells. Determining which processes PTPRZ-B and PTEN have in common will be 
the next step in elucidating a potential therapeutic target. Use of information about 
shared interactions such as those between partners and at the above mentioned 
PDZ-containing proteins will form a solid basis for the start of such an endeavor. 
Furthermore, conditional knock-out of PTPRZ using CRISPR/Cas9 experiments will 
be needed to test this hypothesis accurately in E98 cells, as we have only achieved 
a relatively mild knockdown of PTPRZ (50-80%) in these cells so far. 
Although PTEN and PTPRZ1 are cancer modulating genes in their own right, the 
above hypothesis sheds a new light on the occurrence of PTEN deletion and 
PTPRZ-B upregulation in glioma specimens. Since PTEN and PTPRZ-B at least in 
part share their PDZ domain-containing interactome, the altered expression of either 
one of them will modify the hardwiring of the other and thereby change underly-
ing signaling pathways. Hence, the interaction with their PDZ domain-containing 
partners has a distinct consequence for the two PTPs. PTEN recruitment to the cell 
membrane by means of PDZ domain-mediated anchoring allows a more efficient 
dephosphorylation of phospholipids, both by localizing and stabilizing PTEN but also 
by increasing its enzymatic activity (reviewed in [55]). PTPRZ-B on the other hand 
already resides at the cell membrane, and it has no such impact on the PI3K path-
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way, although it can affect AKT through FYN [70]. Determining which processes are 
affected by both proteins and which are not, could therefore provide new therapeutic 
insight and is worth investigating.
PTPN13 regulates PTPRZ-B dependent and independent pathways in glioblastoma.
The list of protein interactors that bind PTPRZ-B [34] will undoubtedly grow in the 
coming years. Interactions listed in databases like BioGrid, String and InAct currently 
add up to 138 interactors. We found experimental evidence for a novel interaction 
with the large non-transmembrane protein PTPN13, also a protein tyrosine phos-
phatase. PTPN13 consists of a KIND domain, a FERM domain, five PDZ domains 
and finally the protein tyrosine phosphatase catalytic domain. This handful of PDZ 
domains enable PTPN13 to bind a wide range of protein C-terminus [27], among 
these the PDZ binding motif of FAS that ends with the sequence ‘SLV’ [68], the 
same as in PTPRZ-B (Chapter 5). PTPN13 is contributing to the endocytosis and 
degradation of FAS, also known as the death receptor. High cell surface levels of 
FAS makes cells sensitive to apoptosis signals mediated by the FAS ligand. Reduc-
tion of FAS levels, by PTPN13-triggered internalization, increases cell resistance to 
apoptosis [68]. Furthermore, PTPN13 is subject to autophagy. Cells within a popula-
tion with high autophagy degrade PTPN13 which sensitizes cells to FAS induced 
apoptosis, thereby selectively determining cell-fate  [35]. Interestingly, we observed 
high levels of cell death in glioblastoma cells upon PTPN13 shRNA-mediated knock-
down (Chapter 5). Intriguingly, the PTPN13 knock-down in E98 glioblastoma cells 
had a similar effect as for PTPRZ-B knockdown, namely a reduction in proliferation, 
however, there were also distinct differences. For one, PTPRZ-B knockdown did 
impair migration whereas knockdown of PTPN13 showed a trend towards increased 
migration (data not shown). Moreover, PTPN13 knockdown resulted in massive cell 
death and cell fusion (Chapter 5), which is not seen in E98 cells upon depletion of 
PTPRZ-B (Chapter 4). Thus, PTPN13 impinges on glioma formation and growth 
also in PTPRZ-B-unrelated ways. Investigating these PTPRZ-coupled and PTPRZ-
independent processes and determining the autophagic potential of the different 
cells within the E98 population might elucidate new pathways and entry points for 
treatment. 
PTPN13 indeed has been recognized as a player in the cancer field, displaying both 
oncogenic as well as tumor suppressive functions, depending on the cellular context 
of its activity and on the available partners [27]. First I will describe evidence for a 
tumor suppressor function for PTPN13 and then turn to studies that highlight its 
tumor-promoting contribution. In breast cancer cells PTPN13 was found to dephos-
phorylate IRS-1. This leads to reduced phospho-Akt levels, hence to inhibition of 
the PI3K pathway, making cells more vulnerable for apoptosis (reviewed in [28]). 
Furthermore, lower PTPN13 levels, due to either increased protein degradation, pro-
motor hypermethylation or reduced mRNA levels, have been associated with a more 
tumorigenic character of the specimens, implying PTPN13 as a tumor suppressor 
[36, 73, 82]. In line with this, mutations in PTPN13 have been found in several carci-
nomas [39, 65, 79]. PTPN13 down-regulation by miR-26a has also been implicated 
as a reason for EGFR inhibitor resistance.
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Tumorigenic functions for PTPN13 have also been suggested. For instance, PTPN13 
mediates the degradation of the PI3K p85β regulatory subunit, thereby preventing 
the inhibition of PI3K by excess free p85β through competition with p85-p110 dimers 
for IRS1 binding (reviewed in [28]). Furthermore, in Ewing’s sarcoma a chromosomal 
translocation results in expression of an aberrant transcription factor, EWS-FLI1, 
which strongly up-regulates PTPN13 protein levels, thereby boosting cell growth and 
motility [1]. Finally, as mentioned before, PTPN13 controls FAS cell surface levels in 
several cancer types and thus facilitates their resistant to apoptosis (reviewed [28]). 
Combined, these findings support the importance of PTPN13 in cancer [80]. 
We can conclude that the role of PTPN13 is complex. The specific localisation adn 
function of PTPN13 will depent on its many binding partners (reviewed in [27]). 
There is one additional aspect I would like to address here: our reproducible finding 
that PTPN13 knockdown in E98 cells causes glioblastoma cell fusion (Chapter 5). 
The amount of cells that fuse varies within and between experiments. Small cells 
with only a few nuclei are observed but also cells that contain over a hundred nuclei 
were observed after PTPN13 knockdown. The speed at which the fusions occur rule 
out that the underlying mechanism reflects a defect in cytokinesis, reminiscent of the 
findings of Erdmann et al.[38]. Instead, we see intriguing parallels with a glioblasto-
ma subtype that displays giant cells containing multiple nuclei [61]. In the WHO clas-
sification this giant cell glioblastoma is a variant of especially IDH WT glioblastoma 
[51]. This variant is rare, making extensive studies difficult, but it is worthwhile to 
have a close look at PTPN13 levels in the various glioblastoma subtypes. Formation 
of multinucleated giant cells also happens during osteoclast formation, where it is 
dependent on PI3K-activated proteins that drive the necessary cytoskeletal remod-
eling [59]. As mentioned above, PTPN13 has an effect on PI3K activity and PTPN13 
knockdown could therefore affect PI3K-dependent cell fusion. Furthermore, PTPN13 
has been linked to actin dynamics and thus could facilitate fusion via cytoskeletal 
adaptations (reviewed in [27]). E98 cells are PTEN-deficient, so it would be interest-
ing to subject PTEN-wildtype cells to PTPN13 knockdown experiments and monitor 
fusion events. It also remains to be seen whether its role in cell fusion can be pin-
pointed to one of its interaction domains and/or requires the PTP’s catalytic activity. 
PTPs as treatment targets
Based on the comparison of relative expression levels in normal and neoplastic 
brain tissue and expression and survival data from relevant databases, we identified 
a number of PTPs (Chapter 3) that could serve as possible entry points for glioma 
treatment. However, whereas many small compounds and biologicals exist that act 
on tyrosine kinases, only very few (ant)agonists have been established for PTPs 
[75]. We found that many PTPs were downregulated in glioma specimens (Chapter 
3) and increasing either their activity or amount thus seems an appealing treatment 
strategy. Unfortunately, such an intervention is much more difficult than inhibiting 
enzyme activity. Knowledge on transcriptional regulatory mechanisms that act on 
PTP genes is not at an applicable level yet, and details on how to boost PTP en-
zymatic activity is sparse, hard to modulate or limited to a few members only [75]. 
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For example redox modulation, allosteric regulation and protein oligomerization are 
among these regulatory mechanisms. The latter two strategies touch upon aspects 
that will be discussed below since these reflect PDZ domain-mediated interactions 
and receptor-type PTP dimerization, respectively. Also the pharmaceutical inhibition 
of PTP activity is difficult to achieve, because of the highly conserved PTP catalytic 
domain structure  [37]  . 
PTPRT was found to be significantly down-regulated in glioma specimens and upon 
re-expression in vitro a reduction of proliferation was obtained (Chapter 3). PTPRT is 
part of the R2B receptor-type PTP family that also comprises PTPRM, PTPRU and 
PTPRK. All four members are single-pass transmembrane proteins that are post-
translationally cleaved, resulting in their extracellular domain being shed. This shed 
portion can then bind again to the rest of the molecule at a different site [21]. Also 
PTPRM was significantly downregulated in glioma samples as compared to normal 
brain tissue [14] but for both PTPRU and PTPRK the trend towards down-regulation 
did not meet our criteria  (Chapter 3). The involvement of the R2B RPTP subfamily 
as tumor suppressors in diverse cancer types is well documented [21]. For glioma, 
notably PTPRK mutations that associate with clinical outcome have been reported, 
and reconstitution of PTPRK in glioma cells resulted in reduced proliferation and mi-
gration and an improved response to therapy [3, 4]. Since β-catenin and EGFR are 
PTPRK substrates, PTPRK re-expression lowers EGFR and β-catenin phosphoty-
rosine content, hence  improves sensitivity to EGFR inhibition and reduces β-catenin 
expression levels [3]. Assuming all R2B family members act in a similar way, our 
findings on PTPRT and PTPRM relevance in glioma suggest that a combined use of 
Temozolomide and EGFR inhibitors might prove fruitful when tumors carry dysfunc-
tional R2B PTPs.
A cautionary note should be issued, however, as endogenous, smaller isoforms of 
PTPRM and PTPRU were found to act tumorigenic in glioma samples, even when 
full-length proteins were expressed at reduced levels [15] [83]. Similar results were 
found in gastric cancer [50]. Apparently, nuclear-localized isoforms act as dominant-
negative by sequestering β-catenin and preventing its dephosphorylation by full-
length PTPRM and PTPRU. In line, tumor-associated mutations in PTPRK not only 
affect its phosphatase activity but also lead to abnormal proteolytic processing [3]. 
Therefore it is important to understand in more detail how proteolytic processing 
affects the activity of R2B receptors before considering compounds that block their 
cleavage in tumor treatment. 
PTPRZ-B as a drug target
Several attempts have been made to utilize PTPRZ-B, a major contributor to glioma 
tumorigenicity, as a therapeutic target. The most successful, at least from a de-
velopment point of view, is a peptide derived from PTPRZ-B’s extracellular moiety 
that forms part of a peptide-based glioma vaccine called IMA950 [64].  Currently 
this vaccine is in phase I/II clinical trials. Historically, the first preclinical attempt to 
target overexpressed PTPRZ on glioma cells in vivo dates back to 2006 when a 
saporin-coupled antibody that targets the PTPRZ-B extracellular domain was found 
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to significantly delay human U87 glioma tumor growth in a subcutaneous mouse 
xenograft model [25]. The most recent endeavor involved the development and test-
ing of SCB4830, a small inhibitory compound that specifically targets the PTPRZ-B 
catalytic site [31]. Here, C6 glioblastoma cells had been transplanted into rat brains 
and the inhibitor was applied as a liposome complex by means of daily intracer-
ebroventricular injections to find a reduction in tumor growth. 
We reported that the extracellular and intracellular domains of PTPRZ-B regulate 
different aspects of glioblastoma behavior (Chapter 4), indicating that combining a 
therapeutic antibody, which targets the extracellular domain, with an inhibitor for the 
intracellular catalytic domain may have synergistic effects. However, in our set-up 
we also found that it is not so much the catalytic activity of PTPRZ-B that is impor-
tant for glioma cell proliferation but rather the protein interactions mediated by its 
C-terminus [12]. Perhaps we missed a contribution of PTPRZ-B enzyme activity in 
our knockdown rescue experiments because PTPRZ-B knockdown was incomplete. 
PTPRZ-B homodimerizes upon ligand binding, leading to inactivity of the catalyt-
ic domain due to sterical hindrance [33, 54].  It is also conceivable that PTPRZ-B 
forms inactive dimers when at high concentrations, as in glioma specimens. In such 
a scenario, PTPRZ-B knockdown would actually increase its activity. Likewise, re-
expression of a catalytically inactive mutant may rescue by heterodimerizing with 
endogenous PTPRZ-B, as it still can bind ligands and can sterically inhibit the activ-
ity of the wildtype partner. In sharp contrast, a PTPRZ-B variant that was blocked in 
its C-terminal binding domain was not able to rescue E98 proliferation impairment 
that resulted from PTPRZ-B knockdown. But perhaps both enzymatic activity and C-
terminal protein interactions govern the same processes. After all, PTPRZ-B will only 
dephosphorylate substrates that come within close range and this may well require 
binding of the enzyme and the substrates for PSD95 or MAGI1. Therefore, com-
pounds that also block PDZ domain binding sites may have added value in glioma 
treatment regimens as well. 
C-terminal binding motifs as a potential targeting mechanism for 
treatment.
PTPRZ-B is not the only PTP, and certainly not the only transmembrane protein, 
that is bound by a specific C-terminal binding motif. Submembranous orchestration 
of protein complexes using C-terminal binding domains may also serve to regulate 
substrate specificity for the catalytically very efficient PTP family [10]. Especially the 
sequence conservation within the C-terminal tails among RPTP orthologs under-
scores their importance in regulating PTP function. Multiple PTPs whose expression 
was found to be significantly altered in gliomas and correlated with survival (PTPRZ, 
PTEN, PTPRT), contain a PDZ binding motif [10]. Further investigation is thus need-
ed to map the relevant interactions with PDZ domain-containing proteins and to de-
velop interaction-specific intervention molecules. Some compounds that specifically 
block PDZ interactions have been discovered, and these might prove beneficial in 
treating glioma. For instance, the peptide that blocks PDZ1 and PDZ2 of PSD95 [8] 
may disrupt the interaction with PTPRZ-B and affect glioblastoma cell proliferation. 
As mentioned before, PTPRZ-B and PSD95 can interact with many proteins in a 
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PDZ-dependent way, including PTEN, posing an enormous puzzle on how to keep 
the actions of such protein-protein interaction-disrupting compounds both targeted 
and effective. Recently, a compound that prevents the syntenin PDZ domain from 
binding targets was shown to increase radiosensitivity and decrease growth of glio-
mas in vivo [45]. Because of the conservation of PDZ domains and their interacting 
PDZ binding motifs, this compound may block more than only syntenin-mediated 
interactions. Potentially it could even disrupt interactions that involve PTPRZ-B.
Further proof for the potential validity of PDZ domain-mediated interactions as thera-
peutic targets in glioma comes from study of two additional PTPs: PTPN13 and 
PTPN4. A small molecule that blocks the afore-mentioned association of PTPN13 
and FAS is currently under development to treat idiopathic pulmonary fibrosis (pat-
ent pending: US Patent Application 20120148528; published international patent 
WO/2012/064763). Such a small molecule would sensitize cells to apoptosis and 
might have future applications in glioma as well. Furthermore, a peptide targeting 
PTPN4’s PDZ domain has shown to be effective in inducing cell death in a glio-
blastoma cell model in vitro [5]. Targeting the enzymatic activity of PTPN4 can be 
achieved using a PDZ-blocking compound [53], giving us additional options for tar-
geting the enzymatic activity of PTP’s.
Concluding remarks.
In this thesis I presented evidence that many PTPs (with the exception of PTPRZ-B) 
are expressed at much lower levels in gliomas than in healthy tissue, in line with an 
anti-tumor role. PTPs, currently underrepresented as potential therapeutic targets, 
thus deserve further study despite their stigma of being difficult to block pharmaco-
logically. We argue that, apart from initiatives to specifically target the catalytic PTP 
domains, strategies that aim at protein interactions mediated by these enzymes, 
notably PDZ domain-based interactions, provide appealing routes to modify PTP 
functioning. Currently little is known about the PTP targets that we have identi-
fied, such as MTMR7, DUSP26 and PTPRN2, in glioma (Chapter 3). The effect of 
DUSP26 on tumorigenicity is documented [63, 69, 81] but the underlying mechanism 
still needs to be disclosed. For PTPRT and PTPRM compounds that block proteoly-
sis could prove beneficial, and drugs that block interactions with the C-terminus of 
PTPRZ-B likely affect glioblastoma proliferation. Interestingly, also PTPRT contains 
a C-terminal PDZ binding motif that, in the light of our PTPRZ-B findings, is worth 
investigating. Understanding the interplay between TK’s and PTP’s is crucial to de-
sign combination therapies with kinase inhibitors, PTP (ant)agonists and/or protein-
protein interaction-blocking compounds that ultimately may combat diffuse gliomas 
effectively.
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Thesis Summary in English
Patients diagnosed with glioblastoma that undergo standard treatment currently 
have a very low five-year survival rate of only 5%. Novel therapeutic modalities for 
this devastating type of brain cancer are therefore urgently needed. Unfortunately, 
our current knowledge about the development, growth and cellular homeostasis of 
brain tissue and the transformation of brain cells into cancer is still rather limited. It 
is therefore important to study the mechanisms that govern these processes in more 
detail before new avenues for treatment can be opened up. 
In this thesis, I present new findings regarding the role of one of the key cellular regu-
latory mechanisms, protein tyrosine phosphorylation, in diffuse glioma. Phospho-
tyrosine content of cellular proteins is determined by the balanced action of protein 
tyrosine kinases (TKs) on the one hand and – their counterparts – protein tyrosine 
phosphatases (PTPs) on the other. Thus far the role of PTPs in brain tumorigenesis 
has not received much attention in the literature despite the fact that these proteins 
can both function as oncogenic drivers as well as tumor suppressors, depending on 
the cellular context in which they exert their activity.
In chapter 2 we investigated new ways to reduce the abnormally high level of phos-
phorylation by tyrosine kinase c-MET in glioma cells. We used the new compound 
cabozantinib to inhibit the kinase activity of both VEGFR and c-MET and observed 
that this resulted in reduced migration and proliferation of glioblastoma cells in vitro 
and led to a reduction in tumor load and an increase in survival in mouse models for 
this brain tumor. 
Apart from the effects of chemical phosphorylation inhibitors in specific growth regu-
latory pathways we also examined the potential role of PTPs in regulating tumori-
genic pathways in a more broader sense, by assessing the expression levels of the 
majority of PTP family members in glioma samples. In chapter 3 we describe how we 
explored the overall relation between PTP expression and the malignancy grade of 
glioma tumors. We identified several PTPs which are downregulated in gliomas and 
whose expression level correlates with patient survival data. Two of the most notice-
able candidates in the PTP family are DUSP26 and PTPRT. Low expression of these 
PTPs correlated with reduced survival. Upon increasing the expression of either one 
of these two PTPs in a glioblastoma cell model, we observed a reduction in prolifera-
tion and migration of these tumor cells, in line with a tumor suppressive role for these 
PTPs. Furthermore, we confirmed the results of other studies, and showed PTPRZ1 
expression to be high in glioma, specifically in oligodendroglioma, tumor samples. 
We next focused on PTPRZ1 as a possible oncogene in glioma and studied its 
mechanism of action using a clinically relevant glioma cell model that recapitulates 
the diffuse infiltrative character of the tumor. In chapter 4 we describe how different 
domains of PTPRZ-B have distinct roles in glioma diffuse migration and prolifera-
tion signaling, as inferred from studies with truncated proteins. We discovered that 
shRNA-mediated knockdown of PTPRZ-B resulted in a reduction of proliferation as 
well as migration of E98 tumor cells. Re-expression of the extracellular domain of 
PTPRZ-B was able to rescue the migratory phenotype, but not the effects that knock-
down of endogenous PTPRZ-B has on proliferation. In contrast, re-expression of the 
full-length wild type protein or a catalytic dead PTPRZ-B variant fully rescued both 
knockdown effects.  Only when the PDZ-binding domain at the PTPRZ-B C-terminus 
was blocked by a VSV-epitope tag, the full-length protein lost the ability to rescue 
the reduced proliferation phenotype. Thus, the intracellular moiety of PTPRZ-B, in 
particular the PDZ-binding target at its 3’terminal end, is involved in the regulation of 
cell proliferation. 
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In chapter 5 we continued this line of research and searched for interactors of the 
intracellular domains of PTPRZ-B that regulate glioma proliferation. We describe 
how the entire PTPRZ-B intracellular domain was used in unbiased (i.e. with BIO-
ID methodology) and targeted (i.e. with co-immunoprecipitation technology) binding 
studies.  We uncovered a new PTPRZ-B interactor, PTPN13, also a member of the 
large family of PTPs. PTPN13 is highly expressed in glioblastomas and shRNA-
mediated reduction of its expression strongly impaired survival of tumor cells in vitro. 
Interestingly, knockdown of PTPN13 triggered the fusion of glioblastoma cells into 
giant multinucleated cells. We further obtained indirect evidence that transmem-
brane anchoring of the PTPRZ-B intracellular domain might be important for proper 
regulation of its biological activity, because the cytosolic intracellular domain did 
not rescue cellular proliferation in a similar manner as the full-length, membrane-
anchored proteins.
Lastly, in chapter 6 I discuss the implications of the findings presented in this thesis 
and give an outlook on new research lines to further elucidate the role that PTPs 
have in the etiology of gliomas. Focus is on a few specific themes, i.e. on the links 
of PTPRZ1 and MET with stem cell-like characteristics, the role of the PDZ binding 
domain of PTPRZ-B, and on the function of PTEN as an central node in regulating 
PDZ-associated aspects of tumor cell behavior. Also possible ways in which PTPs 
may be used as druggable targets for combating glioblastoma are described. The 
new insights in the complex biology of phosphotyrosine signaling in glioblastoma 
growth and migration may ultimately lead to the development of new treatment op-
portunities for these devastating tumors. 
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Proefschrift samenvatting in het Nederlands
Patiënten met de diagnose glioblastoom die standaard behandeling krijgen heb-
ben helaas nog steeds een zeer lage vijf-jaars overlevingskans (slechts zo’n 5%). 
Nieuwe therapieën voor deze verwoestende tumoren zijn daarom dringend nodig. 
Helaas is onze huidige kennis op het gebied van ontwikkelen, groei en cellulaire 
homeostase van hersenweefsel en het ontstaan van kanker niet toereikend. Om 
nieuwe, meer effectieve therapieën te ontwikkelen is het nodig om de mechanismen 
die deze processen aansturen in meer detail te bestuderen.
In dit proefschrift laat ik nieuwe bevindingen zien met betrekking tot de rol van één 
van de belangrijke cellulaire processen, fosforylering van eiwitten, in diffuse gliomen. 
Dit proces wordt bepaald door de balans tussen de activiteit van proteïne tyros-
ine kinases (TKs) enerzijds en de activiteit van proteïne tyrosine fosfatases (PTPs; 
protein tyrosine phosphatases) anderzijds. Tot op heden is de rol van PTPs in de 
tumorvorming in hersenen nog sterk onderbelicht gebleven in de wetenschappelijke 
literatuur. Begrijpen hoe deze eiwitten hun rol uitoefenen is belangrijk omdat ze zow-
el tumorgroei kunnen stimuleren als hinderen, afhankelijk van de context van de cel. 
In hoofdstuk 2  beschrijven we een nieuwe aanpak om het abnormale niveau van 
fosforylering door de tyrosine kinase c-MET in glioblastoom-cellen te normaliseren. 
Een nieuw experimenteel medicijn, cabozantinib, werd gebruikt om zowel de kinase-
activiteit van c-MET als van VEGFR te remmen. Dit resulteerde in een vermindering 
van migratie en groei van glioblastoom-cellen in vitro en een reductie van de grootte 
van tumoren in muizen, met een verbetering in hun overleving als gevolg.
Behalve naar het effect van chemische blokkering van fosforylering, hebben we ook 
gekeken naar de potentiële rol van PTPs in het reguleren van tumorigene processen 
in bredere zin. Hiervoor hebben we de expressie van het merendeel  van de PTP-
eiwitfamilieleden bepaald in glioombiopten. In hoofdstuk 3  beschrijven we hoe we 
hebben gekeken naar de globale relatie tussen PTP-expressie en glioom-gradatie. 
We hebben een aantal PTPs geïdentificeerd die een lagere expressie hebben in 
gliomen en wiens expressie correleert met de overleving van patiënten. Twee in het 
oog springende kandidaten uit de PTP-familie zijn DUSP26 en PTPRT. Lage expres-
sie van deze twee PTPs correleerde met een verminderde patiënt-overleving. Toen 
we de expressie van deze twee PTPs afzonderlijk omhoog brachten in een celmodel 
voor glioblastoom, nam de groei en migratie van deze tumorcellen af. Dit wijst op 
een tumor-onderdrukkende werking van deze PTPs.  Verder zagen wij ook de reeds 
eerder beschreven sterk verhoogde expressie van PTPRZ1 in gliomen, met name 
in oligodendrogliomen. 
Vervolgens hebben we ons gericht op PTPRZ1 als mogelijk tumorgen in diffuse 
gliomen. Om het werkingsmechanisme van producten van dit gen te ontrafelen ge-
bruikten we een glioma celmodel dat het typerende diffuse infiltratieve groeigedrag 
van gliomas goed weerspiegelt.  In hoofdstuk 4 beschrijven we dat verschillende 
domeinen uit het PTPRZ-B eiwit een eigen rol hebben in migratie en groeisignaler-
ing van E98 tumor cellen. Verlaging van de endogene PTPRZ-B niveaus in E98 
cellen zorgde voor een verminderde migratie en afname van celgroei. Re-expressie 
van het extracellulaire deel van PTPRZ-B in deze cellen leidde to herstel van het 
migratie-fenotype, maar hielp niet om de effecten op proliferatie te compenseren. 
Her-expressie van het hele natieve eiwit of een katalytisch dode variant daarvan nor-
maliseerde daarintegen zowel de effecten op migratie als ook op proliferatie. Alleen 
wanneer het zogenaamde PDZ-bindingsdomein aan de C-terminale kant van PT-
PRZ-B geblokkeerd was door plaatsing van een extra stukje eiwit, een VSV-epitoop, 
werd het positieve effect van intacte PTPRZ-B op proliferatie weer teniet gedaan. 
Wij concluderen hieruit dat het intracellulaire deel van PTPRZ-B, meer specifiek 
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het PDZ-bindingsmotief  op het 3’ einde daarvan, een rol heeft in de regulering van 
celgroei. 
In hoofdstuk 5 gaan we hierop verder en beschrijven we hoe gezocht is naar part-
ner-eiwitten welke interactie vertonen met de intracellulaire domeinen uit PTPRZ-B, 
d.w.z. het deel van het eiwit dat de glioom proliferatie aanstuurt. We gebruikten 
daartoe nieuwe hypothesevrije methodes zoals BIO-ID of gerichte methodes zoals, 
immuunprecipitatie om bindende eiwitten te identificeren. Daarbij vonden we een 
nieuwe PTPRZ-interactiepartner, PTPN13, een eiwit dat ook zelf lid is van de grote 
familie van PTPs. PTPN13 komt in relatief hoge concentraties voor in glioblastomas 
en shRNA-remming van expressie van dit eiwit had een sterk remmend effect op 
overleving van tumorcellen in in vitro kweek. Een interessante waarneming was dat 
remming van expressie van PTPN13 leidde tot fusie van glioblastoom cellen, waarbij 
gigantisch grote multinucleaire cellen worden gevormd. Additioneel, verkregen we 
ook indirecte aanwijzingen dat membraanbinding van het intracellulaire domein van 
PTPRZ-B belangrijk is voor regulatie van de biologische activiteit. Wanneer het eiwit 
los in het cytosol voorkomt mist het het vermogen om de celproliferatie te stimuleren 
wat het volledige membraangebonden eiwit wel heeft. 
Tot slot, in hoofdstuk 6, bediscussieer ik de vindingen die in dit proefschrift  be-
schreven staan. Ook geef ik een vooruitblik op vervolgonderzoek dat nodig is om 
de rol van PTPs in de etiologie van gliomen nog beter te doorgronden. Ik richt me 
daarbij op een paar specifieke themas, zoals de band die er lijkt te bestaan tussen 
PTPRZ1 en MET genexpressie en karakteristieken van tumorstamcellen, de rol van 
het PDZ-domein van PTPRZ-B, en de centrale regulerende rol van PTEN in het door 
PDZ-domeinen gestuurde gedrag van tumorcellen. Ook worden opties beschreven 
voor het gebruik van PTPs als doel-eiwitten voor de behandeling van glioblasto-
men met medicijnen. Nieuwe inzicht in fosfotyrosinesignaleringsmechanismen en 
hun betekenis voor groei en migratie van glioblastoom tumorcellen zal uiteindelijk 
bijdragen tot de ontwikkeling van nieuwe vormen van therapie voor deze hoogst ag-
gresieve vorm van kanker. 
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Anna Maria (Annika) Bourgonje was born on October 11th 1987 in Epe, where she 
also grew up. Ever since she saw Spiderman on cartoon network as a little girl, 
where he got his powers by accident using a neogenic recombinator, she was in-
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graduated with the profile Nature and Health with advanced chemistry and physics. 
After high school she contemplated becoming a doctor and going into psychiatry 
to study human behavior, but fate brought her to the bachelor’s degree program 
in biology instead. At the University of Groningen she majored in Behavioral and 
Neuro-sciences.To further understand different aspects of behavior and the basis 
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she applied to the research master Behavioral and Cognitive Neurosciences major 
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she combined her interest in DNA with her interest in the human brain in two intern-
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after graduation from her Masters at the University of Groningen in 2011- she  ap-
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Radboudumc, working on a research project under supervision of dr. Wiljan Hen-
driks. On the first of April 2012 she started her PhD project of which the results are 
presented in this thesis. Her work entailed many aspects of tumorigenicity of brain 
tumors and in particular she studied the effect of the protein tyrosine phosphatase 
class of enzymes on the tumorigenic behavior of glioblastoma cells. In pursuit of 
these results she learned many new techniques including RNA expression deter-
minations,  microscopic techniques, statistical methods and handling of large data 
sets.  During the course of her Ph.D. trajectory she attended multiple courses given 
by the Graduate school associated with the Radboud institute for Molecular Life 
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provided in this thesis). Since june 2017 Annika is working as a data analyst at Val-
ueCare, a company that analysis large data sets from mental health care institutions.
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